Jazz的Ziihera获FDA批准用于一线HER2阳性晚期胃食管腺癌

----- 0001628280-26-058864-index-headers.html -----
<SEC-DOCUMENT>0001628280-26-058864-index.html : 20260825
<SEC-HEADER>0001628280-26-058864.hdr.sgml : 20260825
<ACCEPTANCE-DATETIME>20260825160636
ACCESSION NUMBER: 0001628280-26-058864
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 14
CONFORMED PERIOD OF REPORT: 20260825
ITEM INFORMATION: Other Events
FILED AS OF DATE: 20260825
DATE AS OF CHANGE: 20260825
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jazz Pharmaceuticals plc
CENTRAL INDEX KEY: 0001232524
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
EIN: 981032470
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33500
FILM NUMBER: 261315762
BUSINESS ADDRESS:
ADDRESS IS A NON US LOCATION: YES
STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE
STREET 2: WATERLOO ROAD
CITY: DUBLIN
PROVINCE COUNTRY: L2
ZIP: D04 E5W7
BUSINESS PHONE: 353-1-634-7800
MAIL ADDRESS:
ADDRESS IS A NON US LOCATION: YES
STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE
STREET 2: WATERLOO ROAD
CITY: DUBLIN
PROVINCE COUNTRY: L2
ZIP: D04 E5W7
FORMER COMPANY:
FORMER CONFORMED NAME: JAZZ PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030513
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>jazz-20260825.htm
<DESCRIPTION>8-K
<TEXT>
Document 1 - file: jazz-20260825.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991pr.htm
<DESCRIPTION>EX-99.1
<TEXT>
Document 2 - file: exhibit991pr.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>jazz-20260825.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
Document 3 - file: jazz-20260825.xsd
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>jazz-20260825_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
Document 4 - file: jazz-20260825_lab.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>jazz-20260825_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
Document 5 - file: jazz-20260825_pre.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<TEXT>
Document 6 - file: image_0a.jpg
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>jazzpharma_logoxfullcolora.jpg
<TEXT>
Document 7 - file: jazzpharma_logoxfullcolora.jpg
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 9 - file: R1.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 10 - file: report.css
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 11 - file: Show.js
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 13 - file: FilingSummary.html
Document 13 - RAW XML: FilingSummary.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 16 - file: MetaLinks.json
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-26-058864-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 17 - file: 0001628280-26-058864-xbrl.zip
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>jazz-20260825_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 18 - file: jazz-20260825_htm.html
Document 18 - RAW XML: jazz-20260825_htm.xml
</DOCUMENT>
</SEC-DOCUMENT>

----- 0001628280-26-058864.txt -----
0001628280-26-058864.txt : 20260825
0001628280-26-058864.hdr.sgml : 20260825
20260825160636
ACCESSION NUMBER: 0001628280-26-058864
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 14
CONFORMED PERIOD OF REPORT: 20260825
ITEM INFORMATION: Other Events
FILED AS OF DATE: 20260825
DATE AS OF CHANGE: 20260825
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jazz Pharmaceuticals plc
CENTRAL INDEX KEY: 0001232524
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
EIN: 981032470
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33500
FILM NUMBER: 261315762
BUSINESS ADDRESS:
ADDRESS IS A NON US LOCATION: YES
STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE
STREET 2: WATERLOO ROAD
CITY: DUBLIN
PROVINCE COUNTRY: L2
ZIP: D04 E5W7
BUSINESS PHONE: 353-1-634-7800
MAIL ADDRESS:
ADDRESS IS A NON US LOCATION: YES
STREET 1: FIFTH FLOOR, WATERLOO EXCHANGE
STREET 2: WATERLOO ROAD
CITY: DUBLIN
PROVINCE COUNTRY: L2
ZIP: D04 E5W7
FORMER COMPANY:
FORMER CONFORMED NAME: JAZZ PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030513
8-K
1
jazz-20260825.htm
8-K
jazz-20260825
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
August 25, 2026
Date of Report (Date of earliest event reported)
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
Ireland
001-33500
98-1032470
(State or Other Jurisdiction
of Incorporation)
(Commission
File No.)
(IRS Employer
Identification No.)
Fifth Floor, Waterloo Exchange,
Waterloo Road,
Dublin 4,
Ireland
D04 E5W7
(Address of principal executive offices, including zip code)
011-
353
-
1
-
634-7800
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Ordinary shares, nominal value $0.0001 per share
JAZZ
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 8.01. Other Events.
On August 25, 2026, Jazz Pharmaceuticals plc (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra
®
(tislelizumab-jsgr) and chemotherapy (HER2+ IHC 3+ or IHC 2+/ISH+), and Ziihera plus chemotherapy (HER2+ IHC 3+).
A copy of the press release is filed herewith as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
Number
Description
99.1
Press Release dated August
2
5
, 2026
104
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
By:
/s/ Neena Patil
Name:
Neena Patil
Title:
Executive Vice President and Chief Legal Officer
Date: August 25, 2026
EX-99.1
2
exhibit991pr.htm
EX-99.1
Document
Exhibit 99.1
U.S. FDA Approves Ziihera
®
(zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Ziihera
plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front-line GEA
Company to host investor webcast on Aug. 25 at 4:30 p.m. ET
For U.S. media and investors only
DUBLIN, August 25, 2026
–
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera
®
(zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA):
Ziihera
plus Tevimbra
®
(tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and
Ziihera
plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+).
"This approval is a major step forward for people with HER2+ advanced GEA.
Ziihera
is now the first and only bispecific HER2-targeted antibody combined with a PD-1 inhibitor and chemotherapy approved for all HER2+ advanced GEA patients, regardless of PD-L1 status, establishing a new standard of care in first-line treatment," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. "The HERIZON-GEA-01 results include the longest median overall survival reported in a Phase 3 trial in this setting, at 26.4 months. We are grateful to the gastric cancer community, including patients, caregivers, investigators and advocacy organizations, whose partnership made this possible."
GEA, which includes gastric, gastroesophageal junction and esophageal cancers, is the fifth most common cancer worldwide and remains associated with poor outcomes despite advances in treatment.
1
Approximately 20% of patients have HER2+ disease.
2,3,4
In the United States, more than 31,000 new stomach cancer cases are diagnosed each year.
5
“People with advanced HER2+ GEA deserve treatment options that reflect the unique biology of their disease. Understanding what a HER2+ diagnosis means is an important part of navigating treatment decisions and helping patients and families make informed choices about care. Today's approval gives people diagnosed with HER2+ GEA a much-needed new treatment option and more choice in how their cancer is treated,” said Martha Raymond, MA, CEO and Founder of GI Cancers Alliance.
The approval is based on results from the Phase 3 HERIZON-GEA-01 trial, which were published in the
New England Journal of Medicine
and first presented at ASCO GI 2026,
with PD-L1 subgroup data presented at ASCO 2026. The trial remains ongoing, with additional analyses planned.
Key HERIZON-GEA-01 Results
•
Progression-free survival (PFS): Both
Ziihera
-containing combinations significantly improved PFS in the overall HER2+ population, reducing the risk of disease progression or death by 35% and extending median PFS to 12.4 months versus 8.1 months with trastuzumab plus chemotherapy.
•
Overall survival (OS): In the overall HER2+ population,
Ziihera
plus tislelizumab and chemotherapy demonstrated a statistically significant and clinically meaningful OS benefit, reducing the risk of death by 28% compared with trastuzumab plus chemotherapy and achieving a median OS of 26.4 months versus 19.2 months, representing a greater than seven-month improvement and the longest median OS reported in a Phase 3 trial in HER2+ advanced GEA.
•
PFS and OS benefits were generally consistent across major prespecified subgroups, including geographic region and PD-L1 status.
•
Ziihera
-containing regimens demonstrated a manageable safety profile consistent with prior zanidatamab studies, with diarrhea as the most common adverse reaction, predominantly early in onset. Loperamide prophylaxis was administered during the first cycle, and diarrhea was managed with antidiarrheals and treatment modifications as needed, resulting in few discontinuations of
Ziihera
.
“This approval represents an important advancement in the treatment of metastatic HER2+ GEA,” said Geoffrey Ku, M.D., HERIZON-GEA-01 study co-author and associate attending physician on the Gastrointestinal Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center. “Importantly, similar outcomes were seen in patients whose tumors were PD-L1 positive or PD-L1 negative, suggesting that this regimen has the potential to benefit a broad range of patients. It further underscores what we have known for more than 15 years: HER2 testing at the time of diagnosis for advanced or metastatic gastroesophageal adenocarcinoma is critical to optimally guide treatment selection.”
The company will host an investor webcast on Tuesday, August 25, at 4:30 ET / 9:30 p.m. IST to discuss the FDA approval of
Ziihera
in first-line HER2+ GEA and provide updates on the zanidatamab development program. The webcast may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website.
The U.S. Prescribing Information for
Ziihera
contains Boxed Warnings for diarrhea and embryo-fetal toxicity.
Additional Important Safety Information related to ZIIHERA use in GEA is provided below. Please see full Prescription, including Boxed Warnings at https://pp.jazzpharma.com/pi/ziihera.en.USPI.pdf.
About Gastroesophageal Adenocarcinoma
GEA, including cancers of the stomach, gastroesophageal junction, and esophagus, is the fifth most common cancer worldwide, and approximately 20% of patients have HER2+ disease.
1,2,3,4
HER2+ GEA has high morbidity and mortality, and patients are urgently in need of new treatment options. The overall prognosis for patients with GEA remains poor, with a global five-year survival rate of less than 10% for metastatic disease.
6
About Ziihera
®
(zanidatamab-hrii)
Ziihera
(zanidatamab-hrii) is a bispecific HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces CDC, ADCC, and ADCP. These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.
7
Gastroesophageal adenocarcinoma (GEA): In the United States,
Ziihera
is indicated for the first-line treatment of adults with HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction and esophagus, in combination with tislelizumab-jsgr and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC
2+/ISH+ as detected by an FDA-authorized test); and in combination with fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ as detected by an FDA-authorized test).
Biliary tract cancer (BTC): In the United States,
Ziihera
is also indicated for the treatment of adults with previously treated, unresectable or metastatic HER2+ (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.
7
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
7
Ziihera is also approved in the European Union and other countries.
Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is being developed by Jazz and BeOne Medicines under license agreements from Zymeworks, which first developed the molecule.
The FDA granted three Breakthrough Therapy designations for zanidatamab's development: one as a single agent for previously treated HER2 gene-amplified BTC, one in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab for first-line HER2+ unresectable locally advanced or metastatic gastric, gastroesophageal junction (GEJ), or esophageal GEA, and one for the treatment of adults with previously treated, locally advanced, unresectable, or metastatic HER2+ colorectal cancer (CRC). The FDA also granted two Fast Track designations for zanidatamab: one as a single agent for refractory BTC and one in combination with standard-of-care chemotherapy for first-line GEA. Additionally, zanidatamab has received Orphan Drug designations from the FDA for the treatment of BTC, gastric (including GEJ) cancer, and esophageal cancer, as well as Orphan Drug designations from the European Medicines Agency for the treatment of BTC, gastric/gastroesophageal junction cancer, and esophageal cancer. Jazz continues to pursue additional regulatory approvals for zanidatamab in markets worldwide.
Important Safety Information for ZIIHERA
WARNING:
DIARRHEA and EMBRYO-FETAL TOXICITY
ZIIHERA, in combination with fluoropyrimidine- and platinum-containing chemotherapy, with or without tislelizumab-jsgr, can cause severe diarrhea, including life threatening and fatal cases. Use antidiarrheal prophylaxis during the first cycle when ZIIHERA is given in combination with these drugs. Manage with antidiarrheals and supportive measures as clinically indicated. Interrupt, reduce the dose or discontinue ZIIHERA based on severity.
Embryo-Fetal Toxicity: Exposure to ZIIHERA during pregnancy can cause embryo-fetal harm. Advise patients of the risk and need for effective contraception.
Diarrhea:
ZIIHERA can cause severe diarrhea.
When ZIIHERA is used in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr, severe, life threatening, and fatal cases of diarrhea can occur despite loperamide prophylaxis. The risk of severe and life threatening diarrhea is higher when ZIIHERA is administered with chemotherapy and tislelizumab-jsgr, with a higher risk in patients aged ≥ 65 years compared to younger patients. Advise patients to increase oral fluids, begin antidiarrheals, and notify their healthcare provider immediately if diarrhea occurs
.
Administer antidiarrheal prophylaxis with loperamide in cycle 1 for all patients receiving ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy with or without tislelizumab-jsgr. Begin loperamide at the first loose stool when ZIIHERA is administered in combination with chemotherapy. Administer fluids, electrolytes, and additional antidiarrheal agents as necessary. Before
modifying the dose of ZIIHERA, evaluate, modify or discontinue drug(s) contributing to diarrhea in accordance with their respective prescribing information. Withhold, reduce the dose, or permanently discontinue ZIIHERA based on severity.
If treating patients with ZIIHERA in combination with FOLFOX, do not administer the fluorouracil bolus.
ZIIHERA in combination with chemotherapy and tislelizumab-jsgr
Diarrhea was reported in 85% of 330 patients in clinical studies, including Grade 4 (2.1%), Grade 3 (24%), and Grade 2 (31%) events. Fatal outcomes resulting from diarrhea occurred in 1.5% of patients. Diarrhea leading to dose reduction of ZIIHERA occurred in 10% of patients, and permanent discontinuation of ZIIHERA occurred in 3.9% of patients.
In cycle 1, diarrhea at Grade 4 severity occurred in 1.5% and Grade 3 severity occurred in 15% of patients despite use of loperamide prophylaxis. The median time to onset for cycle 1 diarrhea was 6 days and median time to resolution was 18 days.
ZIIHERA in combination with chemotherapy
Diarrhea was reported in 81% of 395 patients in clinical studies, including Grade 4 (1.3%), Grade 3 (20%) and Grade 2 (33%). Diarrhea leading to dose reduction of ZIIHERA occurred in 10% of patients, and permanent discontinuation of ZIIHERA occurred in 1.8% of patients.
In cycle 1, diarrhea at Grade 4 severity occurred in 0.8% and Grade 3 severity occurred in 14% of patients despite use of loperamide prophylaxis. The median time to onset for cycle 1 diarrhea was 6 days and median time to resolution was 18 days.
Embryo-Fetal Toxicity:
Based on the mechanism of action, ZIIHERA can cause fetal harm when administered to a pregnant woman. There are no human or animal data on the use of ZIIHERA in pregnancy. In literature reports, use of a HER2-directed antibody during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death.
Verify the pregnancy status of females of reproductive potential prior to the initiation of ZIIHERA. Advise pregnant women and females of reproductive potential that exposure to ZIIHERA during pregnancy or within 4 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception while receiving ZIIHERA and for 4 months following the last dose of ZIIHERA.
Left Ventricular Dysfunction (LVD):
ZIIHERA can cause decreases in left ventricular ejection fraction (LVEF).
Assess LVEF prior to initiation of ZIIHERA and at regular intervals during treatment. Withhold dose or permanently discontinue ZIIHERA based on severity of adverse reactions.
The safety of ZIIHERA has not been established in patients with a baseline ejection fraction that is < 50%.
ZIIHERA in combination with chemotherapy and tislelizumab-jsgr
LVEF decrease (an absolute decline in LVEF of > 10%, resulting in a final value of < 50%) was observed in 9% of 330 patients in clinical studies. LVD leading to permanent discontinuation of ZIIHERA was reported in 3% of patients. Fatal outcomes due to LVD occurred in one patient (0.3%). The median time to first occurrence of LVD was 6.9 months (range: 1.2 to 29.1 months). LVD resolved in 78% of patients.
ZIIHERA in combination with chemotherapy
LVEF decrease was observed in 5% of 395 patients. LVD leading to permanent discontinuation of ZIIHERA was reported in 1.0% of patients. The median time to first occurrence of LVD was 6.0 months (range: 1.4 to 15.0 months). LVD dysfunction resolved in 70% of patients.
Infusion-Related Reactions:
ZIIHERA can cause infusion-related reactions (IRRs).
Prior to each dose of ZIIHERA, administer premedication to prevent potential IRRs. Monitor patients for signs and symptoms of IRR during ZIIHERA administration and as clinically indicated after completion of infusion. Have medications and emergency equipment to treat IRRs available for immediate use.
If an IRR occurs, slow or stop the infusion, and administer appropriate medical management. Monitor patients until complete resolution of signs and symptoms before resuming. Permanently discontinue ZIIHERA in patients with recurrent severe or life-threatening IRRs.
ZIIHERA in combination with chemotherapy and tislelizumab-jsgr
An IRR was reported in 22% of 330 patients in clinical studies, including Grade 4 (0.3%), Grade 3 (1.2%), and Grade 2 (16%) despite use of prophylaxis. IRRs leading to permanent discontinuation of ZIIHERA were reported in 0.3% of patients. IRRs occurred on the first day of dosing in 17% of patients. Of all patients who experienced IRRs, 60% of reactions resolved within the first day.
ZIIHERA in combination with chemotherapy
An IRR was reported in 24% of 395 patients in clinical studies, including Grade 4 (0.3%), Grade 3 (1.5%), and Grade 2 (18%) despite use of prophylaxis. IRRs leading to permanent discontinuation of ZIIHERA were reported in 1.3% of patients. IRRs occurred on the first day of dosing in 22% of patients. Of all patients who experienced IRRs, 83% of reactions resolved within the first day.
Adverse Reactions
ZIIHERA in combination with chemotherapy and tislelizumab-jsgr
Serious adverse reactions occurred in 59% of 294 patients in HERIZON-GEA-01. Serious adverse reactions in > 2% of patients included diarrhea (17%), IRR (5%), vomiting (4.8%), hypokalemia (4.4%), acute kidney injury (3.7%), pneumonia (3.7%), nausea (2.4%), decreased appetite (2.4%), and anemia (2.4%). Fatal adverse reactions occurred in 2.4% of patients and included acute kidney injury (N=2), cardiac failure, diarrhea, dehydration, hypovolemic shock and intestinal obstruction (all N=1).
Permanent discontinuation of ZIIHERA occurred in 13% of patients. Adverse reactions that resulted in permanent discontinuation of ZIIHERA in ≥ 1% of patients included diarrhea (4.4%) and ejection fraction decreased (2.7%).
The most common adverse reactions (≥ 20%) were diarrhea (83%), nausea (56%), decreased appetite (46%), vomiting (44%), hypokalemia (39%), fatigue (37%), rash (36%), peripheral neuropathy (27%), and IRR (25%).
ZIIHERA in combination with chemotherapy
Serious adverse reactions occurred in 49% of 305 patients in HERIZON-GEA-01. Serious adverse reactions in > 2% of patients included diarrhea (11%), vomiting (3.3%), decreased appetite (2.6%), pneumonia (2.6%), sepsis (2.6%), hypokalemia (2.3%), and nausea (2.3%).
Permanent discontinuation of ZIIHERA occurred in 10% of patients. Adverse reactions that resulted in permanent discontinuation of ZIIHERA in ≥ 1% of patients included ejection fraction decreased (2.0%), IRR (1.6%), and diarrhea (1.6%).
The most common adverse reactions (≥ 20%) were diarrhea (79%), nausea (54%), vomiting (44%), decreased appetite (40%), fatigue (36%), hypokalemia (33%), peripheral neuropathy (32%), IRR (25%), and rash (22%).
Pediatric Use
: Safety and efficacy of ZIIHERA have not been established in pediatric patients.
Geriatric Use
ZIIHERA in combination with chemotherapy and tislelizumab-jsgr
Of 302 patients randomized to ZIIHERA in combination with chemotherapy and tislelizumab-jsgr in HERIZON-GEA-01, there were 139 (46%) patients aged ≥ 65 years. One hundred and six (35%) were aged 65-74 years and 33 (11%) were aged ≥ 75 years.
There was a higher incidence of Grade ≥ 3 adverse reactions observed in patients aged ≥ 65 years (87%) as compared to younger patients (80%). The incidence of Grade 3 or 4 diarrhea was higher in patients aged ≥ 65 years (32%) compared to younger patients (20%).
There was an increased incidence of fatal adverse reactions in patients aged ≥ 65 years (4.4%); including acute kidney injury (N=2), cardiac failure, dehydration, hypovolemic shock and intestinal obstruction (all N=1), compared to younger patients (0.6%), including diarrhea (N=1).
ZIIHERA in combination with chemotherapy
Of 304 patients randomized to ZIIHERA in combination with chemotherapy in HERIZON-GEA-01, there were 130 (43%) patients aged ≥ 65 years. One hundred (33%) were aged 65-74 years and 30 (10%) were aged ≥ 75 years.
No overall differences in safety were observed between patients aged ≥ 65 years and younger adult patients.
Dr. Ku has financial interests related to Jazz Pharmaceuticals.
® TEVIMBRA (tislelizumab) is a registered trademark of BeOne Medicines.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the potential therapeutic benefits of zanidatamab and of combination therapies with zanidatamab, zanidatamab’s potential as a new standard of care in HER2+ first-line GEA and other HER2-expressing cancers and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the successful completion of regulatory activities and uncertain regulatory approval, risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients and other risks and uncertainties affecting Jazz Pharmaceuticals and its development programs, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including Jazz Pharmaceuticals' Annual Report on Form 10-K for the year ended December 31, 2025 and future filings and reports by Jazz Pharmaceuticals. Other risks and uncertainties of which Jazz Pharmaceuticals is not currently aware may also affect Jazz Pharmaceuticals' forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently
made available by Jazz Pharmaceuticals on its website or otherwise. Jazz Pharmaceuticals undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Contacts:
Media:
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Investor:
InvestorInfo@jazzpharma.com
Ireland +353 1 634 7800
U.S. +1 650 496 2717
1
Bray F., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024 April; doi.org/10.3322/caac.21834Digital Object Identifier (DOI).
2
Abrahao-Machado I.F., et al. HER2 testing in gastric cancer: An update WorldJGastroenterol. 2016;22(19):4619-4625.
3
Van Custem E., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-484.
4
Stroes, C.I., et al. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. CancerTreatRev. 2021;99:102249.
5
American Cancer Society. Key Statistics About Stomach Cancer. American Cancer Society. Updated: February 27, 2026. https://www.cancer.org/cancer/types/stomach-cancer/key-statistics.html.
6
Tabernero J., et al. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Taylor & Francis. 2022 July; doi.org/10.2217/fon-2022-0595.
7
ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.
EX-101.SCH
3
jazz-20260825.xsd
XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
0000001 - Document - Cover
link:presentationLink
link:calculationLink
link:definitionLink
EX-101.LAB
4
jazz-20260825_lab.xml
XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line Two
Entity Address, Address Line Two
Entity File Number
Entity File Number
Cover [Abstract]
Cover [Abstract]
Title of 12(b) Security
Title of 12(b) Security
Local Phone Number
Local Phone Number
Document Period End Date
Document Period End Date
Soliciting Material
Soliciting Material
Country Region
Country Region
Entity Address, Address Line One
Entity Address, Address Line One
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Entity Registrant Name
Entity Registrant Name
Amendment Flag
Amendment Flag
Pre-commencement Issuer Tender Offer
Pre-commencement Issuer Tender Offer
Entity Address, City or Town
Entity Address, City or Town
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Entity Address, Country
Entity Address, Country
Written Communications
Written Communications
Security Exchange Name
Security Exchange Name
Trading Symbol
Trading Symbol
Document Type
Document Type
City Area Code
City Area Code
Pre-commencement Tender Offer
Pre-commencement Tender Offer
Entity Central Index Key
Entity Central Index Key
Entity Emerging Growth Company
Entity Emerging Growth Company
EX-101.PRE
5
jazz-20260825_pre.xml
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
GRAPHIC
6
image_0a.jpg
begin 644 image_0a.jpg
MB5!.1PT*&@H -24A$4@ 10 M" 8 !O
Q\
M"7R5Q=7W_\S<):PIX 8DB+A415NQB]K:%JUK<=>@%K60!%JUH*)5DK!
,-N4_VV6
M*5\RRY1]R/2#&E/V]BQ;_A?B_&I3=M%L?&_H5E29%\U[(.^!'=@#FQU02E!B
M$R@=P.!P2=RF[X6)/ PUOQ;1A!B
1L]
M/X%$MEY=A-[OOX@>FD#VF3QYR'L@[X'/L
X&$CYBJ&BX$48G#@?2O
M>5@HAGJ5NPH$"Y+/X3C-KU:VPJ-YT:WQ0%YVZSW054"1!,;ME#'Q.49P P/)
M 0"# &_;&** ##=&[DN=@)D?/8="KE8$^2OO@;P'/E,>Z#2@E/"LI 9COADW
M_E$&DI%L5=BJ?)*3/.B.BLC$'H*Y37]"<7ZU0J_G(>^!SY '.@PHX;QD&'I^
M7HR]$Z('LSU;O;VACDV!$%3B CG5=L?ODB,P.+]2V12WY7GR'M@Q/-!10!$;
M63H
3>."#/Z%7?J7R*?=&OOJ\!S;! ^T#BLS&N-[.1FZ!8"CP
MJ:Q,D'-943FH=S=<@<<_D<-@Y*^\!_(>V'8>: LH"U!B8/SY@(P =IS)JT"$
M065"JA?V^P16*4+];
#-M:NC=$HFH=/R0.?R7XQK<[Z
M)WH,44BI0&UKV?9*NZA'(.C%]=(=>!([=<&[R>2K4-IK-D8?4(/17PQX%4J_
M4(,Q^U&!$#]3D,#H@F![34M;-DS'[%>#\_KE-$H2&%4T&^<6*U1R:/G'3\\#
M4HUQ_6=A].[AX\@G;$9+765[L9YM,@:R 64!2JPUT7)^T=E3P>F+'?!2.2#=
M'27;:I7B(O9@-9%?&QMY.*"WYA&Q=AX[<9LX=CMZ4.*P1<;:^<9&'C0F
MYG^6B9C,&%@[!7@[UL+ZB23-=?GOJ<5UC %F6U2251)6)UR9?)\*L\],=SP0
M6(B<_N&?T1/;X!*X. 2[4E7_@&SX;@Q6N^R/ES]K 04*RW-T[.Q5K_4^.2(7
MU;OS -\ C^-$DO57HS3XT+"]O2E
S)LQ306N2O]AY@1WH165*%.U[*Q4K,>S+I!\W(
M>#.2J]#]U0C/REZF2'L-^?SV]D W]."4D;B%MZUU)Y#PXC%/?&SF>-R4PF?L
M,C4XKR]G^W#:O;4#K$E57P?D#U"]A?F97C&+;\ [%?HTH\F[ !QQBX&AJCLR
MN( ZMUC'?ZL@E[=^5\AK"GG40W[0 P71_U9?[.CMO@)S5U7@YA6,-KJCVYIK
MGS&(%-'P/;#EEV/ ^"O%1UMOCT\Z<_*>OG'""[[QRKW]RFE)7U26
8<1
M# @31?$.>;<4^!*6D_ /?(Z>IME;JF:3Y&0!SY:N0GE1C2T_K<:43YAMRBZ:
M9
"WY%E!W"9&'HH.ZX@_TF1A3
MS*#0MM=NJ7:SDL>PP@OPC@AV6H-NX1?B6?F/L$H2&-6[QI:>5&/*)L\RI=-J
M;-DI/*@.JU;),C7?9#R.C]=@S+?(=QEQ1K4IKZI&V8AK<&X/LK3QAN>:2/DW
M@H[0SN";&NI/T)^A'37T84@#WTQ;=F)-MM[R*=4H^W8X5PBZFN7.&WB5+2VK
M-N57UIC2B=4H_P+EPLNOK:[PG$!97_9-20WU$&>$OIJ)TB^SGT+@;..EW@ 2
MRF=A[%=FF;)+9IGRF36F].*9*/OJ.(R+YHZMT%
G@")>&,(ZL[V# 3Y8<&/X8*.D"9A;)A,]F/XS&>/BP];*U==X2H%AH;_?JL
M2.DQ?+GO$_3,P.B]9Z/TBZ'>5CTA3U]^GN/P?-I[Y2Q35D%?'!WZHY6G-0TZ
MJL/!KBT=15NG!OYJ4WYA-
#@]X
C5JS+R"Y7P#0U46+Z'>L89#X6=2ECISDZA:L3=2^->KA6G?<
M
T!;]84ZEU_TCYHI\F??%5-,QWI;\3.JM%KTP:
MPQ!J[X1I:XMIG[D*Y0-?-[UO<$;_R4KO$<&/(7(=(+>(Q1^6&___9J/LE)9!
M!6!<@;'R4L3&7^T*TU9>68;"G8:B3]S;^(M=\0>ZM?8Y8/$NK&B+H822=%M<
MH3Q 6IU=+?+9QA$9&I/X D"FL(T'$H
2^F)F;?/B5NY!DHJD3D8)"7MI]JC=SSH?%3$A@=)VN6GREJ
M,&8G]M]/U/A[(/(="'8W3*W!W8.-^]EU&-
[/6WQA%= CE-@#Z!;!(&&.^,P2KNHDUEW 57P.1
M_FQ_);RY%B9Z$O"XL28RVELS>2F0#5@AZ+YN>EWDC7E !*,@V(MXJ!A_8W\[
M\'^N0OE^U"^ATA PHG;Q>=;X)U7-1+[RZ%?L943/%B._B9H]Q]-G-O#F8M!Q
M)4J_L(LM? *&\4]P"/UR@*B>#Y-^-(:EIR60",$\5[3M.1S,'
:=
M)WH> OXTY6-5/\(=:]B9J#P!7]E]%]Q0 /E-)"Z/1E4>R8C
G>
M^PGBS0EI^+\4("EL0:^8^/G,/)WT[DCJ&9ETQ2? Z_< .=4;?YT7G&F\+^WG
M[/$5K"OEW#&T?P)E+HWC_4$<2R:*)?O3]EF<.#5)O_8H\IU>Z>I'O>W,T? R
ME@X[,P9;0EZ* 6%RBI@Z4>QFO#LYZ5X/NL]M
>_/Z^FZ'1UTO^!6CE O)[%=_6,2F3,=%_18B*&<=XP%L*&>@&A_3
\\MNVA\[LZL9.@#3B#["@!7/F%B5
MP(SV'C_LX;I]FVW\[B17?XIX?SQM>,%9O6DZ1D9IKXE']CG2J$QRXBN--T=6
MN?HS G\/U_W;$#_10"Z(1A9_@Y4(
+02%9]_WW:
H;BCQ0!4<+2I5ULCO\0+"'Z<9EF\-B#%F"!['UNI!1]=CZ&,B!A.HG8%6
M6ARG*55YA1/P&
C=-(Z+=44#W
M!/KZ,NMQMCP(1UZ$,BV/FY6$@1;>M 4P81(
6#H-CW ]_[^Q68LT@@;"=+ 74H>H=;VFH!
M#BI IF\H=7 B@EU(WM
WPKRU8&&=KI
M4WCC&7;L[T1PLEA_S3H,>O[[J$TWT^
@]IB*+O,F4 "]'Z/\?0>39 M?K
MEPG
FH";DJ"5P,:7 H#7H-&JF#TV+AM
M.I;%FPRL2Q.H94"/K!$1QR"[-OC^)CR2U=]>403F 7.R7A_61I%?VBU0>C8
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M'&8RJG)7!GX%\QV"!_VL6L+]\I3VR+US(F867Q>W!?>H,=
:'QZ %[3
M$ !5\-<((F]QD%#%?U0/!5U@_-N,B#%N.;JGX5>KR*6%* S+"S;K/[S3D."S
M>U<%!9SYT?]0D('@)PP*:UKTDZ^9RKK7JF^Z<20:0KUMY2_S#4W:(HZ7)3Z3
M6=PBURS$>U_8M ?6&# ,O11UOD@@]E/&VD7R6UZF$
&A7Q%ZEGO7X0UTT_D45G2JP&1BY ()G,X@L##2TN\)S"OU?52^/
M0^7K?:D_#/QV+%UEM3OBZC?"U0/KQ!AS.&UX?0DB?PQUMF<70-?AS75>,@F!
M7=L//>D.U'*[-&<:IK$KL%[[E@%I56&0D7X+\0'%D7,M\?2]I*!]65=[NEZ"
M!4T
Z^W-_9TCVO(8?)#=([<\;U*BBO?3R(0. 1I@N&0NI>!.Q/9&\'$]
M$!$,L1XEZY5N[@-K,&!?O+WQ@$)/2MA/WHIQT8#CF"Y "
M&FC#B>3-;@&8!N +$ NXQ.<^=EY3>/-6^;D_JVR186
6[*OSXQO-5">4=(7KI7AG+P#6^/5O1P42E6)_^C/G50
MR@^Z820:7//2.JOI WZ^3&5S[6[3,(WF:R8,D% \!75O5;JZ7X?!Q,%FB)$$
M#R5OQ/CXM3BWNS4XGK9+/# 3+7@RH/A8G'N5O.O-FP+$J%L:NV'GC\%)06R#
M;" #TFS#V@RBZ]H(+9E%3-E6QG5OCL(*3YM^-1EU3[.8 ZO$AGX.=G&K4/ .
M"OI!S=!@5Z"G$ \S;B]O<.][&.!"62Y>P2\LE6YN?1KI]TG;WZMRE9/RS3I+
M8NU3TB,0_8.(V2.)CR-\WJ;@$35LZZ&B^/V 3NP-*ZS);MZ#E:C_
LZ+TS%=PGB_E>-^//LH^&,0TKMQD RFD8:X >R/@B1$_@+C[XMA\2$)
M?GA(L(]+$.:-8 KF_K,*]2_1)O;?!N+9 J-@.,AF-_U&A6MBB":S$D-8O6*O
M;+[KFU$U SE+J(+,!ATVC)2NP"(*V1C3]2CK$S=[7_\1#ZX"[L%TD>E]6:
!5AC[Q.1O13(ZF?J^8ZY*^U-51@X )]XZP@H
MX%20X)XW[+';D'OMHRJT_HQ*U-U0B=N7YTYNX8SH2%]'9;=R<%9CS&%QL^2"
MF%ER5=SVKEMMU_Z:VXB'5.P9M%=RY-(11)K'20YA6SXF^(6'$^"$@TWOR_
%!L^B>K74I7(SY0AY=+:(?:"Z?.H$X;$\1!#P];B/S8K;W
M_%PLL$OFD^=,#U\8)G\GJK:XF(%>V*<#(/[MS5%R#<[=.8YW3WW3]*X(8[^_
M77
9V51W4F:Z1:/#>N
NDV9A8H'F!7\I.R'8F*R_BU,D=A(&O*W1\AV5U=,:H
M\#VHNXPXK@7'LKY3R+_1^A8"-FX67PIK_RABID/DNP(Y H+/4S;&.1W\U6G=
M-1BSLQK<1YG#R"]$BL*I][].^
Z&L%3FP30)G]S-&%I!Q&!5G94CW
M[/P[>_ANX[@R^9#/GQI8..$@[;'
V\$&2Y]VM*W-KD ?,Q/G#8P9_!%&;N'@VH>=\[(Z
D9ULF5N2@L@_/EXESI.JSJ4B>VZ-((S4AO
MBF@82]4X[PMI$W]*C5[G88I4Y'FXS(W>X1SC]"0ZX D!7^D=*]3)N&UIRA=7
M)7WCX3PT'N
L "N1KC]H0U
M_#HD^Y-HB $RW,H\9#1RZ33,6^_\@79PU+Z[7]QV_RW'_+YD#G92%1R#R0+K
MM7(";F([2/E4P1AG8@P8
C#! ]HK,'>U0?!W\\3=
M7J9^",]#\>C#(O)W]3(L[=X8F_'%MU2B]G':M&QG?+#.0-K&"<=>FA9R=>V+
MV9>=FCD>Q\<=4F1'$_LE,P1K7[T"=1UB!>:^,@GSW@&&
G*M3]
M*YRWD!;:Q61]6(9EPI* X+C,OG%*@5]YD#@M$2-]8Z;@UFNY
MQ44GEU'!8HY@0B<
X8OQC8$'1J2][QZ66?T9/C7\);FH!9
MUQ-?$I6OD9]BO&\.*);C[8T'E#16KE#5)6BY%."XPR[K)')'W"R=*HH$@#@Q
M"Z2K"-[E9[-]160W/K?:M1;&7\HSC!]Q.W$G(!$22$;;9=GKTS&ZT%EWAT"^
M24+KP*$)^'5O39
=%K'J!@RW5P',8#CQ/8QAC 8]H/^:W
M*QCX T5DB(B[-8VB#Q)X/!-LHB,U&!(.'IGY7,@'3".U3@7+8'!$ T:V]E$@
MM6$)2FQ_,_#VB(F>!<&'4#DDZ"$#56$#O!IC!\Y&V4% \T\9/"RK)W<.O(R7
M.>2PLX 6Y- Z>US'=ZZ*OJR00SOC87MEL/'GQVSO6K7F8-J\LWC_DTM0OR+7
M'WUQ(-]1VA,=7%]BV2RV@UO:80DDLKYA0W0D^WDB&M8E,>@Q YW%LB^E43"0
M[!T">>0?'5(VK]"QHH
MPIEFP'$118\\'Y! EM@& AR[
MVL1>BYO"]UOQ(S-L68%9-E9-^G*!A+XT;0+9C)Q<8 H7M?(S_QYEEL;MTC.S
MY.U^2S.@:'>%_W@HAM(EZQLP
;,>7N>)YT2M^Q09]/8[U?[S7*C8>
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M:.[V*<@+!(4
#D[H7^8^>5!GWN9PR'!E^-4&K/=W%1(F>]R8
MBVE%7]HC'V&5,.@XXUT=N%7*\ 40M@JD9T&A$E:#L/9B5;S!)??_IGULOHJL
M4".3$AB=#5Y99H"\B<@ -)W-8'*8>G
F #+T>[Z"!]EGR*P/0,?'X2X'B0S^"M?THN(UU^;_0M>;>618#\/3DM5
MI?_G?.PN<>#62S+>%AS:HB^K*[0_3'XUF$SAOB9;.CQ[;[WU!S_!>W\G%'NE
M$?UVZ-=6&E/)!AFOYT*PV$/Z9A Y/(KDMX*?26\#(\Z_"NCRMI(MR2BBWN+(
M]%X8-KPO^O;MQ;WG2JSH27PO#3UA$/IGGL4W&4RN49'[14#_H[E=FU
8,.ZDM35&/"1.'<1V_<4F
HC7C)J'^C1B:%JGB
M;@!KB7Q)!5;T J08JJM4_<]8P@D&!V31NXCGFU"4G=5:UF4J5$9;0OU=\K;4
MXPR$5?,I!RPRH9RZ##&'V,EC \LIQ*:J?H3WF67!>B!T2;8^ZO3>^$PU@,,*
MS+O5U9'RHVHB95^OMF4CXF:OV2)29KT?IRI.C!P[ ^4'DY>@'!9F ]W=$0]E
M;@F6DF=#\,WMY.MV7>!;CZ%?LZT>,#Z-QM>@<@/43GC#]AXS.U+V3:XBOT&[
MSM[-K@M]V(M^GB,\+XO;R*FS
)[PCO?Z74!.VL-DZF;9TE.K(Z5'U-CR
M,V-2>*] #H2Z"=-PZ[IIX8\V7>:'(OA\S$8>J+%EYU1'QAU1;4N/XU>N:6K\
MQ0Q$%^V%U<^5H,&KQWP L;A-WDF>$N+QW%Z7&]%Z!H3?L5E\$;;OHVB*]KVB
M5J^.F:4_G(FR;U >M$&I5WMC!=M?_+%S
7M,4=B==KX(Q/XZ9(3-F14J/"?(U=LR(M"FXGFW8W[E,
ME8>L\=9%/=3V0_B5 MHNMBZS5(&WVDJV)".(LA&7BLJ#Z8P\FFJ2!U*]S1VI
M7G+7SB(/VH@\JE9^HY"+H>C#*H2X)4!?Z ,X$!]3@:*+BU':
O3Y!93]7R%GJW*F5F?JG@LX?X8XUQILI[-!1I"\@_6\*/$G9
M:[TWIQH?F<+>OH@X,:!7^9%FL,IGS&-\KE"525VA5U1F//[LO7^(^4V2H
CN
1'ZS%[G\WWEWJX?>+0(L%W?ZE(E=&@/=R
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MJ&WD >S]I(]*N:)#B$
:\F*7Y.;>D?-%/ Z;]P)]5T
WN"*ZP-B)T4
M))!@L*U[H@IUCXWDA.B 32?CMB65;L[\"MSU<>#AUXR7V.:JE"L>03\>F_1%
MYU6XNMLGXY9E0=\5F/M R@^:4('Z^X--I,V[C+[/U3T!-R4GN=KYE%EO, 8^
M=BTG9MT_*E!W;Y@@H:P]-MLQYP^34/\DY7T"#:E*U#V<\L6E[%-^@2H:D?)%
M%_,%\;^T9S5U?%8:\Q< 2%241!5)SRQ==.\G675N'N?P==0:Z27Z?2OOB:
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M"A7J9NI2@6AH?"Z&
(^;JWMAST!7D-L:32PLRQ,X@
M:UMGQ$[*NY0)-E(V\#&!YMHD]"L)2F2G-_M8Z(OFYV:_A'PN2K-<;G'K,WV<
ME6U]7B^59OW9.@-!J&M#N[+R69Y "SSDS3XS#:"A/!=)4&(NT)[FMK7GEV8[
M-N!MSQ/RK7PM::Y^#3P!J4B) 4(:,.1;L4,;2,SE:^N'H+,5V]6MH4SHLQ99
M;4F9-(.P78$G%TD-O$RR$/(!LP^MMQ!0\'FL>5,AM[+0$W=,4#@N6^_=Z>M8
MO6,:F+
^!
MS[8'L@$E-&%/-+[%Y4F]0GC6$DIV&&0LP2ID< Z&(9QU[#"&Y0W)>R#O@?4]
MT!90N$KQUMM;E"?,9-EQ@@JW.CR1OHGG_0OSJQ/V3![R'MB!/= 64&BC3N+7
MC92Z\[GUX4DTCT!9^"F#X]G1B[$D9F,XSU"0O_(>R'M@1_9 ^X 2[%1^$OJ7
M]WH)5-X-!9N.VYR36QW]OZCB1#D
VN0=R TJH0-,8](3Q
M_BBN49;P"Y*&PNV,K%-?]X)Q^!+"/[K9SM7GJ\M[(.^!+?% 1P$%X?OS
V#8>Z#"@!-4-:'"5
MJ'M27>IXKE1^R;+P5WO*])."H#LMJC^) :,+AF&Q). _J
O,>^ 0]\%^K
MNM. TNJ12MR^/.7-.*@?+XH7 0F!!=OX2@/Z?QYZ>N1!5,B7L3*_,MG&'LZK
MRWM@.WB@RX 2; A_\Y_T@VHS/G6"J+^,DYUG*SZL'C30MQ"#; A."PWT'!Z^
MGA$_& _G5R5;Z,V\6-X#.X '-BF@T$X-YRJ3
\8Z#,K^T JK
MH*1SA9$]9VD-,J$,D"PMY -R 4(>I03P*DGW&:.C5Z7U,/L@?L55R8<,5$$>
M^2OO@;P'/IL>V-2 TM:Z!IZM<,6RE@$FK"Z X? 9C\OXC7
GRAPHIC
7
jazzpharma_logoxfullcolora.jpg
begin 644 jazzpharma_logoxfullcolora.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" (0#'H# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B
7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKCOB!\8
M?!/PKM?/\6^*-,T(;=RQ75P!-(/]B(9=_P#@(-?*WQ(_X*E>"-"::W\&^'M1
M\4SKPMU=L+*V/N,AI"/8HM=-+#UJWP1N>GA
*UMHQN>:9PB*/4D\"OR/\?_\ !1OXQ>,O,BT[4;'PE9OE?+TBT4R%
M?>27>P/NNVOGKQ5X[\2>.KO[5XCU_4]>N,Y$FI7
4U)?')+
M\3ZW#\'8F>M>HH^FK_1?B?LQXP_;#^#7@?S!J/Q TF>5.##ICM?/GTQ 'P?K
MC'?%>+>*O^"I7PTTK?'HFA>(-=E X=HHK:%O^!,Y;_QRORTHKT(970C\3;/H
MZ/". I_Q'*7SLOP_S/O/Q'_P5A\07&X:#\/]-L.H#:E?R76?0D(L?Y9_&O.-
M<_X*7?&?5B?LMQH>BY[6.FAL?]_FDKY3HKKC@L/':"_,]JGD.64OAH+YZ_G<
M]SU3]N'XY:L
WZ#'_ "SC6N7O/VF_BY?%3)\3/%B[
,_$$D\?W)6U2
S@]XHEX:A+1P7W(]KTK]M/XW:-L^S_$35)-N,?:EBN.G3/F(V?QZ]Z[;1
M/^"D7QMTG;]JU;2M9QU^W:7$N?\ OUY?^17R]16
HW>FRR:C;1O):3M$S*95!4E2,CGI
M7!4RF%FX2^\^?Q7!U'E
BBBBOFC\L"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBJ.M:YIWAO2[C4M6O[;3-/MUWS7=Y*L44:^K,Q ^M TF
MW9%ZJ]]J%KI=G-=WMS#:6L*[Y)YW"(B^K,> /K7Q;\
JCAY>?3:.X8U\#?%G]H3X@?&Z\,WB[Q)=:A;AMT>GQD
M16D7IMA7"Y']X@L>Y->M0RVK5UG[J_'[C['+^%\9B[3K?NX^>_W?YV/TF^,'
M_!1SX8_#HS6?A^2;QUJR9&W3&"6BMZ-<,,$>\:N*^*_BO_P4&^+7Q*,]M8:K
M'X-TI\@6VA QS;>VZX.9,^Z%0?2OFBBO?HX"A1UM=^9^B8+A[ 8*S4.:7>6O
MX;?@37U]
37=Y<2W=U,Q>2>=R[NQZEF/)/N:AHHKT#Z3;1!1110,****
M"BBB@ HHHH **** "BBB@ HHHH **** "NA^'/\ R4+PQ_V%+7_T:M<]70_#
MG_DH7AC_ +"EK_Z-6IE\+,JO\.7HS]]Z***_/#^:0HHHH SM:\067A^."2^E
M,,
>BE%W6DE=7>^C]-/4^F
MPF3K&85582M+7T/I2BO,?#WQB5MD.L6^T]/M-N./J5_P_*O1=/U*UU2W6>TN
M([B%OXHVR/H?0U^B9+Q-E7$$.; 5DY=8O22]4_S5UYGCXG!5\([58V7?H6:*
M**^H.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "D)"@DG %>>_&;X]>#/@+X=.J^+-52U9U)MM/AP]U=L/X8X\Y
M/;+'"C(R17Y>_M(?MS>-_CL]UI-C(_A7P>^4_LNSD/FW*?\ 3Q*,%\_W!A?4
M,1FN_#8.IB7=:+N?0Y7D>*S1\T%RP_F>WR[_ -:GVC^T)_P40\$_"DW6D>$Q
M'XU\31Y0_9Y,6-LXX_>2C[Y']V//0@LIK\X?C%^T%XZ^.VK?;/%NN37<"/O@
MTV',=G;]ODB!P#CC<
Y->
?\SW^7;Y
M!1117:>^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !70_#G_ )*%X8_["EK_ .C5KGJZ'X<_\E"\,?\ 84M?_1JU,OA9E5_AR]&?
MOO1117YX?S2%%%% 'GWQF_Y -C_U\_\ LK5Y!7K_ ,9O^0#8_P#7S_[*U>05
M_&/B=_R4E7_##_TD_2
WE[E3P?8CH1]:IT5^6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBJ6M:U8>'=*NM3U2]@T[3K6,RSW5U((XXD'5F8\ 4#2;=D7:^._VJ?\ @H)H
M?PI-YX9\"&W\1^+ES%->9WV>GMT()'^MD']T' /WCD%3X#^UM_P4$U'XB?;/
M"7PWGN-'\+L3%
3<+WM
MB,>O2/\ \E_E]_8W/&GCC7OB+XBNM>\2ZK
^%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%
G6X
MVJB@-+<2$';%$N1N=L' Z<$D@ D5&+D[+
)M1BTO2+-=TL\F223T55'+,3P%')-?D=^U9^V%XB_:,UA["W,VB^"+:3-
MII"M\TQ!XFG(^\_HO*KVR
>_:8_::\1?M(^,6O[]GL/#]HS+IFC(^8[=/[
M[?WI&'5OP& ,5XW7UF"P*H+GJ:R_(_8\BX?A@$L1B%>K^$?^#Y_=YE%%%>N?
M:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5T/PY_P"2A>&/^PI:_P#HU:YZNA^'/_)0O#'_ &%+7_T:M3+X
M695?X
'\TA1110!Y]\9O^0#8_]?/_ +*U>05Z_P#&;_D V/\
MU\_^RM7D%?QCXG?\E)5_PP_])/TG(_\
?:OF-O\ 6PL?ED'O[^]9%%=>$Q=? UXXG#3<)Q=TUNOZ_$SJ4X58
MN$U=,^BO#?B:R\3V(N+1_F'$D+?>C/H?\:UJ^;M$UR\\/WZ7=G+Y
)H"?F0_U'H:_L'@GCFCQ'36$Q=H8F*VZ37>/G
MW7S6FWYWF>5RP;]I3U@_P]?\S;HHHK]9/GPHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MLSQ-XFTOP;X?O];UJ]AT[2K"%I[BZG;:D:#J?KV ZDD
_:0\
M=/J^H;['1;7=%I>D+(62VCSU/8R-@%F[X ' K:_:T_:DU7]I#QKOC,UCX0T
MYV72]-8X)'0SR@$@R,/P4<#N3X/7UN!P2H+GG\3_ /V;A_(EE\%B*ZO5?\
MY*NWKW?R]2BBBO7/M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/]6Q+2Q,%JOYE_,OU71^3T_-\TRUX*?/#X'^'E_D:-%%%?JIX(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (S!%+,0J@9)/05^4/[=_[7#?&;Q$_@WPM>-_P@^ES?O9HC@:G<*2/
M,SWB4YV#H3\W/RX]T_X*+?M5'PKI<_PL\+7>W6+Z('6[J%N;:W89$ (Z/(#E
MO1"!_%Q^:5?29;@[+V]1>G^9^H\+Y+RI8_$+5_"O_;O\OO[!1117T)^E!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !70_#G_DH7AC_L*6O_HU:YZNA^'/_)0O#'_84M?_ $:M
M3+X695?X
'\TA1110!Y]\9O\ D V/_7S_ .RM7D%>O_&;_D V
M/_7S_P"RM7D%?QCXG?\ )25?\,/_ $D_2
19895#(Z]"*FKQOX8^,_[(O!IE
MW)_H4[?NV8\1.?Z'^?XU[)7]S\+<1T.)LOCBZ>DUI./\LO\ )[I]O-,_+
MZEJ5KHVFW>H7T\=K96L3SSSRG"1QJI9F8]@ "?PK
M\5OVKOV@;S]H?XK7NLAY$\/V>;31[1\@1VX/WRO9Y#\S=^0O117I8'#?6*GO
M?"M_\CZ?(,J_M+$WFOW<=7Y]E\_R/)]
'\TA1110
M!Y]\9O\ D V/_7S_ .RM7D%>O_&;_D V/_7S_P"RM7D%?QCXG?\ )25?\,/_
M $D_2
BBBOSP_FD****
M //OC-_R ;'_ *^?_96KR"O7_C-_R ;'_KY_]E:O(*_C'Q._Y*2K_AA_Z2?I
M.1_[E'U84445^4'OA1110 4444 %%%% !1110 4444 %%%% '=_"KQ0=+U0Z
M;.^+6[/R9/"2=OSZ?E7LM?,"L48,I*L#D$=17OW@;Q(/$N@PSNV;J+]U./\
M:'?\1S^=?T_X5<2>VI2R3$2]Z'O0_P /6/R>J\F^B/A\^P?+)8J"T>C]>C.A
MHHHK^ACX\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BOA3XC?\ !3__ (0#XA>)_"__ K3[?\ V)JEUIOV
MK^WO+\[R96CW[/LQVYVYQDXSC)KGO^'MG_5*O_+B_P#N6O067XF2NH_BO\SZ
M2/#F:3BI1I:/^]'_ #/T,HK\\_\ A[9_U2K_ ,N+_P"Y:/\ A[9_U2K_ ,N+
M_P"Y:?\ 9V*_D_%?YE_ZM9K_ ,^?_)H_YGZ&45^>?_#VS_JE7_EQ?_
!
MQ%.+G*.B\U_F85\@S+#TY5JM*T8ZO6/^9]84445PGSX4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !117QM^T#_P42_X47\7=>\#_P#"
MO_[;_LO[/_I_]M?9_-\VWCF_U?V=\8\S;]XYQGC.*WHT:E>7+35V=^#P.(S"
MHZ6&CS22ONEI\VNY]DT5^>?_ ]L_P"J5?\ EQ?_ '+1_P /;/\ JE7_ )<7
M_P!RUU?V=BOY/Q7^9['^K6:_\^?_ ":/^9^AE%?GG_P]L_ZI5_Y<7_W+1_P]
ML_ZI5_Y<7_W+1_9V*_D_%?YA_JUFO_/G_P FC_F?H917YY_\/;/^J5?^7%_]
MRT?\/;/^J5?^7%_]RT?V=BOY/Q7^8?ZM9K_SY_\ )H_YGZ&45^>?_#VS_JE7
M_EQ?_
YLIX;DCGL&,>:]7\&_\%!O@
MIXPD2*3Q)-X?N'.!%K-G)"/QD4-&/Q85E+!XB&\&<=;),QHJ\Z$OEK^5SZ/H
MK+\.^*-&\7:
V?]4J_\N+_[EKIHX>KB+^S5['IX++<7F/-]5AS
5Y5O)-_J_LZ9
MSY>W[PQG/.,5]DU-:C4H2Y:BLS/&8'$9?45+$QY9-7W3T^3?8****P. ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **\\_:!^+?\ PHOX1:]XX_LK^V_[+^S_ .@?:?L_
MF^;<1P_ZS8^,>9N^Z
Q@\
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M.7V_5])^%VEW&8;+;J6K[#UF9?W$1_W4)
Y%?A)XX\8:C\0?&&M>)=6D\W4M6NY+R=AG 9V)
MVKZ*,X [ 5[>5T.>HZKV7YGWG">7_6,2\5->[#;_$_\E^AB4445]4?KX444
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M%OSX^A-
Z=@HHHKO,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#\*OVC/^3A/B?_V-&J?^E
>5Z'^T9_R<)\3_\ L:-4
M_P#2N6O/*_0:?P1]#^D<+_N]/T7Y!1116AU!1110 5]
,_P!WGZ'B9U_R+:_^%GZP4445\,?S
M^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^-O_!0+
M_D[KQY_VX?\ I!;5^R5?C;_P4"_Y.Z\>?]N'_I!;5[64_P =^GZH^ZX/_P!_
MG_@?_I43YYHHK];O@E^QO\&O%'P9\!:SJG@:TN]3U'0+"[NKAKFX!EEDMHW=
MB!( ,L2>!CFOH,3BH85)S5[GZ-FF;4
QR#DU]O?L_?\%.K^RFMM'^*]F+ZT.$'B+380LT?^U-"O#CU,8! 'W6-?
M#OB[P7KW@'6YM'\1Z1>:)JGC
M,NP>9T_WT4[[-;_)_P!(_H#\+^*M'\:Z#::UH.I6VKZ5=IO@N[20/&X^H[@\
M$'D$$'FM6OQ0_9G_ &I/$_[-_BA)K&634?#-U*#J6AR/^[F'0NF?N2 =&'7
M#9%?L/\ #7XDZ!\6O!FG>*/#-Z+[2KY-R-C#QL.&C=?X74\$?SR>+P<\+
M+O%]3\=SC):V4SO\5-[/]'Y_F=11117GGS@5_//7]#%?SSU]'D__ "\^7ZGZ
M;P7_ ,Q'_;O_ +
GZL\SC#_?X?X%_Z5(****\4^%"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^>?^"@7_ ":+
MX\_[
JZ=[V/"S+!?V=BYX7FYN6VMK;I/
M;7N%%%%
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MPO%?[Q4]7^84445F
FY5WGW
M
W?J_\MOD%%%%=A[84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !70_#G_ )*%X8_["EK_ .C5KGJZ'X<_\E"\,?\ 84M?
M_1JU,OA9E5_AR]&?OO1117YX?S2%%%% 'GWQF_Y -C_U\_\ LK5Y!7K_ ,9O
M^0#8_P#7S_[*U>05_&/B=_R4E7_##_TD_2
!(.1^8R/RK
MV>OF.UN)+.YBGB;;+$X=6]"#D5](:3J4>KZ7:WL7W)XP^/3(Y'X'BOZJ\)LY
M^L8&KE51ZTGS1_PRW^Z7_I1\'Q!AN2K&O'[6C]5_P/R+E%%%?O9\F%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?A5
M^T9_R<)\3_\ L:-4_P#2N6O/*]#_ &C/^3A/B?\ ]C1JG_I7+7GE?H-/X(^A
M_2.%_P!WI^B_(****T.H**** "OKC_@F%_R
//^W#_T
M@MJ_9*OQM_X*!?\ )W7CS_MP_P#2"VKVLI_COT_5'W7!_P#O\_\ _\ TJ)\
M\U^ZO[.?_)O?PP_[%?2__22*OPJK]U?V<_\ DWOX8?\ 8KZ7_P"DD5=N;_!#
MU/=XR_W>CZO\CT.BBBOF#\H"BBB@ HHHH **** "BBB@#BOBM\&_"/QK\-OH
MGB[1X=2MN3#-C;/;,1]^*0
A!'%?DI^U5^R;KW[-?B*-VD?5_"5_(RZ
M?JP3!R!GRI@.%D SCLP!(Z,%_:"N:^(_P]T3XJ^"=6\*^(;47>E:E"8I%Z,A
MZK(A[.K ,#V(%>AA,9/#2MO'L?29/G5;*ZB3=Z;W7ZKS_,_ ROIC]A7]I6;X
M&_$V'2-6NRG@OQ!*MO?+(WR6LQXCN1Z8.%?_ &#DY*K7C'Q@^&&I_!KXD:[X
M/U?Y[K3)S&LRJ0L\1 :.51Z,A5L=LX[5QU?7SA#$4^5ZIG[17HT
K;J
M]_KX2I3=*;A+='\^8G#SPM:=">\6T%?SSU_0Q7\\]>_D_P#R\^7ZGZ)P7_S$
M?]N_^W'T-_P3]_Y.Z\!_]O\ _P"D%S7[)5^-O_!/W_D[KP'_ -O_ /Z07-?L
ME7-FW\=>GZL\SC#_ '^'^!?^E2"BBBO%/A0HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /GG_@H%_P FB^//^W#_ -+[
M:OQMK]DO^"@7_)HOCS_MP_\ 2^VK\;:^KRG^ _7]$?L/!_\ N$_\;_\ 28GZ
M&?\ !)/_ )JK_P!PK_V\K]#*_//_ ())_P#-5?\ N%?^WE?H97BYC_O4_E^2
M/A>)?^1K6_[=_P#24%%%%>
L>"M5N[JPL-3\G
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M7^84445F
3J6H1#2;(@X;S9\JQ4]BL?F./]RO
(/!W@6"3]W:0/J]VH/!>0F.('W54E/TD%=N#I>VKQCTW^X]W(\)]
&9X]*DP?[6U+_ $:TVG^)
M7;F0?]
54S2C#2.I\ABN+,#1TI)S?EHOO?\ D?C!X7^&_BWQN5'AWPOK.N[C
M@'3;"6X''7E%->I:'^PW\
_3&>M?M#&B
MQHJ(H1%& JC ]!3JX)9M4?PQ2_KY'SE7C+$R_A4HKUN_P#(_(_3O^":OQIO
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M\S\,Z*_3/XE?\$K_ GJR37'@CQ-?^'[DY9;/4U%W;$]E##:Z#W)<^U?'7Q>
M_8T^*OP92>ZU7PZ^J:/%DMJVBDW5N%'\38 >,>[JHYKU*.-H5M(RU\SZW!YY
M@,
&/^PI:_^C5KGJZ'X<_\E"\,?]A2U_\
M1JUUR^%GLU?X
'\TA1110!Y]\9O\ D V/_7S_ .RM7D%>O_&;
M_D V/_7S_P"RM7D%?QCXG?\ )25?\,/_ $D_2
:?V3Q!AZC=HS?)+TEHO
MNE9_(\C-:'UC"375:KY?\ ]UHHHK^Y3\N"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /PJ_:,_Y.$^)_\ V-&J?^E<
MM>>5Z'^T9_R<)\3_ /L:-4_]*Y:\\K]!I_!'T/Z1PO\ N]/T7Y!1116AU!11
M10 5]
OKC_ ()A?\G(W7_8!NO_ $9#7'C/]WGZ
M'B9U_P BVO\ X6?K!1117PQ_/X4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7XV_P#!0+_D[KQY_P!N'_I!;5^R5?C;_P % O\ D[KQ
MY_VX?^D%M7M93_'?I^J/NN#_ /?Y_P"!_P#I43YYK]U?V<_^3>_AA_V*^E_^
MDD5?A57[J_LY_P#)O?PP_P"Q7TO_ -)(J[
[QE_N]'U?Y'H=%%%?,'
MY0%%%% !1110 4444 %%%% !1110!^>G_!5?X8HJ>$/B#;1!7+-HMZX'WN&E
M@/Z3C/\ NBOSRK]CO^"@7AM?$7[*WBYO+\R?3FM;Z'@G:5G0.>G_ #S:2OQQ
MK[#+*CGA[/H['[7PKB'6RY1E]AM?K^I]Y_\ !*+QH]OXP\<>$W
?2OU]KQ
>NW)_^7GR_4]S
M@O\ YB/^W?\ VX^AO^"?O_)W7@/_ +?_ /T@N:_9*OQM_P""?O\ R=UX#_[?
M_P#T@N:_9*N;-OXZ]/U9YG&'^_P_P+_TJ04445XI\*%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\\_\% O^31?'G_;
MA_Z7VU?C;7[)?\% O^31?'G_ &X?^E]M7XVU]7E/\!^OZ(_8>#_]PG_C?_I,
M3]#/^"2?_-5?^X5_[>5^AE?GG_P23_YJK_W"O_;ROT,KQ
_[%>W_ /2N[KXVK[)_X*H?\G">'O\ L5[?
M_P!*[NOC:ON,%_N\/0_?LB_Y%M#T/W5_9S_Y-[^&'_8KZ7_Z215Z'7GG[.?_
M ";W\,/^Q7TO_P!)(J]#KXNI\
/C\2/VC/'.KK)YEK'J
M#V%L0
:1I)&9W8EF9CDDGJ2:^ARFGK*I\C])X-P]YU<2^EHKYZO\ )#:*
M**^D/U(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***5$
M:1U1%+.QP%49)/I0 E>N_ ?]EKQ[^T)J 'A[3?LVBH^RXUR^S':18Z@-C,C#
M^Z@)Y&<#FOI[]E/_ ()SR:Q':>*OBO!+:VC8EM?#&2DL@ZAKEAR@_P"F8PW]
MXK@J?T2TG2+'0=-MM.TRSM]/T^U0106MK$L<42#HJJH 'H*\/%9E&G[E'5]
M^A\!FW%-/#-T<%[TN_1>G?\ +U/G+X%_L"?#?X/K;7^I6H\9^(XP&-]JL8,$
M;^L5ORJ\\@MN8=B*^EU4(H50%4# ' I:*^;J59U7S3=V?EV)Q=?&3]IB)N3
M\_T[!11161R!1110 4444 %%%% !1110 4444 ?/GQR_8?\ AI\;(KB[.F+X
M7\1R$L-8T>-8R['O+%PDF3U) ;_:%?G[X\_8]\??L]_$?P[=ZE9C6?#/]KVJ
MQZ]IREH0#,N!*OWHFZ?>^7)P&:OV%ILD:31LDB*Z,,%6&0?PKT:&.JT5RWNN
MQ]-E_$&,P*]FWSP[/]'T_+R'4445YQ\R%%%% 'GWQF_Y -C_ -?/_LK5Y!7K
M_P 9O^0#8_\ 7S_[*U>05_&/B=_R4E7_ P_])/TG(_]RCZL****_*#WPHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *DM[A[6XBGC.V2-@ZGT(.14=%5
M&3@U*+LT)ZZ,^F;&[34+&WNH_N31K(OT(S4]
OR*&;CD+G-?G5\9/VQOBA\:I9X=4U^72=%D
M) T?1RUM;[?[KX.Z3_@;$>@%>GA\OK5US;+S/JLNX
/0/#&O:ZZ])+CRK2)OH=SM^:BOR^HKV:>5T8_&VS[G#\(X&FOWS
/7.9VSV]*^+J*?U+#_P B*_L++'_RX1]^
M:1_P5EU2-P-4^'%G
JO"0..S1/GO_\ 6KTWPG_P5,^&^JLD>NZ!K^@R
M-C,D<<5U"OKDJP;\DK\MJ*REEV&E]FWS..KPQE=1:4^7T;_5M'[E?#G]ICX7
M_%:2*'PUXSTR\O) -MC-(;>Y/L(I0K'\ :].K^>>O>_@K^VQ\3_@O-;V\&LO
MXBT&,@-I&M.T\87TC
XC#U<+4=*M%QDNC"BBBLSG"LKQ1XJT?P3H5SK6OZG:Z/I-KM\
M^]O)!'%'N8(NYCP,LRCZD5JU\\_\% O^31?'G_;A_P"E]M6M*'M*D8/JTCKP
M=%8G$TZ$G92DE][L=E_PU3\'O^BE>&?_ 91_P"-'_#5/P>_Z*5X9_\ !E'_
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M_P S#_4W"_\ /V7X'[B?\-4_![_HI7AG_P &4?\ C1_PU3\'O^BE>&?_ 91
M_P"-?AW11_9-/^9A_J;A?^?LOP/W$_X:I^#W_12O#/\ X,H_\:L:?^TS\*-6
MU"VL;+XA^';J\N95AA@BU"-GD=B JJ,\DD@?C7X9UV7P7_Y+%X$_[#UA_P"E
M$=3+*:<8M\S,JG!^&A"4E5EHO(_>:BBBOF3\J,KQ1XJT?P3H5SK6OZG:Z/I-
MKM\^]O)!'%'N8(NYCP,LRCZD5P'_ U3\'O^BE>&?_!E'_C7&_\ !0+_ )-%
M\>?]N'_I?;5^-M>S@\##%4W.3MK8^XR/(*.:X:5>I-IJ36ENR?ZG[B?\-4_!
M[_HI7AG_ ,&4?^-'_#5/P>_Z*5X9_P#!E'_C7X=T5W_V33_F9]%_J;A?^?LO
MP/W$_P"&J?@]_P!%*\,_^#*/_&C_ (:I^#W_ $4KPS_X,H_\:_#NBC^R:?\
M,P_U-PO_ #]E^!^XG_#5/P>_Z*5X9_\ !E'_ (T?\-4_![_HI7AG_P &4?\
MC7X=T4?V33_F8?ZFX7_G[+\#]Q/^&J?@]_T4KPS_ .#*/_&C_AJGX/?]%*\,
M_P#@RC_QK\.Z*/[)I_S,/]3<+_S]E^!^XG_#5/P>_P"BE>&?_!E'_C1_PU3\
M'O\ HI7AG_P91_XU^'=%']DT_P"9A_J;A?\ G[+\#]Q/^&J?@]_T4KPS_P"#
M*/\ QH_X:I^#W_12O#/_ (,H_P#&OP[HH_LFG_,P_P!3<+_S]E^!^XG_ U3
M\'O^BE>&?_!E'_C1_P -4_![_HI7AG_P91_XU^'=%']DT_YF'^IN%_Y^R_ _
M
L/\ THCK]YJ\G&X6.%E%1=[GQV?913RF=.-.3ES)[^04445YI\L%
M%%% !1110 4444 %?C;_ ,% O^3NO'G_ &X?^D%M7[)5^-O_ 4"_P"3NO'G
M_;A_Z06U>UE/\=^GZH^ZX/\ ]_G_ ('_ .E1/GFOW5_9S_Y-[^&'_8KZ7_Z2
M15^%5?NK^SG_ ,F]_##_ +%?2_\ TDBKMS?X(>I[O&7^[T?5_D>AT445\P?E
M 4444 %%%% !1110 4444 %%%% 'D'[7D<4G[,OQ'$TGE)_9$K!L9^88*C\2
M /QK\1J_:+]N35UT7]E7Q_,Q4&6UAME#=S)<11\>_P Q/X5^+M?593_"D_/]
M#]=X.3^IU'_>_1'T-_P3]_Y.Z\!_]O\ _P"D%S7[)5^/7_!.W36OOVK_ K,
M Q%G;WTYQCH;66/G\9!7["UY^;?QUZ?JSYOC!WQ\/\"_.05_//7]#%?SSUTY
M/_R\^7ZGJ<%_\Q'_ &[_ .W'T-_P3]_Y.Z\!_P#;_P#^D%S7[)5^-O\ P3]_
MY.Z\!_\ ;_\ ^D%S7[)5S9M_'7I^K/,XP_W^'^!?^E2"H+V]M]-M)KJ[GBM;
M6%#)+-,X1$4
(?M+_M=^$?V<-,\B[8:UXKGCWVNA6T@#X[23-@^
M4GN02W\(."1^6?QN_:<\?_'W4'D\2ZS(NE[]T.BV1,5E#SD?NP?G(_O.6;WK
M##8"IB/>VCW/.RKA[$YDE4?N4^[Z^BZ_D?I%\4?^"B?PD^'LDUIIM]<^,]1C
MROEZ(@:W#>\[$(1[IOKYK\8?\%6/&5](Z^&?!NC:/"3@-J4TMY)CU^4Q '\#
M7PW72>$_AKXM\=N%\-^&-8UXEMN=-L99P#[E5('X]*]Z&7X:DKR5_4_1*'#>
M682/-5CS>
U
M8$^.PP!Z'1[#!_\ (%8MC^Q3\;M0MQ-%\/-21#VGDAA;H#]UW![^E)J'[%?Q
MNTVW,TWP\U-T&>+=XIFX&?NHY/Z5IRX+:T?P.E4LC7NI4O\ R0],\,_\%.?B
M[HTB_P!I0Z#K\7\7VJR:)S]#$Z@'Z@_2OH;X7_\ !4CP5XADBM?&V@WWA.=C
MM-[:M]MM1_M-A1(OT"M]:_-_Q9\/_$_@.Y%OXD\.ZKH$S'"IJ=E);EOIO49_
M"L&E/ X:JM(V]":W#^5XN-XTTK]8Z?\ _ _?[PCXTT'Q]HD.L>'-7L];TR;
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MQMU!B8-5TK3!_=M=+C8#C_IIOKYDL=/NM4NDMK*VFN[A_NPP1EW;Z
^+GB",267PX\2&,\AY].D@4].AD"YZ]OZ5W_5<+2WBOG_ ,$^A_LG*,(O
M>IQ7^+7_ -*.V_X>!?'S_H?/_*/8?_&*FM?^"A7QXMW+2>,XKH$8VRZ19 #W
M^6$5D?\ ##?QS_Z)]>?^!5M_\=JIJ'[%OQMTN'S)OAWJCK@G%N8IVX]D
1RT2I?^2'K'A[_@J)\5M+D4:EI?AO68
7X
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M
A]#?\/4/A1_T+WC+_P K3_Y*KZP\%^*K3QUX.T'
MQ+81S0V.LV$&HV\=RH658YHUD4. 2 P##."1GN:_ "OW5_9S_P"3>_AA_P!B
MOI?_ *215V9AA*6'C%T^I[?$>3X7+*5.>'3NVUJ[]#T.BH;N[@L+6:ZNIH[:
MVA1I)9IF"I&@&2S$\ DDU\ _M,?\%*?L%U=^'/A,(9VC)BF\37";TW=#]F
MC(PV/^>C9!YPI&&KS:&'J8B7+!'RV RW$YE4]GAXW[OHO5_TS[?\=?$KPK\,
MM+_M'Q7X@T_0;0YV/?3JAD(ZA%^\Y]E!-?-7C+_@IS\)?#\TD.CV^N>*'7[L
MUI:""!C]9F5Q_P!\5^6_BCQ;K7C?6I]7\0:K>:SJ
7=],TLA]!ECP!V X
M':LFOH*654XK]X[L_2<+P?A::3Q,W)^6B_S_ !/T5U#_ (*T64
5Y5Q)#_
M *S8F<^7N^Z,9QSC-?A57[)?\$_?^31? ?\ V_\ _I?
#K/Q+XEL]3OK&ZOT
MTY(]*BCDE$C1R2 D22(-N(F[YR1QZ>F5\;?\%4/^3>_#W_8T6_\ Z27=>1AJ
M<:M:,);,^+RO#PQ6-I4*OPR=F'_#U#X4?]"]XR_\ K3_ .2J]]^ /Q^\/?M&
M^#KSQ+X:L]3L;&UOWTYX]5BCCE,BQQR$@1R.-N)5[YR#QZ_AG7ZG_P#!*_\
MY-[\0_\ 8T7'_I):5[&-P5&A1YX;GVN?9#@LOP3KT$^:Z6K/LFBN=^('Q!T#
MX7>$K_Q+XFU&/3-(LDW232
OR&-0?;!_'K7PS6]X3^'_ (G\>7)M
M_#?AW5=?F4X9-,LI+@K]=BG'XU]'3R[#TE>>OJ?IN'X:RW"0YJRYFNLGI]VW
MWW/==2_X*(?'6^DW0^*K73AG.VVTFU(^G[R-C56#_@H-\>H95=_&Z3*.L
T\D,+= ?NNX/?TJMK'['/QJT* RW/P
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M'OB[X-L/$_AB_6_TN[7@]'B
CD7^%U/4?B,@@GYO%8.>%>NJ[GY?FV2U\J
ME>7O0>TOT?9G4T45S_CSQ[H'PS\+7WB+Q+J4.E:19INEN)CU/95'5F)X"C))
MZ5PI.3LCP(QE.2C%7;.@KQGXO?M>?"[X*O-:Z[XCCN]7CZZ3I0^TW0/]U@IV
MQG_KHRU\"?M*_P#!0CQ;\5IKK1/!
?H#XZ_X*O7T
MDDL7@WP+;P("?+NM=NFD+#L3#%MQ_P!_#7C^M_\ !2+XVZM([6NK:5HP;.%L
M=+B8+TZ>;YAX]_6OG/P[X3USQA>_8]!T;4-;N^/]'TZUDN).>GRH":]2TG]C
M3XUZU );?X=:O&I&<7:I;-_WS(RGMZ5ZGU;"4=&E\_\ @GUJRO)L%I.$%_B=
M_P#TIF__ ,/ OCY_T/G_ )1[#_XQ71>'O^"E7QIT5T-Y>Z-KP P5U#353=TY
M_
[3A3?IR_H??7PV_X*K:-?S16W
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MTL^)W[
U*(D-8: GVM\CJ"X(B!]F<&OFGQA_P5@N&=H_
M"O@".-!]VYUB^+$_6*-1C_OLU^?-*JEV"J"S$X '4U[]/+*$/BU/T7#<*Y=0
M7[Q.;\W^BM^-SZNUK_@IE\9M4+&V?0-'ST%EIQ;'3_GJ[_Y-
7]
M37B_X*"?'J.16;QRLJ@Y*-H]C@^QQ #^1KI]#_X*9?&7264W;Z#K0'47NG%<
M]?\ GDZ>OZ#WSP-Q^Q#\<;>%I'^'M^57J(YX';\ )"37#^*/@3\1O!4;RZYX
M%\0:9 N
9=:)>!C[XAD _P#1E?5?PE_:P^%_QJDCMO#OB:!=5?@:5J -
MM=$^BH_#GG^ M7XBTJL48,I*L#D$=17/5RRA/X/=9YV*X4P%=?N;P?EJON?Z
M-']"]%?EA^R]_P %#/$7PYO+70/B)
WNK=P\
'_A1NTW3U)CD\23Q_OYQW\B
M-A^[7K\S#<<\!"*ZJ&&J8B5H(];+\KQ.9U.2A'1;M[+^NVY]T_$[XY> _@W9
MBX\8>)K'1BR[H[9V,EQ(/5(4!=A[A<5\E_$#_@JQX=T]I(/!G@V_UAN0+O5I
MUM(P?4(@=F'U*&OSAU;5K[7M2N-0U*\N-0O[AS)-=74K22R,>I9F))/UJI7T
M5+*Z,/XGO,_3,'PE@Z*3Q#
QP/IF G]:\E\)?![QUX\19/
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M?9@#7X(5K^%?%VM^!=
X/!Z$5QULKI25Z
M;L_P/%QG".$JIO"R<']Z_P _Q/Z :*^#?V6_^"CUOXDN+/PQ\56M].U"0K%;
M^)(E$=O,W0"X4<1DG^-<)SR$ S7WA'(LB*Z,'1AD,IR"/45\[6H5,/+EJ(_,
M\=E^(RZK[+$1MV?1^C'4445SGFA1110 445\[?M-_MI>$?V>89=+BV^(O&;)
MF/1[>3"P9&0UP_.P8Y"C+'C@ [JTITYU9
:3/H'4-0M=
M)LIKR^N8;.TA4O+<7$@CCC4=2S$X ]S7S+\3_P#@HM\)/A_)-:Z9>W7C/4$R
M-FBQ@P!O>=R%(]TWU^:_QF_:0\??'C4GG\5:W++8A]\.DVI,5E!Z;8@<$C^\
MV6]Z\QKZ*CE45K6=_)'Z5@>#Z<4I8V=WV6B^_=_@?
ORF( _@:\PU3_@HI\<]08F#Q/9Z8,YVVNDVS#IT_>(]?/.
MB^']4\27@M-)TV[U2Z/2"R@>9_\ OE037J.B_L?_ !HUZ-7MOAQKD0;I]M@%
MJ>F>DI4CK7H?5\)1WBEZ_P#!/H_[,R?!JTZ<%_BL_P#THZ8?\% OCX"/^*\S
M_P!P>P_^,5U&@_\ !3#XRZ3(K7DNAZV@/*WNG;,CZQ,E<*W[#OQR52Q^'U[@
M#/%S;D_EYE<7XI_9\^)G@F%YM;\!^(+"V09:Y?3Y6A7ZR*"OZT>SP<]$H_@"
MPV2U_
>T&?FO-#N1*/\ OS)MQ_W\/T]?
MKKX4?M#?#WXV6Y;PAXEM=2N57?)8/F&ZC'
9C.$\%73>'O3E]Z^Y_HS
M^A"BOS6_9A_X*0ZGH=Q9>&_BK(^JZ62(HO$BKFYMQT'GJ!^]7_;'SCDG>3Q^
MCVDZM9:]I=IJ6FW<-]I]W$LUO=6[AXY4895E8<$$5\YB,-4P\K37S/S',
F>3YT.GHCSM
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M(I.6' /TKLZ^>?\ @H%_R:+X\_[
"*/?YWF[-GEROG'DMG..HZ]OQ,K]#/^"2?_-5?^X5_P"WE>]C,#1H
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M_@<=7EB*R?,[=>RM^A^I_P#P]0^%'_0O>,O_ "M/_DJM/PO_P %,?AAXL\2
MZ3H=IH/BZ.[U*[ALH7FL[41J\CA%+$7)(&6&< _2OR=KLO@O_P EB\"?]AZP
M_P#2B.N>66X=1;2?WGGU>%LNA3E))Z)]3]YJ***^2/QDXSXP?%32?@G\.=7\
M::Y;WEUI>F>3YT.GHCSMYDR1+M#LJGYI%)RPX!^E?-/_ ]0^%'_ $+WC+_P
M"M/_ )*KT/\ X*!?\FB^//\ MP_]+[:OQMKWL!@Z6(I.<][_ .1^A<.Y)A,R
MPLJV(3NI-:.VED_U/VS_ &=_VJ/"?[3'_"0?\(OI^LV']B?9_M']KP11[_.\
MW9L\N5\X\ELYQU'7M[+7YY_\$D_^:J_]PK_V\K]#*\W&4HT:\J<-E;\CYC.L
M)2P./J8>C\*M^,4_U"BBBN,\0***PO&WCG0?AQX:O/$'B75+?2-(M%W2W-PV
M![*HZLQZ!0"2> *:3;LBHQE.2C%7;-VO+_BQ^TQ\-O@HKIXJ\3VMMJ 7
Q; ]Z^ /VC_ /@HUXI^(4]SHOP]:?PCX
1R2S,3DDD]237O8?*Y27-6=O(_0LNX
M1J54JF-ERK^5;_-[+\3]%/'G_!5VQADDA\%^!I[I?X;S7+H1?^08]V?^_@^E
M>+Z]_P %,OC)JTC&S?0=$4GA;+3M^.G_ #U=_P#)-?*%=YX5^ OQ(\<1I+H7
M@7Q!J5N_W;F'3I?)/3_EH5"]_6O66#PM)7<5\_\ @GV,,DRG!QO*G'UD[_GH
M>EM_P4"^/;,2/'84$]!H]A@?^0*LZ?\ \%#OCM9R;IO%UO?#(.RXTFT XZCY
M(E//U^F*PH_V'_CE+&KK\/KX*P##=
1R]VU+_ ,D/:?"W_!4[XCZ:Z+KGAWP_K<"X
MW-"DMK,WK\P=E_\ '*^@?AS_ ,%/OAMXHDAM_%&F:IX-N7^],Z_;+53Z;XP'
MZ_\ 3/'TK\R/$W@7Q)X+F6+Q#X>U7096. FIV4MLQ/IAU%8E3/+\-45TK>AC
M6X=RO%1O&'+YQ?\ PZ_ _?[PEXTT#QYH\>J^'-9L=
_$[Q5\*-?CUGPEKEWH>H+PSVS_+(/[LB'*NO^RP(K],/V5?^"@6
MC?%ZXM/"_C=+;PYXNE/EV]RA*V5^W95+$^7(?[I.&/0Y(6O#Q.75**YH:K\3
MX+-.&<1@8NK0?/!?>OEU]5]Q]@T445Y!\6%%%% !1110 5B^+?&F@> ]'DU7
MQ'K-CH>G1\&YOYUB3/H"QY/L.37R%^U)_P %$]+^'=S=^&/APMKX@\0QDQW&
MKR?/96;="J ?ZYQSWV@X^]RH_.'QY\1_$_Q/UR36/%6N7FNZ@Y)\V[E+!,]5
M1?NHO^RH 'I7L8;+:E9
,;E3CS+6+[-;<=?WDN&_$(0?7U\"\4?\%6/'-\[CP_X/T'2
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MM0#[Q2&6VF;_ ($)"H_[X[UXSJO[&WQJT>/?
OI&S&O,O$
MG@KQ#X-N!!X@T'4]"G)P(]2LY+=L^F'44_882KHHI^G_ !K+\GQ>D(0?^&W
MZ'Z6?#O_ (*D> ?$$D=OXMT'4_"4K=;F$B^ME]
.C &OP)KH? GQ"\2_#'Q!#K?A76KO0]4BX$]
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MS]:^!*55+L%4%F)P .IKZ*EEM"G\6K/TO"\+9?AU^]3F_-Z?
JB
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M1=GV9\QC^$*
WW[KYW/W%HKQS]F_]J#PK^TCX:-WI+?V=KMJ@.H:
M'<2!IK<]-RGCS(R>C@#J 0IXKV.OG)PE3DXS5FC\RKT*N&J.E6C:2Z!1114&
M 4444 %%%% 'R_\ \%'?%W_",_LPZM9JVR77+^UTY2#S]_SV_-8&'XU^0]?H
MI_P5C\3;-/\ AYX=1\^9+=W\R;NFT1QQG'OOEY]C7YUU]AED.7#I]V_\C]LX
M5H^RRV,OYFW^GZ!1117JGUX4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 ^&&2YFCAAC:661@B1HI+,Q. !U)-?J1^Q7^PW:?"VUL?&_CJ
MT2[\9R*);33Y0&CTL$<$CHTV#R>B]!R-U<=_P3O_ &28]/L[+XK^+K+=>3#S
M/#]C.O\ JD(Q]K93_$W.S/0?..2I'W]7S688UMNC3>G5_H?E?$F?2G*6"PKT
M6DGW\EY=^^VVY1117SY^
S:IXLT?1LB[U"&-QUC5MS_]\C)KF+WXQZ3"2+:V
MN;D_WB BG\SG]*\=HK\3Q_BQG6(;6$A"E'TYG][T_P#)3Z>CD&&A_$;D_N_K
M[STN;XU3-GR=*11VWSEOY**B_P"%T7O_ $#;?_OMJ\YHKY67B#Q--W>,?_@,
M%_[:=RRC K_EW^+_ ,STN'XU3+CSM*1AWV3E?YJ:U[+XQZ3-@7-M
MD;':_P#WR<&M>OE^NBT+Q]K.@E5BNFN(!_RPN/G7\.X_ U^D93XNPDU#-L/;
M^]#7_P E>O\ Y,_0\7$
KAY
L
M
05_&/B
M=_R4E7_##_TD_2
GUXE\);S[-XN2+/%Q"\?Y8;
M_P!EKVVO[/\ #+&?6N'*<'O3E*/X\R_"2/S7/*?L\9)_S)/]/T"BBBOU8\$*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\*
MOVC/^3A/B?\ ]C1JG_I7+7GE>A_M&?\ )PGQ/_[&C5/_ $KEKSROT&G\$?0_
MI'"_[O3]%^04445H=04444 %?7'_ 3"_P"3D;K_ + -U_Z,AKY'KZX_X)A?
M\G(W7_8!NO\ T9#7'C/]WGZ'B9U_R+:_^%GZP4445\,?S^(2%!). *_.#]LS
M]OJZU.\U#P+\,=0>TL(6>WU'Q%;-A[A@<-';.#\J=09!RW\.%Y;NO^"CG[44
MW@W2O^%7^&;LPZOJ< DUFZB;YH+5P<0 CHT@Y/HG^_Q^9M?19?@E)*M57HOU
M/TSAO(83BL=BE>_PK]7^GW]@)+$D\FBBBOHS]/"BBB@ HHHH **** "BBB@
MHHHH N:/K%]X?U2UU+3+R?3]0M9!+!=6TA22)P
%FV54LTH.$M)KX7V_P"!
MW/Z Z*\Y_9]^,EA\>/A3HOBZR5(9KE/*OK5#G[-=)Q+'ZXSR,\E64]Z]&KXB
M47"3C+='X-5I3HU)4JBM).S"OGG_ (*!?\FB^//^W#_TOMJ^AJ^>?^"@7_)H
MOCS_ +
J_,[LK_W_ _^./\ Z4C\;:***^\/Z("BBB@ HHHH
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MPJK]U?V<_P#DWOX8?]BOI?\ Z215VYO\$/4]WC+_ '>CZO\ (]#HHHKY@_*
MHHHH **** "BBB@ HHHH ***;)(L:,[L$11DLQP /4T ?%7_ 5,\>1Z/\(O
M#OA6.3%WK>I_:'7/6"W0EL_]M)(O^^37Y?5[Q^VG\
Y9@?[NP=J\'K[?!471H1B]]S][R'!RP. ITYJTGJ_5_
MY*R/MK_@E7X4?4/BWXL\0M&6@TO1Q:[NRR3RJ5_\=@D_6OT^KY-_X)K_ SD
M\$_ $Z[=P^5>^)[QKU=PPWV=!Y<0/L2)''M(*^LJ^8Q]3VF(DUTT/RCB+$K$
MYE5<=HZ?=O\ C<*_GGK^ABOYYZ]/)_\ EY\OU/J>"_\ F(_[=_\ ;CZ&_P""
M?O\ R=UX#_[?_P#T@N:^_/VS/VNK3]G;PVFE:,8;WQUJ<1-I;O\ ,EG$
P:1T
M!/8$GM7(?$#QYK7Q0\::KXGU^Z:]U;4IS-*_8=E11V50 H'8 "NZMA%B,2IS
M^%+[]6?08[)EF&:1KUU^[C%?-WEIZ=S-\0>(-2\5:U>:OK%]/J6IWDAFN+NY
M
R;9M-\.W:92%>HEN4/5CP1&>%_B!)POWZ %
M & *Y,5F7LW[.A]_^1XV<<3K#MX; 6NM.;HO1=?78^?_ (2_L+_"7X41PS+X
M?3Q-JR $ZCKX%R=WJL1'EI@\@A=P]37OMO;Q6L,<,$:0PQJ%2.-0JJ!T Z"
MI**^=J5)U'>;N?FN(Q5?%2YZ\W)^;"BBBLSE*NI:79ZU8RV>H6D%]9S#;);W
M,2R1N/0JP(-?'G[1/_!.'PEXYL;O5_AVD7A+Q$ 9!IZY&GW1Z[=O_+$GL5^4
M?W>
E7J4)
&=5\&Z_?Z)K=A-IFK
M6,IAN;2X7:\;CL?Y@C@@@C@UH_#OX@:W\+/&FE>*?#UVUGJVG3"6)_X6'1D8
M=U925([@FOTE_P""D/[.UOXW\ -\1](M0OB'P]&/MWECFYL<_,3ZM$3NS_=W
M]<"ORWK[+#5XXJES6\FC]PRS'TLXPGM&M])+SZ_)G[N? _XN:7\Q8N+7=N:VN%XDB;Z-G!XR"I[UWE?F3_P2X^+4FA_$#6_A]=S'[#KD!O[
M*-CPMU"/G '^W%DD_P#3%:_3:ODL70^KUG!;=#\;SC ?V;C)T%\.Z]'_ );?
M(***YWXB>.-/^&G@77?%6J'_ $'2;.2[D4'!?:N0@_VF.%'N17(DY.R/&C&5
M22A%7;/F7]O+]KF3X+:&O@WPG=!/&NJ0[Y;J,@G3;<\;_:5\$+W49;CY<_E-
M--)
*M;F\_5-5N6N)B,[5
MSPJ+GHJJ JCL% IO@'P/J_Q+\9:1X7T&V-UJVJ7"V\$?8$\EF/954%B>P4GM
M7V^&P\<+2MUZL_>\JRZEE&%Y7O:\G_71="U\-?A?XG^+OBBW\/\ A329M6U*
M;DK&,)$G=Y'/RHH]2?;J:_1?X(_\$R/"'A:WM]0^(EZ_BW5N&;3[5W@L(CZ9
M&))>>Y*@]"IKZ&_9X_9[\.?L[>!8=#T6)9]0F"R:EJKJ!+>S
M&]!TW0;7 !BTZU2 -CN=H&3[GFMVBBO&;;=V?$2E*;YI.["BBBD21W%O%=0R
M0SQI-#(I5XY%#*P/4$'J*^
HZ+$(XRW_32
M 81QGK@*Q_O5](T5K3JSI/F@['7A\77PD^>A-Q?E_6I^&7QX_9]\6?L\^+#H
MWB6U#6\V7L=4MP3;7D8/5&(X89&Y#R,CL03YI7[K?';X+Z+\>?AOJ?A768T5
MID,EE>[ SV=P!^[E7OP>"!C
]?A]XK\,ZAX+\3:MH&JP_9]3TNZDL[F/.
M0LD;%6P>XR.#W%?78'%_68VE\2/V?(
[QDJK'N&0\G<:^PJ_"K]GWXI3_!G
MXQ^%_%L;LMO97:K>(O\ RTMG^29<=_D9L>X![5^Z<
_[%>W_ /2N[KULL_WA>C/L.%/^1DO1
MGQM7[J?L[,$_9Y^&+,0JCPMIA)/0?Z)%7X5U^@O[27[2#_#W]DCX6?#S0;KR
MM?\ $/A#36OY8V^>VL3:QJ5]C*0R_P"ZK^H->QF%&5?V=./5GVW$F#J8]X?#
MTMW)_)6U9P'[
>1UA4@X'1C\Q
MS\N/CFI]/T^ZU:^M[*RMY;R\N9%AAMX$+R2.QPJJHY))( K]-OV3/\ @GOI
M7@>UL_%7Q,LX-9\2,!+;Z+)B2UL.X,@Z2R?7**>FX@,-I3HY?24?^'9WU<1@
M>',)&'W+K)]_\WT^Y'QU\$OV*_B=\<(8-0T_2ET/P_+@KK&LEH8I%]8EP7DX
MS@JNW(QN%?77@G_@E/X0L(5?Q7XPU?6+C&3'I<4=G$#Z'>)&(_%?Z5]R@!0
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M[B^,.M6OP4;X9VI^S:+<:U)K-ZZ.=UTQBACCC8?W4,);J
4O+8^$K"1ETK2MW"KT\Z0
M#K(P_P"^0=H[D\;\&?@3XQ^//B8:-X2TQKHI@W-]-E+6T4G[TLF,#OA1EC@X
M!Q6[^S/^SCK?[2'CU=&T]S8Z1:!9M4U5D++;1$\ >LC8(5>^">@-?LA\,?A?
MX<^#_@^R\->%].CT_3+9>< &29\#=+(W5W;')/L!@ <>)Q4,%%4J2U_(\/-
M,WH9%1C@\)%
;[M_P#!?G\Z_!'_ ()Q_#OX
B09^?TS(6!Z[5KZKTW2[/1;&*ST^T@L;.$;8[>VB6.-!Z!5 JU17S%2M
M4K.]1W/RG%8[$XV?/B)N3_#Y+9!1116)PG/^-?A_X;^(VCOI7BC0['7=/8']
MS?0+(%)_B4GE6_VE((]:_/']JS_@G3-X+T^[\5_"\76I:3"&EN_#\K&6XMT&
M26@;K(H'\)RXQP6[?I=177A\54P\KP>G8]C+LUQ66S4J,O=ZQZ/^NY_//7TI
M^PU^TE/\"_BA!IFJ793P9K\J6]_'(W[NVE/$=R/3:3AO52
$U]S_ ,TS^@/Q3XHTKP3X
0H.!W
M)VOCE^U]K/Q<^"_@/P$IGMX],LT&MS,V/M]Q$2D.<'E0BK(<]7?I\@)\D^$W
MPMUSXS>/M*\)>'H!+J%_)@R/GRX(QR\KGLJC)/KP!DD"O/P6#6&3JU=_R1\Y
MD>2PRN,\7B[
*?C-XJ@\/>$M*EU/4)!N
<&21
MSPBCU/7@#)(%?I#\#/\ @FKX(\#VL%_X]D_X337
RRG;L)8%X7/]Z, \Y(;I7Y
M<_$KX:>(OA'XQOO#'B?3WT_5;1N5/*2H?NR1MT9&[$?3@@BOWPKYM_;F_9UM
M_CA\)[O4=/M5;Q?X?B>\T^5%^>>,#,MN?4, 2H_OA>@+9]K!8Z=.2IU'>+_
M^[R'B"MAZL\?GV_(_(71=9OO#NK6>J:9=2V.HV
TK5[&88=5J3D
MMT?:<1Y;''8.52*]^&J].J_KJ?KS1117QI^(!7E7[27Q^TG]G7X:W7B._5;O
M493]GTS3MV&NK@@D ^B*/F9NP&.I /JM?C9^W)\
+M0\2^)=0DU+5[Y]\DK\!1_"B+T55' 4< "L73=-N]8U"WL;"UF
MO;VX<10V]O&7DD
?CL)IN0GNJ G!^\IXK[B^'?P(^'W
MPGMXX_"GA+2](DC&W[4D >Y;_>F?,C?BU=Y17R-;%5:[]]Z=NA^-8[-\9F$F
MZT].RT7W?YA1117(>,%%%% 'E'Q7_9:^&7QF@G/B+PM9C490?^)M8(+:\5O[
MWF( 6QZ/N'M7YI_M4?L2^)/V>2^MZ?-)XC\%/)M&HI'B:S)/RK<*. #P!(/E
M)X^4D _L'535M)LM>TN[TW4K2&^T^[B:&XM;A \
""*]##8VKAVM;
MQ['T>69YBLNFES
4\
M6=ZQ^50>R2GY
-U>/0S26TT
!]HC)CFX[ N
MC$#T(KTBOAI1<).+W1^ 5:4J-25*>\6T_D%%%%29!5+6M:L?#ND7NJ:G=16.
MG6<+3W%S,VU(HU&68GT %7:_-?\ X*2?M-2ZYK;?"GP[>8TNQ99-
)C0AHMV^R_K8\B_;"_; U7]
MH;Q#+I.DRS:=X"L93]DLP2K7K \3S#N3U5#PH]\FOFRBOLG]A7]C)?B]=1^.
MO&EH_P#PAMK+BRL9 5_M253@D]_)4C!_O'*] U?82=+!TNR1^V3GA,CP=[
W^K9Y_P#LU_L2^-/V@_*U5_\ BFO!^[!UB\B):?!Y%O'D&3GC=D*.>201
M7Z.?"']B_P"%7P=A@EL?#D.MZQ&!G5M;5;J;=_>52-D9_P!Q0?4FO;;2T@L+
M6&UM88[:VA18XH84"I&@& J@< 5-7RV(QU6N[7LNQ^19EG^,S"32ER0[
M+]7U_+R$50BA5 50, <"EHHKSCYH*9-"EQ$\4J+)&ZE61QD,#P01W%/HH ^
M>/C'^PG\*OBY;S31Z+'X3UILE=2T%%@^;_;A \MP3UX#'^\*_-C]HS]D_P 9
M_LX:FC:M$NJ^';B39::[9H?)D;DA'4\QR8&=IX.#M+8./VNK,\3>&=*\9:!?
MZ)K=A#J>DWT1AN;2X7
&Q]6@[2=X_P!;'U65\18O 24:
MC
J,<
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MK_[0GQ"M?#.B+Y$6/.OM0D4F.S@! :1O4\@*O
#I?FS]SR_ 8
M;),*VWLKREW_ .!V7ZF+\+_A/XJ^,GBB'0/"6D3:K?O\SE/EB@3."\CGA%'J
M>O09) K]&O@?_P $S_!G@^WMM0^(%RWB_61AFL8G:*PB/I@8>7'JQ /]VOI3
MX,_!7PM\"?!L'AWPM8BW@&'N;J3#3W
)\1BY.GA7R0_%_/I\C)\-^$]$\&Z:FGZ!H]CHE@GW;;3[9((Q_P%0!
M6M117CMMZL^*E)R=Y.["BBBD2>4_%C]EWX:?&BWF_P"$C\,6IU"0'&JV*BWO
M%/KYBCYL>C[A[5^
2XCCQ=62]
*_7&FR(LB,CJ'1A@JPR"/0UWX?&U<.]'==CZ'+<\Q>722C+FA_*
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M_@DG_P U5_[A7_MY7YYU^AG_ 23_P":J_\ <*_]O*^KS'_=9_+\T?L/$O\
MR*JW_;O_ *4C]#****^+/PL**** "BBB@ HHHH *^>?^"@7_ ":+X\_[
?\ @H%_R:+X\_[
'JOS/3RO_ '_#_P"./_I2/QMK
M]#/^"2?_ #57_N%?^WE?GG7Z&?\ !)/_ )JK_P!PK_V\KZO,?]UG\OS1^P\2
M_P#(JK?]N_\ I2/T,JIJNDV.O:;
">/=?6ZMM=$##*LP.#R"1WK\H*_9+_@H%_R:+X\_[
#?_"?M/_C=
M?&W_ 23_P":J_\ <*_]O*_0RO'S"I..)DD^WY(^)XCQ%:&:58QFTO=ZO^5'
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M2D9)[*JC^)F) '4D5^-G[3'[3?B/]I#Q@U]?L]AX>M7(TS14
VYA]_C
MY2KZS+\&J,55FO>?X'['PYDL<'26*KK]Y+;^ZO\ -]?N[A7UC^S7_P $^_%G
MQDM;77_%$LO@_P *3 21-)%F]O$/0QQG[BD='?KP0K YKU;]@W]B>VU&RL?B
M7\0=.$\,N)M$T6Z3*,O5;F93U!_@4\8^8YRM?HC6.,S%P;IT=^YP9YQ,Z$WA
ML$]5O+MY+_,\F^%/[*_PP^#4,1\/>%;1M00#.JZ@HN;MCZB1\[,^B!1[5ZS1
M17SDIRJ.\G=GYC6K5<1+GJR
"]0\+^)K%;W
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MNBBBO$/A KX#_P""A'[8%QH,EU\+?!=\T%ZR;==U*W;#1*P_X]48=&((+D=
M0O4L!]7_ +27Q@B^!?P;\0^+<1R7UO%Y-A#)R)+J0[8@1W )W$?W5:OP]U34
M[O6M2N]0O[B2[OKN9[BXN)FW/+([%F9CW))))]Z]S+<*JDO:SV6WJ??<+93'
M%5'C*RO&+T7=_P# _/T*U>A?!?X"^,OCYXD&C^$]--QY9!NK^
9*P]L@ <99E'>OV
MH^%'PH\.?!?P59>%_"]D+33[8;G=L&6XD(&Z65L?,[8Y/; 'JXW&K#+E
MCK)GV&>YY'*XJE25ZC^Y+N_T1\[?!G_@FW\.? -O!>>+O,\
Q7[MMI]ND$8^BH *TJ*^5J5JE
M9WG*Y^08K'8G&RYL14
YB62
M-QZ%6!!JU10--IW1\G?'3_@G5\//B39W%[X2@C\#>(<%D:R3_096_NO!T0>\
M>W'7#=*_,?XJ?"CQ-\&?&%WX:\5:
?4$'!! _
M>FO#?VO/V=;+]H7X67EE#;QKXJTU&NM&NR &$H&3"6_N2 ;2.@.UOX:]G!YA
M.G)0JN\?R/M\EXBK86I&CBI
\?._;^D?B]9WD^GW<%U:S26]S ZRQ31
M,5='4Y5E(Y!! .:_8[]BG]I#_AH3X7!M3E7_ (2[1"EKJJ@ >=D'R[@ = X4
MYZ?,KX &*_&Z2-X9&CD5D=2596&"".H(KZ"_81^*LOPO_:,\/*\I33-?<:+>
M(3\I\Y@(F]L2B/GT+>IKV\=AU7HMK=:H^[X@RZ./P4I)>_#5?JOFOQL?LI11
M17Q9^&!1110!^6'_ 50_P"3A/#W_8KV_P#Z5W=?&U?9/_!5#_DX3P]_V*]O
M_P"E=W7QM7W&"_W>'H?OV1?\BVAZ'[J_LY_\F]_##_L5]+_])(J]#KSS]G/_
M )-[^&'_ &*^E_\ I)%7H=?%U/CEZGX7BO\ >*GJ_P PK,\3>)--\'>'=2US
M6+I+'2]/MWN;FXDZ)&H))]SQT')/ K3KX8_X*D?%Z;0?!6@?#ZPG\N37'-]J
M 4\_9XF'EH?9I/F_[8UIAZ+KU5374Z,MP
2WT.T9XM(TMC\MK"2.2!P9'P"S>H Z* /(D1I'5$4L[' 51DD^E)
M7WY_P37_ &9K37&D^*WB2S6X@MIV@T*WF3*F5#B2YP>#M;Y4/9E<]54U]E4J
M4\'1O;1;(_<,5B,/DN"YDK1CHEW?;_-^K,K]F[_@FOJ?BZUM?$'Q/N+G0--D
M DAT&VPMY*IY!F8@^4/]G!?DYV$5]Z?#GX#_ ^^$MM%%X4\):9I,D8Q]K6
M27+?[TSYD;\6KO:*^1KXNKB'[ST[=#\7Q^<8S,9-U9VC_*M%_P 'YA1117&>
M*%
M?"F^D:1
^\/ZI=:;J=G/I^H6LABGM;F,I)$X."K*>0:_H,KY-_;L_9-M?C)X/NO%_
MARP5?'6DP^81 GS:E;J.8F ZNHR4/4XV]QCW<'F,E)4ZSNNY^AY)Q-5C4CA\
M<[Q>BEU7KW7GN?F#\,_B5KWPC\:Z;XI\-WAL]4L7W*>J2*>&C=?XD89!'Y8.
M#7[8_ OXQZ/\=_AII7B[1SY:7*^7=6A;
*4\N-&/RQ7J*6C8>F]0R''4E,]*]#,<,JU/VB^*
M/Y'T7$V5QQF&>(@O?AKZKJOENO\ @GZLT445\@?BX4444 %%%% 'Y4?\%0_$
M!U3]H33=.5OW>F:%!&5_Z:/++(3_ -\LGY5\?5[]^WEK']M?M7>.Y V8X);:
MU49SCR[6)6'3^\&/XUX#7W>%CRT(+R1_0F44_99?0C_=7XJX4445U'KA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %>^?L7_L]']H'XN6]KJ$+-
MX6T<+>ZLXR ZY_=P9[&1@1Z[5
5KNOJNK:@
MS##J9%!BB/<;(]H([,7]:\['8CZO1?+N]$?,\09B\OP;<'[\M%^K^2_&Q] 6
M]O%:V\<$$:0PQJ$2.-0JJH& !T ':I***^+/PH**** &O(L:,[L$11DLQP
M/6O)/''Q-EOVDL=(D:&U'RO<+PTG^[Z#]32_$_QLU[<2:/928MHSB>13_K&'
M\/T'ZGZ5YW7\P
493.T(Z3FMV^L8OHEU?79:;_<93E,8Q6(Q"NWL
MNWFPHHHK^>3[ **** "BBB@ HHHH **** "N\\$_$R?2&CL]49KFQZ+*>7B_
MQ'ZCMZ5P=%>WD^=8[(L4L7@:G+);KHUVDNJ_X=69RXC#4L5#V=577];'TY#-
M'
_Y^M>SU
M_;/"_$N&XGP*Q5'W9K2
#^(YL'C,/\ RRC+_P "37_MI\-Q%"U2G/NFON_X<****_H,^0"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _"K]HS_ ).$
M^)__ &-&J?\ I7+7GE>A_M&?\G"?$_\ [&C5/_2N6O/*_0:?P1]#^D<+_N]/
MT7Y!1116AU!1110 5]
OKC_@F%_P G(W7_ & ;
MK_T9#7'C/]WGZ'B9U_R+:_\ A9^L%<_\0?&MA\.? ^N^*-3;%CI-G+>2+NP7
MV*2$'^TQPH]R*Z"OCW_@IYX\D\-_ >P\/V\NR;Q%J<<4JY^];P@RM_Y$$/YU
M\;0I^VJQAW/P_+\+]
'/);OHGV\S\2-2_9/^,>EV_G3_#?
MQ$R8S_H]DTS?]\ID_I7F&I:7>:-?2V>H6D]C>0G;);W,;1R(?0J0"#]:_H/K
MRK]H#]G/PI^T)X1NM,UJQ@BU=8F_L_6DC'VBTDP=I##!9,GE"<'Z@$
Y^'E%:7B;P]>^$?$>JZ'J4?DZCIEU+97,8.
M=LD;E&'Y@UFU]&G?5'Z:FI)-;!11104%%%% 'W%_P2V^*TFB_$+7O -U-_H6
MM6QOK1&[74(^8#_>B))_ZY"OTVK\,?V:?%S^!OC]X UE7,:0ZQ;Q3,O7R9'$
M4O\ XX[5^YU?)YI3Y:RFNJ/QSBW#*CCE6C]M?BM/RL%?//\ P4"_Y-%\>?\
M;A_Z7VU?0U?//_!0+_DT7QY_VX?^E]M7GX;^/#U7YGS65_[_ (?_ !Q_]*1^
M-M%%%?>']$!1110 4444 %%:,?AS5I"H32[URW3;;N<_3BHM5T74-"N%M]2L
M+K3YV7>L5U"T3%22-P# '&0>?8TKHGFBW:Y3HHHIE!1110 4444 %=E\%_\
MDL7@3_L/6'_I1'7&UZW^RO\ #/Q#\3/CAX4M] L&NAIVHVVHWLYXBMH(I5=G
M=NW P!U)( K.K)1A)OL
L5U"T3%22-P# '&0>?8U3H&FFKH****!A1110 4444 =E
M\%_^2Q>!/^P]8?\ I1'7[S5^(7[*_P ,_$/Q,^.'A2WT"P:Z&G:C;:C>SGB*
MV@BE5V=V[<# '4D@"OV]KYC-I)SBO(_)^,IQE7I13U2=PHHHKP3\\"BBB@ H
MHHH **** "OQM_X*!?\ )W7CS_MP_P#2"VK]DJ_&W_@H%_R=UX\_[
,O]WH^K_(]#HHHKY@_* HHHH ****
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M>P_F2> 2>!7[#_L??LNV?[-_@5A>>3>>,=5"R:I>Q_,J8^[;QG'W%R
BV7AO1;#2=-MTM-/L8(
M[:VMXQA8XT4*JCV %7J**^*/PEMMW85_//7]#%?SSU]'D__ "\^7ZGZ9P7_
M ,Q'_;O_ +<%?:/_ 3G_9EA^(WBF7XA^)+/SO#VA3A-/MYE^2[O =Q!ZK$
M"#[L5Z[6%?&=G:3:A=P6MM$TUQ.ZQ1QH,EV8X 'N2:_=WX*_#6T^$/PK\->$
M;15VZ99I',Z# EF/S2R?\"D9V_&NS,L0Z-+ECO(]OBC,98+"*E3=I5-/1=?\
MCMJ***^0/Q<**** "BBB@ HHHH IZQI-KKVD7VF7T*W%C>P/;3PMT>-U*LI^
MH)%?@?XZ\+3^!_&WB#PY
E_M2_$
M.&)=JM?K.>,?-)%'(WZL:]_*9/GE#R/T3@VLU7JT>C2?W.WZG,?LY^+G\"_'
MCP%K:/Y:6^L6RS-S_J7<1RC\4=A^-?NG7\]=O<26EQ%/$VR6-@Z-@'!!R#S7
M]"E/-X^]"7J:<:4TJE"IU:DONM_F%?%'_!4KXB2:!\)O#WA*WE,
*OC5H%EINCZCJ%AIVB)E[:U>1!-
M)-*7&5!'W5B]_P!*X,OBI8B-^FI\[PY1C5S*FY[1N_NV_&Q\.5^A/_!*_P"$
MD4I\3_$B]A#R1M_8^G,P^Z<+).XSWP8E!'JX[U\+_P#"N?%G_0L:S_X+Y?\
MXFOV#_8C\&OX'_9C\%V5Q:R6E[<0RWMRDJ%'WRS.XW @$$(4'T45[N95N6A:
M+WT/T'BC&*EE[A3EK-I?+=_E;YGNE%%%?(GXP%%%% !1110 4444 %?DS_P4
MP\#Q>%_VBAJUO$$B\0:9!>R%1@&9"T+_ ([8XR?=J_6:OSF_X*SV'EZQ\-+W
M:G[ZWU"'
%Z,^PX4_P"1DO1GQM6AKGB'4?$MU!
>V_-?65)1
MIQ
<%%%% !7QM_P50_Y-[\/?\ 8T6__I)=
MU]DU\;?\%4/^3>_#W_8T6_\ Z27==N"_WB'J>[D7_(RH>I^6%6M)TN[UW5+/
M3=/MWN[^\F2WM[>,9:21V"JH'J20/QJK7U;_ ,$W/ABGCG]H*/6[J(26'ABT
M>_\ F&5-PW[N$?4%G<>\8K[*M45&G*H^A^X8W%1P>&J8B7V5?_+[V?HO^S3\
M"]/_ &??A3I?AJV6*74V47.J7D8_X^+I@-YSC)5>%7_94=\UZI117P
*U:>(J2JU'>4G=A1114&(4444 %%%% '@G[
K2>T6G]Z_P" %?JE_P $U_@7%X%^%
,_/
M+(J+Q]6%?OGH.BVGAO0].TBPB\FQT^VCM;>/^Y&BA5'X "GFM9QIJFNI?%^-
ME1P\,+!_'J_1?YO\B_1117RQ^2!1110 4444 %%%% 'X<_M1> (OAC^T#XX\
M.VT2P6=OJ#3VT2C"I#,HFC4>P211^%>=Z#K5SX;US3M6LG\N\L+F.Z@?^[(C
M!E/Y@5]0?\%,M-CL?VF))D&&O-'M)WXQD@O'^/$8KY1K[W#R]I1C)]4?T/EM
M1XG TISUO%7^[4_H,T;5(=
QU*W.;>\@CN(S_LNH8?H:N5P'[/EQ)=_ /X
M:SRMOED\,Z:[M@#)-K&2>*[^OA)+EDT?S[6A[.I*'9M'EW[3WQ$D^%?P#\;>
M)+>4P7MO8-#:2+U2XF(AB8?1Y%/X5^'%?K!_P4QDU6Z^ ^EZ/I%C=W\^H:W#
MYT=I"TI\E(I7)(7)^^(^V/TK\P/^%<^+/^A8UG_P7R__ !-?497&,:+D]VS]
M9X2ITZ."E4;5Y2_!:+]3V+]A3X21?%O]H;18;Z$3Z1HBMK%XC#*N(F41H<\$
M&5H\@]5#5^RM?!O_ 2S^'E]X=TSQ]KFJZ7=6%U<36ME!]L@>)MB+([[=P&0
M2Z9_W17WE7E9E4]I7:Z(^0XHQ3Q&8."?NP22_-_G^ 4445Y1\@%%%% !1110
M 4444 ?#_P#P53\#Q:E\+_"OBI(@;K2M4-D[@<^3/&2
*GU/X,^)-"DD+MI6LF6,$_
O_ 24E=HOBG&6)C5M+8+G@$_:\G]!^5?H57@8^/+B9I?UH?G/$4%3S2LE
MW3^])A1117GGSIYE^TA\7X?@;\&_$7BPE#?6\/DZ?%(,B2ZD^6($=P"=Q']U
M6K\/-2U&YU?4+J_O9WN;RZE:>>>0Y:21B69B>Y))/XU]T?\ !5#XI'4O%GAC
MX?VLV;?38#JEZJG@SR92)3[J@8_2:O@^OKLMH^SH\[WE^1^T<+8%8;!>WDO>
MJ:_+I_G\SU+]FGX)7?Q^^+FD>%82\-@2;K4KI!S!:H1YA'N
FY_,;W&ST%?8M>-F.(=6KR+:/\ 3/A^)LQ>,QCHQ?N4
M]/GU?Z?(****\H^/"BBB@ HHHH **** /%OVN_@C'\=O@EK6C0PB37+)3J&D
MOMRWVB,$A!_OKN3_ ($#VK\4""I((P:_H8K\1_VNOA\GPS_:+\;Z-!%Y-DUZ
M;ZU4#Y1%.HF55]EWE?\ @-?1Y36?O4GZGZ=P=C&_:8.3_O+\G^AZ'_P3I^*3
M_#_]H:RT>:;9I?BB%M-F5C\HF +P-]=P*#_KJ:_76OY_/"?B*Y\'^*=&UZR.
M+S2[V&^@.
V[;[>YB6:-O56 (/Y&L
(7VE9^J_P" _P "PS!%+,0J@9)/05^*_P"V)\='^/'QKU;5
M+6X,OA[3F.GZ0H/RF!"091_UT;<_K@J.U?I)^W;\6#\*OV=M>:VF$6JZYC1K
M/!PP\T'S6'?B(28/8E:_&RMLJHZ.L_1'=P?@%:>-FM?A7ZO]/O)K&QN-3O;>
MSM()+F[N)%BAAB4L\CL0%50.I)(&*_:G]D[]GNR_9X^%=GI+11MXCOE6ZUF[
M7!,DY'$8;ND8)5>WWFZL:^#/^":WP;7Q]\9)_%M_#YFE^$XEGC#+E7O)-RPC
MG^Z [\=&5/6OU
O1?+?Y^04445\^?G 44
M44 %%%% !1110!G^(-!T_P 5:'?Z-JUK'?:9?P/;7-O*,K)&X(93^!K\._V@
MOA#>? SXM:_X0N3))!:3;[*XD',]J_S1/Z9VD XX#!AVK]U*^#O^"J'PM74?
M"7ACX@6L.;G39SI=ZZCDP29>(GV60,/K-7KY;7=.KR/:7YGVG"V/>&QGU>3]
MVII\^G^1^>O@7QIJ?P[\9:-XFT>7R=3TJZCNH&/0LISM;U4C*D=P2*_=KX>^
M-K#XD>!]"\4:8
+L&JN&CBHK6#L_1_
M\&WWGV?7SS_P4"_Y-%\>?]N'_I?;5]#5\\_\% O^31?'G_;A_P"E]M7S^&_C
MP]5^9^:Y7_O^'_QQ_P#2D?C;7Z&?\$D_^:J_]PK_ -O*_/.OT,_X))_\U5_[
MA7_MY7U>8_[K/Y?FC]AXE_Y%5;_MW_TI'Z&4445\6?A84444 %%%% !1110
M5\\_\% O^31?'G_;A_Z7VU?0U?//_!0+_DT7QY_VX?\ I?;5TX;^/#U7YGIY
M7_O^'_QQ_P#2D?C;7Z&?\$D_^:J_]PK_ -O*_/.OT,_X))_\U5_[A7_MY7U>
M8_[K/Y?FC]AXE_Y%5;_MW_TI'Z&4445\6?A84444 ?//_!0+_DT7QY_VX?\
MI?;5^-M?LE_P4"_Y-%\>?]N'_I?;5^-M?5Y3_ ?K^B/V'@__ '"?^-_^DQ/T
M,_X))_\ -5?^X5_[>5^AE?GG_P $D_\ FJO_ '"O_;ROT,KQ
)?^1K
M6_[=_P#24%?._P"W1\<)/@K\#-0.G7'D>(=>;^R]/93\T>X$RRCTVQYP>S,E
M?1%?DI_P4B^*1\=?'Z30+>;?IOA:V6Q0*
_BY$=4@\WPIH(2^U-6'RS\_N
MK<_[[ Y_V4?OBOG>OV6_89^#\?PC_9^T,30"/6=>0:O?L1ALRJ#$A]-L>P8]
M2WJ:^DQ^(="B^7=Z'ZAQ#F+R_!-P=IST7ZOY+\;'T!'&D,:QQJJ1J JJHP !
MT %.HHKXL_"PHHHH **** "BBB@ KY4_X*)?!%/B;\%)O$EE &UWPF'OD95^
M:2TP/M"?0*!)_P!LSZFOJNJ^H:?;ZMI]S8W<2W%I
"Q$,1#>+_X=?-'\]]?
L6W]H6B
M,>EQ#@.%'JT;$G_KB*^/OB9X-E^'GQ$\3>&)MQ?2-1N+(,W5UCD*JWX@ _C7
M5?LP^,G\ _M"> -:1_+2/5X;>9LXQ#,?)E_\
-)7
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M] OAG6X_$WAO2=7A&(=0M(KM/]V1 P_0UIUY]^SS*\_P!^&
'H?OV1?\BVAZ'[J_LY_\
MF]_##_L5]+_])(J]#KSS]G/_ )-[^&'_ &*^E_\ I)%7H=?%U/CEZGX7BO\
M>*GJ_P PK\AO^"C_ (BEUK]J;6K.0L4T>PL[&//96A$_'XSM7Z\U^.'_ 4%
MA>/]K?QPSJ561;!D/J/L-N,_F#^5>KE7\=^GZH^NX/BGF$F^D'^<3YVK]XO@
MCX.@^'_P@\&^'H$"+I^E6\3X_BD\L&1OJSEF_&OP=K^@+PCJT.O^$]%U2W*M
M!>V4-S&4 "E7C5A@#COF[?+!=-3V^-)2]G0BMKO\ 2WYLUJ***^:/RP**
M** "BBB@ HHHH _&#]M[X50_"7]HKQ%8V<(@TO5-NL64:KM58YBQ=5'95E65
M1CLHKQ;P[KMWX7\0:9K-A)Y5]IUU%=V\G]V2-PZG\"!7ZO?MC?L:ZC^TOXD\
M/:QI6NV.B3Z=:26DYNX7
C?^ LU?78?'
M4?8Q526MM3]ER[B# O!4XXJJE.UFFGTT[=3]&?"?B*V\8>%M&UZR.;/5+*&^
M@YS^[E0.O/T85JUP_P $/ FH?#'X3>&/">J7\.IWNCV:VC75NK*CJI(3 ;GA
M=H_"NXKY222DU'8_(*T81J2C3=XINWH%%%%08A1110!^&O[4&H/J?[1GQ,F?
M=E?$-]!\QSQ'.T8_117F-=9\7+I+_P"*WC2YC#".;6KV10W4 SN1G\ZY.OT&
MFK0BO(_I+#1Y*$(]DOR"BBBM#I"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ]'_ &
Z@C728SNMX\RS#\8T>OW050BA5
M 50, <"ORO_ ."7/A=-6^/&L:Q*FY=)T65HS_=EEDC0'_OCS!^-?JC7RF:U
M.:LH=D?CW%^(=3&QH](+\7K^5@HHHKQ3X4*YOQ]XB/ASP]++$VVZF/DP^H)Z
MM^ S^.*Z2O'?C%J1N->M[,'Y+:+)'^TW)_0+7P7'&<3R3(JU>D[5)6A%]G+K
MZI7:\T>ME>'6*Q482V6K^1P.<\GDT445_"Y^I!1110 4444 %%%% !1110 4
M444 %%%% !7MWPP\2-KFA?9YVW75GB-F)Y9/X3^A'X>]>(UUGPOU0Z;XLMXR
MV(KH&%OJ>5_4#\Z_1^ ,ZGD^>T4W^[JM0DO\6S^4K:]K]SQLVPRQ&%EWCJOE
MO^![I1117]O'Y@%%%% 'GWQF_P"0#8_]?/\ [*U>05Z_\9O^0#8_]?/_ +*U
M>05_&/B=_P E)5_PP_\ 23])R/\ W*/JPHHHK\H/?"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *^F-/F\^PMI>N^)6ZYZ@&OF>OH[PU)YGAW2G
MQC=:1''_ 5_0_@]4MB<93[Q@_N
A_M&?\ )PGQ/_[&C5/_ $KEKSROT&G\$?0_I'"_
M[O3]%^04445H=04444 %?7'_ 3"_P"3D;K_ + -U_Z,AKY'KZX_X)A?\G(W
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MW=V?FLI.3
,O%;(R1&S;S+&V;H'DE'#X/.Q"
KZ'P#^V8+1?VH?B+]B(:'^TB6Q_STV)Y@_P"^]U>,5
H7T\ES
&_LE
MIY.J>-[^(FPTPG*PJ
TQ'*QC\V/ [LOY"?$3XC>(O
MBMXLO?$GBC4I=4U6Z;YI)#\J+DXC1>B(,\*.!5'Q=XNUCQYXDU#7]?U";5-7
MOY3-<74YRSL?T P !@ 5D5]EA,'#"Q[R[G[=D^2T
%O#5FUU?W39DD(/E6T0(WS2-_"BYY/
M?@#)(!4I**YGL9U*D:47.;LENR7X/?![Q+\
:XDR(;6(
M$;I96Q\JC/U)( !) K]F?@'\!_#G[/G@2V\/:#"'G8+)?ZDZ@37L^,%V]!UV
MKT4>^2:_[/?[/?AK]G7P1'H>AQ_:+V;;)J.JRH!->R@?>/\ =49(5 <*#W))
M/J-?(8W&O$/EC\*_$_%L]SR69S]E2TI+\?-_H@HHHKRCY$**** "BBB@ HHH
MH *\'_:G_:R\/_LV^&P"(M8\77B'[!HRR8P/^>TQ'*QC\V/ [LM+]K?]K?1_
MV
UB<2K4^
MB_F_X'G]Q>^(GQ&\1?%;Q9>^)/%&I2ZIJMTWS22'Y47)Q&B]$09X4<"N:HHK
MZM)15D?L,(1IQ4(*R04444RPHHHH *[;X/?![Q+\
:XD
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MB^++&QM8E@M[6VURZCBAC4!51%$@"J !P *X6O9M!_8W^,GBC0].UG2_ U
MW=Z9J-M'=VMPMS;@2Q2*'1@#(",J0>1GFOIJDJ<5^\:^9^JXF>&@D\2XI=.:
MWZG.?\-&?%C_ **?XR_\*"[_ /CE'_#1GQ8_Z*?XR_\ "@N__CE=E_PPW\<_
M^B?7G_@5;?\ QVC_ (8;^.?_ $3Z\_\ JV_^.UA[3#=X_@<'UC*OYZ?WQ.-
M_P"&C/BQ_P!%/\9?^%!=_P#QRC_AHSXL?]%/\9?^%!=__'*[+_AAOXY_]$^O
M/_ JV_\ CM'_ PW\<_^B?7G_@5;?_':/:8;O'\ ^L95_/3^^)QO_#1GQ8_Z
M*?XR_P#"@N__ (Y1_P -&?%C_HI_C+_PH+O_ ..5V7_##?QS_P"B?7G_ (%6
MW_QVC_AAOXY_]$^O/_ JV_\ CM'M,-WC^ ?6,J_GI_?$XF?]H3XIW4+13?$K
MQA-$WWDDUZZ93]09*Q]1^*7C/6(_+O\ Q=KU['@C9<:E-(,'J,%N^*]._P"&
M&_CG_P!$^O/_ *MO_CM2VW["/QVNY?+3P!<*V,YDO[2,?FTH%/VN&6TH_@4
ML5ED-54IKYQ/!Y)'FD:21F=V)9F8Y))ZDFFU]3:#_P $U_C5J[(+NPT?1 V,
MF_U-&VYQU\D2=,]L]#7K/@W_ ()/ZA(\
:_,QJY]EM%>]63]-?RN? %>P_ []E#XB?'RZA?0='>ST-FQ)KFH@P
MVB ==K8S(1TVH&.<9P.:_3'X8_L&_![X9R17*^'CXEU&/D7?B!Q=8/M%@1=>
M<[,CUKZ#AA2WB2*)%CC10JH@P% X ["O+K9LK6HKYL^3QW&$;.&"AKWE_E_
MG]QXC^S7^R5X0_9OTLR6"G6/$]Q'LN]
?+CR.@))[DX&/<:**^
M?J5)5).4W=GYOB,15Q51U:TN:3ZA11169SA7\\]?T,5_//7T>3_\O/E^I^F\
M%_\ ,1_V[_[<>N?LC^'HO%'[2WPZL9E5XEU:*Z96Z'R
/
M/^W#_P!(+:O:RG^._3]4?=<'_P"_S_P/_P!*B?/-?T,5_//7]#%=.
_'Y?VAOC!=ZY9(\6@V,(T_2XY!M9H%9F\QA
MV9V9FQU *CM7L992E*NJEM$?:\*X2K5QRQ"7NPOKYM6M^)XG7[)?\$_?^31?
M ?\ V_\ _I?
%Z,^PX4_Y&2]&?&U?IC_P2M^'<>F?#[Q5XUFC'VK5;Y=/
M@9ARL,*AF(/HSRD'_KD*_,ZOVF_8C\/KX;_99^']N$"M/9O>L<#+&:9Y03Z\
M.!] *]C-)\M#E75GVW%E=TLO]FOMR2^6_P"B/
_P"QHM__ $DNZ[<%_O$/
M4]W(O^1E0]3\L*_2G_@D_H,4'@;Q[K0"^==:E;V9/?;%$7';UF/>OS6K]3O^
M"5RC_AGWQ"V!N/BBX!..?^/2T_Q-?29D[89_(_4.*9..632ZM?G<^RJ***^.
M/Q(**** "BBB@ HHHH *_GGK^ABOYYZ^CR?_ )>?+]3]-X+_ .8C_MW_ -N/
M:/V,]*BUC]J+X=6\OW$U+[0./XHHWE7OZH*_;"OQL_X)_@-^UUX#R,_\?_\
MZ07%?LG7/FS_ 'T5Y?JSSN,9/Z[3C_<7YL****\0^#"BBB@ HHHH **** /R
MP_X*H?\ )PGA[_L5[?\ ]*[NOC:OLG_@JA_R<)X>_P"Q7M__ $KNZ^-J^XP7
M^[P]#]^R+_D6T/0_=7]G/_DWOX8?]BOI?_I)%7H=>>?LY_\ )O?PP_[%?2__
M $DBKT.OBZGQR]3\+Q7^\5/5_F%%%%9G*%%%% !1110 4444 %%%% !113)I
MH[:&2::18HHU+O(Y 55 R22>@ H ^
O"'C_"OQWK[=_X*)?M4:+\4'T_X?^$+Z/4]%TZY^V:AJ5N
\K7=S]NX8PE3"9>E55G)N5ON7Z'Z&?\ !)/_
M )JK_P!PK_V\K]#*_//_ ())_P#-5?\ N%?^WE?H97SV8_[U/Y?DC\XXE_Y&
MM;_MW_TE!117._$;Q)_PAOP]\4:_G;_96EW5]G&<>5"S_P#LM>>DY.R/FHQ<
MY**W9^+'[3GCMOB3\?O'6O\ F>9!-J
,'9&@0$^Y K8HHKX%MMW9_.LI.3
[
9UCC0=68G 'YFON<+#V="$?(_H')Z"PN7T:?\ =3?J]7^9^O?_
M 3R^'*^ _V:]'O9(O+O_$4TFK3DCG:QV0C/IY<:-_P,U],5D>#_ Y!X/\
M".B:#:X^S:78P6,6!@;(HU1?T45KU\76J>UJ2F^K/PK&XAXK$U*[^TV_\@HH
MHK$X@HHHH **** "BBB@ KRG]JKP6OC_ /9U\?Z/Y7G2G2I;N! ,DS0#SHP/
M
9-\,R&-U]5(P1^57"3A)270WH570JPJQWBT_N/Y[*
M^O\ _@F#XP;0_P!H&]T5W(@US2)HEC[&6)EE4_@BR_\ ?5?)NN:6^AZUJ&G2
M'=)9W$ENQ]2C%3_*O6/V-]>/AS]I_P"'5V&V^9JBV>?^NZ-!CJ.OF?\ Z^E?
M<8F*J4)KR/W[-*:Q& K0[Q?Y71^V=?//_!0+_DT7QY_VX?\ I?;5]#5\\_\
M!0+_ )-%\>?]N'_I?;5\;AOX\/5?F?AN5_[_ (?_ !Q_]*1^-M?H9_P23_YJ
MK_W"O_;ROSSK]#/^"2?_ #57_N%?^WE?5YC_ +K/Y?FC]AXE_P"156_[=_\
M2D?H91117Q9^%A1110 4444 %%%% !7SS_P4"_Y-%\>?]N'_ *7VU?0U?//_
M 4"_P"31?'G_;A_Z7VU=.&_CP]5^9Z>5_[_ (?_ !Q_]*1^-M?H9_P23_YJ
MK_W"O_;ROSSK]#/^"2?_ #57_N%?^WE?5YC_ +K/Y?FC]AXE_P"156_[=_\
M2D?H91117Q9^%A1110!\\_\ !0+_ )-%\>?]N'_I?;5^-M?LE_P4"_Y-%\>?
M]N'_ *7VU?C;7U>4_P !^OZ(_8>#_P#<)_XW_P"DQ/T,_P""2?\ S57_ +A7
M_MY7Z&5^>?\ P23_ .:J_P#<*_\ ;ROT,KQ
)?^1K6_P"W?_244]8U
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M=PHHHI$A1110 4444 %%%% !1110 4444 %%%
YR>]<#7WF'ING1C![I']"Y;AY87!TJ,]XI7]>I^ZO[.?\ R;W\
M,/\ L5]+_P#22*O0Z\\_9S_Y-[^&'_8KZ7_Z215Z'7PU3XY>I^ XK_>*GJ_S
M"BBBLSE/RP_X*H?\G">'O^Q7M_\ TKNZ^-J^R?\ @JA_R<)X>_[%>W_]*[NO
MC:ON,%_N\/0_?LB_Y%M#T/W5_9S_ .3>_AA_V*^E_P#I)%7H=>>?LY_\F]_#
M#_L5]+_])(J]#KXNI\
+HHF%GK.
MF_9)' R//@
V8Y(\#OM-?I]7D?[4GP)M_VA/A#J?AK,<.KQ$7FE7,APL5
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M'I[3_P!MD?5
GRK]Y+B-A^#"J57M!@-UKFGPKU>XC7\V%=N!YOK5+DWYHV]
M;HSJ6Y)7VL?25%%%?Z,'XV%%%% 'GWQF_P"0#8_]?/\ [*U>05ZY\:) NCZ?
M'_$TY8?@I_QKR.OXO\3FGQ+52Z1A_P"DH_2LC_W*/J_S"BBBORH]X**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ)\(R>9X6T@XQ_HL0_)0*^=
MJ^B?",?E^%M(&<_Z)$?S4&OW[P?O_:&*[
O.O^&Q_@K_T4;1O^_C?_$UYY_P4J_Y-AOO^PI9_^A&OR/KV\'@88FGS
MR;6I]YDG#]#-,*Z]2;3NUI;R\C]L_P#AL?X*_P#11M&_[^-_\31_PV/\%?\
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MHH *^N/^"87_ "
MKB':FCT\%EN*S"7+AX7\^B^?],^]JX#QE\?_ (;?#UI(_$/CC0]-N(_O6KWJ
M-./^V2DO^E?CO\2OVG?BA\69)AXC\9:E/9R]=/M9/LUKCICRH]JGCN03[UY=
M7LT\I_Y^2^X^YPW!KM?$U?E%?J_\C]=?$G_!2/X*:&SBTU/5M?*_] W377=Q
MT!F\OZ5YUKG_ 5=\'V^_P#L?P-K=\/X?MUQ#;9^NTR8_6OS/HKMCEF'CNF_
MF>]3X4RV'Q)R]7_E8^[?$'_!6#Q3<*W]B> M(TX_P_VA>2W>/3.P19KROQ5_
MP46^-GB1&2WURQ\/QMU72M/C!QZ!I0[#\"#7S-175'!X>&T%^?YGJTLCRVC\
M-!?/7\[G4>,OBGXQ^(DQD\3^*-7UXYW!+^\DE1?]U2=J_0 5R]%%=:2BK)'L
MPA&FN6"LO(****984444 %%%% !7]#%?SSU_0Q7SN
?-CD("#@=7((& &9?R#\7>+M8\>>)-0U_7]0FU35[^4S7%
MU.
9/<3'D]@H'15 P
M HX K#K[/"86.%C_>>[/W')\GI952MO-[O]%Y?F%%%%=Q]"%%%% !1174?
M#/X9^(?B[XRL/#'ABP:_U2[;@=$B0?>DD;^%%'4_@,D@%-J*N]B)SC3BYS=D
MB7X5_"WQ#\9/&^G^%?#-I]JU.\;[SG;'#&/ORR-_"BCDGKT !) /[(_LX_LX
M^'/V
L2(!+=R ?\ CL:Y.U,\9).2235_9F_9F\/?LW>#
M186 6_U^[56U36'3#W#C^%?[L:G.U?Q.22:]DKY''8UXA\D/A_,_&,^SV68S
M]A0=J2_\F\WY=E\WY%%%%>2?'!1110 4444 %%%% !7SU^UQ^UMI'[-_AL6M
MKY.I^-]0B+:?IK'*Q*
MP4#HJ@8 4< 5[.!P+K/VE3X?S/M^'\A>.DL3B5:DO_ ";_ ('?[B+Q=XNU
MCQYXDU#7]?U";5-7OY3-<74YRSL?T P !@ 5D445]8DDK(_8HQ44HQ5
MD@HHHH*"BBB@ KK?A7\+?$/QD\;Z?X5\,VGVK4[QOO.=L<,8^_+(W\**.2>O
M0 $D Q?#/X9^(?B[XRL/#'ABP:_U2[;@=$B0?>DD;^%%'4_@,D@']C/V9OV9
MO#W[-W@T6%@%O]?NU5M4UATP]PX_A7^[&ISM7\3DDFO.QF,CAHV6LGL?,YUG
M5/*Z7+'6H]E^K\OS+7[./[./AS]G'P4ND:0HO-6N0KZGK$B 2W<@'_CL:Y.U
M,\9).223ZU117QTYRJ2
//\ MP_](+:OV2K\;?\ @H%_R=UX\_[
>OH\G_Y>?+]3]-X+_YB
M/^W?_;CZ&_X)^_\ )W7@/_M__P#2"YK]DJ_&W_@G[_R=UX#_ .W_ /\ 2"YK
M]DJYLV_CKT_5GF<8?[_#_ O_ $J04445XI\*%%%% !1110 4444 %?C;_P %
M O\ D[KQY_VX?^D%M7[)5^-O_!0+_D[KQY_VX?\ I!;5[64_QWZ?JC[K@_\
MW^?^!_\ I43YYK^ABOYYZ_H8KISC_EW\_P!#T^-/^8?_ +>_]M"BBBOG#\R"
MBBO&/C-^UY\,O@:TUKKNNK>ZU$.=&TH"XN@<9PP!"QG_ 'V7J*N$)5'RP5V;
MT
M15
MVQRB'VIGO4^#**_BUF_1)?YG[$ZQ_P %"O@7I6X1^+9M1D7.4L]+NCZ=VC53
M^![5P^M?\%2?A78;TL-%\3ZI(/NLMK!%&>?5IMP_[Y[U^5U%=$
F42+_V:O)?&'_!3/XO>
M(EDBTH:)X8C885[&R,LH^K3,ZY^BBODZ&&2XE6.*-I9&.%1 23]!7IO@_P#9
M?^+/CR2-=&^'^N2QR?
YS5PQ=!S5&F[ORV-Z&<9?.O
M#!8:5V[VY5HK)O?;ITN?)-?LE_P3]_Y-%\!_]O\ _P"E]S7XVU^R7_!/W_DT
M7P'_ -O_ /Z7W-<>;?P%Z_HSQ>,/]PA_C7_I,CZ&HHHKY0_'@K\L/^"J'_)P
MGA[_ +%>W_\ 2N[K]3Z_+#_@JA_R<)X>_P"Q7M__ $KNZ];+/]X7HS[#A3_D
M9+T9\;5^Y_[-=LEI^SO\,DCSM/AK3I#D]VMHV/ZDU^&%?NK^SG_R;W\,/^Q7
MTO\ ])(J]'-_X
_[%>W_ /2N[KXVK[)_X*H?\G">'O\
ML5[?_P!*[NOC:ON,%_N\/0_?LB_Y%M#T/W5_9S_Y-[^&'_8KZ7_Z215Z'7GG
M[.?_ ";W\,/^Q7TO_P!)(J]#KXNI\
M^U"UTRV>XO+F&TMT&6EG<(B_4G@5^,OC;]N'XT^.6<3^-KS2+=ONP:(JV07Z
M/&!(?Q8UXSK7B+5?$EU]IU?4[S5+CG]]>W#S/SUY8DUZL,IF_CE;\?\ (^MH
M<&UY:UZJ7HF_\C]PM=_:.^%?AHLNH_$3PS!(N
DJ>GIWKS_ %[_ (*Q:+"'&B_#
MR_O#_"U_J26_XD*DGY9K\WZ*Z(Y9AX[J_P ST:?"N60^*+EZM_I8^SO%G_!4
MSXDZLKQZ'H&@:#&V<2/')=3+Z8+,%_-*^>?B7^T=\2OB\CP^*O%^HZC9.
\%Z[J\;G FM=/E:(?63;M'XFO?\
MP!_P30^+7BIHY-=&E^#[0X+?;KH7$^WU6.'<,^S,M:
Y!KT;_ %9\F45]^?'G]A#P3\ ?V8_&'B7[??>)/%=JMFL.H7!\B&$O>01N
M8X5/='8?.S]>,5\!UT4*\,1%RALG8]+ 9A0S*G*KA[N*=NW1/]3]#/\ @DG_
M ,U5_P"X5_[>5^AE?GG_ ,$D_P#FJO\ W"O_ &\K]#*^3S'_ 'J?R_)'X]Q+
M_P C6M_V[_Z2@KQC]LK5&TC]E_XBSKG+Z8;?@ \2NL9_]#KV>OGG_@H"2/V1
M?'F./^/#_P!+[>N;#J]:"\U^9Y.6QYL;0B^LX_FC\;:^O/\ @E_I*ZA^T;?7
M++G[!H%S.K'/#&6"/\\2-U]Z^0Z^X/\ @E+:,_Q6\9W((V1Z*L97OEIT(_\
M0#^=?88UVP\_0_;,]ER997?E^>A^G%%%%?#GX$%%%% !1110 4444 %%%% !
M1110 4444 ?@1\1M6;7_ (@^)]3
5FY_.G_ SU73="^)'A
M34M9+C1[/5K2XO3&F]O(29&DPO<[0>.]
5?!7_ )_M9_\ !8W^
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MU^R7_!0+_DT7QY_VX?\ I?;5^-M?5Y3_ 'Z_HC]AX/_ -PG_C?_ *3$_0S_
M ())_P#-5?\ N%?^WE?H97YY_P#!)/\ YJK_ -PK_P!O*_0RO%S'_>I_+\D?
M"\2_\C6M_P!N_P#I*"BBBO./F HHHH ^>?\ @H%_R:+X\_[
5^AE>+F/^]3^7Y(^%XE_Y
M&M;_ +=_])1\J_\ !2S5&T_]F.[@&<7VK6EN< = 6D_]IBOR1K]3_P#@J@3_
M ,,]^'_?Q1;_ /I)=U^6%>]E:MA_FS]!X3CRY;?O)_H??_\ P29TE9=:^).I
ME?G@M["V5N>DC3L0.W_+)?TK]&:^"O\ @D[:,GA'XAW)(V27UI&%[Y6.0G_T
M,?E7WK7@Y@[XF7R_(_/>))
_C+^W1\+/@[)<6,FK-XEUR$E&TW0]LQ1QQB23(
MC3!ZC<6&#\O:OCOXB?\ !4;XA>())(?"6BZ7X3M#]V:8&]NA[[F C_#RS]:[
MZ.!KUM5&R\SZ'!Y!F&-2E"G:+ZRT_P"#]R/U(K%U[QIX>\*KG6]>TS1QC.;^
M\C@_]#8>H_.OQ*\8?M)?%+Q\TG]N>/==NHI#EK:.\:" _P#;*/:GZ5YQ)(\T
MC22,SNQ+,S'))/4DUZ4,H?VY_
#)O6M62]%?\6U^1^W&M?M=?!G0=WVG
MXCZ#+MZ_8KG[5W _Y9!L]:XC5O\ @HE\#--)$/B>[U,CK]DTJY'<]Y$7_)K\
M?**ZHY316\F>K3X/P4?CG)_
.78:.\;_,]&GPSE=/64+^K?Z-'T]XT_P""D7QE\5))
M%87VE^%X7R,:38@OM_WYC(0?<8_"OG/Q7XTU_P =:L^I^(]:O]=U!A@W.H7#
MS.!G.T%B<#GH.!7HW@O]D7XQ>/)$&F> -8AB;D3ZE$+&/'J&G* CZ9KZ1^&O
M_!*OQ!J$D5QX[\66>DVW#-9:*AN)R.ZF1PJH?
TPF%V:7IN:_6LGRE/E
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M'0_'<,86.^8'R;U5&%CG YX' D ) X(8 ?E5\2?A7XJ^$/B*70_%NBW.C7Z
MY*"9?W
^&OB9H4FC>*=$L]
M>MA
F5()'M7Z$_%W_@ECI>HO->_#CQ(VDR')72=;W2
MP9]%G4;U'^\KGGK7QY\2OV3/BQ\*6D?6_!NH2629/]H::GVRWVC^(O'G8/\
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M%% !1110!^"?Q
8_P"]3^7Y(_"^)?\ D:UO^W?_ $E!1117
MG'S 5\^^._\ D<-5_P"NQ_D*^@J^??'?_(X:K_UV/\A7X1XO?\BK#_\ 7S_V
MV1]5P]_O$_3]48-%%%?RB??!1110 4444 %%%% !1110 4444 %%%% !77?"
MW2VU'Q9!*5S%:J9F/OC"_J?TKD:]R^&OAHZ!H(EF3;=W>)'SU5?X5_+GZDU^
MD^'^2SSC/*4FOW=%J
2_&B^$FI:=: \Q1-(1_O''_LM>
PMHNFR)5Z8Z "OZ'\'J=\3C*G:,%][E_D?'\12]RFO-_
MH6****_IX^'"BBB@ HHHH **** "BBB@ HHHH ^5_P#@I5_R;#??]A2S_P#0
MC7Y'U^NO_!2.U>X_9=U5T VPZC9R/SV\S;_-A7Y%5];E7\!^O^1^R\(_\BY_
MXG^2"BBBO8/M@HHHH *^R?\ @E?_ ,G">(?^Q7N/_2NTKXVKZE_X)LZ]#H_[
M3VGVTK!6U33+NSCR?X@HFQ^4)KDQBOAY^AXF=1
'_ ()^ ]0\5^);GR;"U&V.%,&6YE.=D,:DC<[8/T ). "1V=?C
MY^W=^T)/\:OB]=Z7I]RS>$_#DCV5E&K?)/,IQ-<<==S#:I_N*IXW&OE,'AGB
M:G*]EN?C^2Y6\TQ/LWI!:R?EV]6<1^T1^TYXO_:,\1M=ZU
Z-MX=T#4]=G!P8]-LY+AA]0@.*3:2NR92C!
S?G[1K=TL9Q_P!
EO*_IJ?/XK/\NPB?-54GVCK^
M6GWL_,:BOKO_ (*1^ _#OPY^)'@W1_#&BV6A:;'H((M[*$1JS?:)1N;'+,<<
ML
>OZ&*^=
MSC_EW\_T/S'C3_F'_P"WO_;0HHHKYP_,@HHKQ']J3]J30?V;?"/GS^7J7BF^
M1AIFCA\&0]/-DQRL2GJ>K$8'
3(OVK/VH]&
M_9M\%F;,&H>+;Y"-+TEF/S'H9I,
+M0\2^)=0DU+5[Y]\DK\!
M1_"B+T55' 4< "N=K[+!X2.%CWD]V?N&39-3RJEWJ/=_HO+\PHHHKO/HPHHH
MH ***W/!'@C6_B-XIT_P[X=T^74]8OY/+@MX1R>Y8GHJ@9)8\ DTFTE=DRE
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M0]/-DQRL2GJ>K$8'
^??)*_ 4?PHB]%51
MP%' KU\#@77?M)_#^9]ID&0RS"2Q&(5J2_\F_X'=_)>4/C?QOK?Q&\4ZAXB
M\1:A+JFL7TGF3W$QY/8*!T50, *. *PZ**^M225D?LL8QA%1BK)!1113*"
MBBB@ KHOA[\/=?\ BEXNT_PUX:T^34M7OGV1Q)P%'\3NW154
"-
M;^(WBG3_ [X=T^74]8OY/+@MX1R>Y8GHJ@9)8\ DU^Q'[*/[+>C_LV^#?)
M)AU+Q;?J&U/5E3KT(AB)Y$2G\6/S'' 7@Q>+CA8]Y/9'SF
3V ]MHHKXV
MI4E4DYS=VS\/Q&(JXJK*M6=Y/<****S.<**** "BBB@ HHHH **** "BBB@
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MT_5GF<8?[_#_ +_ -*D%%%%>*?"A1110 4444 %%%% !7XV_P#!0+_D[KQY
M_P!N'_I!;5^R5?C;_P % O\ D[KQY_VX?^D%M7M93_'?I^J/NN#_ /?Y_P"!
M_P#I43YYK^ABOYYZ_H8KISC_ )=_/]#T^-/^8?\ [>_]M"J^H:A:Z387-]?7
M,5G96T;337$[A(XT499F8\ DDU8K\X?^"E/[2]Q>:P?A-X?NC'8VHCFUV:
M%B#-*0&CMN/X5!5V]6*CC8<^-AZ$L144$?#Y9E]3,\3&A#3JWV7?^NI@_M6?
M\%#M8\:75YX8^&5U/HGAU6:*;7(\QW=[C(_='K%&?7ASQRO*GXEDD>:1I)&9
MW8EF9CDDGJ2:;7O7[+?[(_B3]I/67GC=M%\(V<@2]UB1,Y;KY4*_QR8QGLH(
M)Z@-]A&%'!T]-$C]MI4<%DF&;5HQ6[ZOU[O^D>$V]O+>7$<$$3SSR,$2.-2S
M,QX '4U[GX"_8?^,_Q 6.6V\&W.D6;_ /+SK;K9 ]]CD2$?1#7ZI_!W]F[
MX?? JPCA\*Z!##?!-LNK70$U[-Q@EI2,C/\ =7:OH!7IU>-5S9WM2C]Y\/C.
M,9W<<'3T[R_R7^9^:/AC_@E%XKO%4^(?'.CZ63U73;66\(_[[,5>GZ'_ ,$I
MO EN!_;'C'Q#?MW^Q+!; _\ ?225]OT5Y\LPQ,OM6/FZO$F:5?\ E[;T27Z7
M/E[1?^";_P $=*V_:M'U36<=?MNJ2KGK_P \BGK^@KT'0?V0?@QX
?GYQ?->P45S2Q%:6\W]YYE3,\=5^.M)_P#;S,G0O"6A^%XRFC:-
MI^D(1@K8VL<(QUQ\H%:U%%8-MZL\Z4G)WD[A7YY_\%;/^:5?]Q7_ -LZ_0RO
MSS_X*V?\TJ_[BO\ [9UZ&7?[U#Y_DSZ7AK_D:T?^WO\ TEGYYU^R7_!/W_DT
M7P'_ -O_ /Z7W-?C;7[)?\$_?^31? ?_ &__ /I?
_[%>W_P#2N[K]3Z_+#_@JA_R<)X>_
M[%>W_P#2N[KULL_WA>C/L.%/^1DO1GQM7[J_LY_\F]_##_L5]+_])(J_"JOW
M5_9S_P"3>_AA_P!BOI?_ *215Z.;_!#U/I^,O]WH^K_(]#HHHKY@_* HHHH
M**** "OC;_@JA_R;WX>_[&BW_P#22[K[)KXV_P""J'_)O?A[_L:+?_TDNZ[<
M%_O$/4]W(O\ D94/4_+"OU/_ ."5_P#R;WXA_P"QHN/_ $DM*_+"OU/_ ."5
M_P#R;WXA_P"QHN/_ $DM*^CS/_=WZH_3>*_^1:_5'V31117QY^*A1110 444
M4 %%%% !7\\]?T,5_//7T>3_ /+SY?J?IO!?_,1_V[_[
SD4_-:0@#S;@>C#
SE^"57][46G1=S[?AO(H8M?7,4KPZ+OYOR_/\ /3\4>*M8\:ZY
M
?!6TM;R]L8O%WBE0&DU34
MX@\<;_\ 3&$Y5 .Q.7_VNP]G$8REA59[]C[C,LYPF4Q4):RZ17]:+^DC\QOA
MW^S#\4OBM%#/X;\%:G=V4HRE]<(+:V8>JRRE5;\":^@O"G_!+'XBZHJ2:[XC
MT#0HV&3'"TMU,OL0%5?R
%4S6M+X$D?GV(XNQU1_N8J"^]_CI^!\'Z
M!_P2?\-6ZK_;?C[5;\_Q?V?8Q6OY;VDKT#1?^"9GP:TO'VE?$&L8_P"?W40N
M>O\ SR1/7]![U]845R2QN(EO-GBU,^S.K\5=_+3\K'AVA_L1_ _P^0;;X>Z?
M,1S_ *=-/=?I+(PKTKP[\+_!OA!D.A>$M#T5D.5;3]-A@(.
#_ /<)_P"-_P#I,3]#/^"2
M?_-5?^X5_P"WE?H97YY_\$D_^:J_]PK_ -O*_0RO%S'_ 'J?R_)'PO$O_(UK
M?]N_^DH*^>O^"@"EOV1O'H4$G%@>/:_MZ^A:\9_;(THZS^S!\1;<9RFEM
3ELN7&T)/I./YH_$VOM_P#X)2W3I\6/&5L,>7)H
MBR'CG*SQ@?\ H9KX@KZY_P""8.L+IO[2%U;,1G4-!NK90?420R_RB-?88U7P
M\_0_;,]CSY;77E^6I^K]%%%?#GX$%%%% !1110 4444 %%%% !1110 4444
M?STR1O#(T
E_LRZ?8ZM^T%\/['4M/M-5T^ZUBWMY[.^A6
M:&5';:0R-PW![]P*Y;XEZ0?#_P 1O%6EL-K6.K7=L1SQLF=>_/:KOP8UE?#O
MQ@\"ZJY 2QUVQN6+=,)<(QSR../6OT"?O4W;JC^CZ]ZN&FX]8O\ %'[2?\,Y
M_"C_ *)AX-_\)^T_^-T?\,Y_"C_HF'@W_P )^T_^-UZ'17P?M)_S,_GKZUB/
M^?C^]GGG_#.?PH_Z)AX-_P#"?M/_ (W1_P ,Y_"C_HF'@W_PG[3_ .-UZ'11
M[2?\S#ZUB/\ GX_O9YY_PSG\*/\ HF'@W_PG[3_XW1_PSG\*/^B8>#?_ G[
M3_XW7H=%'M)_S,/K6(_Y^/[V>>?\,Y_"C_HF'@W_ ,)^T_\ C='_ SG\*/^
MB8>#?_"?M/\ XW7H=%'M)_S,/K6(_P"?C^]GGG_#.?PH_P"B8>#?_"?M/_C=
M'_#.?PH_Z)AX-_\ "?M/_C=>AT4>TG_,P^M8C_GX_O9YY_PSG\*/^B8>#?\
MPG[3_P"-T?\ #.?PH_Z)AX-_\)^T_P#C=>AT4>TG_,P^M8C_ )^/[V>>?\,Y
M_"C_ *)AX-_\)^T_^-U);_L^_"VSN(KBW^&OA"">)P\
@VJLC Y# B/((/
M>N_HH]I/^9B^M5_^?C^]A7SS_P % O\ DT7QY_VX?^E]M7T-7SS_ ,% O^31
M?'G_ &X?^E]M6N&_CP]5^9U97_O^'_QQ_P#2D?C;7Z&?\$D_^:J_]PK_ -O*
M_/.OT,_X))_\U5_[A7_MY7U>8_[K/Y?FC]AXE_Y%5;_MW_TI'Z&4445\6?A8
M4444 %%%% !1110 5\\_\% O^31?'G_;A_Z7VU?0U?//_!0+_DT7QY_VX?\
MI?;5TX;^/#U7YGIY7_O^'_QQ_P#2D?C;7Z&?\$D_^:J_]PK_ -O*_/.OT,_X
M))_\U5_[A7_MY7U>8_[K/Y?FC]AXE_Y%5;_MW_TI'Z&4445\6?A84444 ?//
M_!0+_DT7QY_VX?\ I?;5^-M?LE_P4"_Y-%\>?]N'_I?;5^-M?5Y3_ ?K^B/V
M'@__ '"?^-_^DQ/T,_X))_\ -5?^X5_[>5^AE?GG_P $D_\ FJO_ '"O_;RO
MT,KQ
)?^1K6_[=_P#24?&__!5!2W[/>@$ D+XHMR?;_1+NOROK];_^
M"E6E'4/V8;VX&<6&JV=P<'U9HN?^_M?DA7O96[X?YL_0>$Y
X^*GQ$N/!.C71'A+PY<-$_E,=M[>+\LDC=BJ'
,KMDGC3=/-[R2
MMEWZ=S]*WQ.84Z#Y(ZL[\TXDPV7R=&FN>:^Y>K_1?@?E+X%_8$^-/CA8Y3X8
M7P]:OTGUVX6V(^L7,H_%*]M\,_\ !)[7;A4;Q#\0-.L#U:/3+"2Y_ ,[1_GM
M_"OTCHKQ9YGB)?#9?UYGPU?BO,:K]QJ'HO\ .Y\4:'_P2K^'=KM.J^*O$FH.
M.2+9H+=#]08W./H:[[1/^"<_P/TD+]H\/7VL,H'S7VJ3C)XY(B9!V],
7R=ORL>4>'_V4O@]X996L?ASX?9UP5>\LENF!'0@
MR[CGWKT?1_#^E^';?[/I6FV>F0
'H?OV1?\BVAZ'[J_LY_\F]_##_L5]+_])(J]#KSS]G/_
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MW>OW=ILB+(C(ZAT88*L,@CT->C3S6M'XTG^!]/AN+\;2TKQ4U]S_ T_ _GI
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M
_?U_P ]S]Y:*Y/X4_$C2OB]\/=#\7Z*V;#5+<2B
M-CEH7!*R1-_M(X93[K765\=).+:>Y^)SA*G)PFK-:,****1 4444 ?C+^WEH
MO]B?M6^.HP ([B2VND(XSYEM$S=_[Q8?AFO :^P?^"H?A\Z7^T)INHJO[O4]
M"@D+8_Y:)++&1_WRJ?G7Q]7W>%ES4(/R1_0F45/:Y?0E_=7X*P4445U'KA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?H9_P23_ .:J_P#<*_\
M;ROT,K\\_P#@DG_S57_N%?\ MY7Z&5\7F/\ O4_E^2/POB7_ )&M;_MW_P!)
M04445YQ\P%?/OCO_ )'#5?\ KL?Y"OH*OGWQW_R.&J_]=C_(5^$>+W_(JP__
M %\_]MD?5
^TP+#>GEX>B2^_LWZ']:_"\HX2QF>976Q^ ]Z=.5G#JU9.\>[
M7;KTUT?U.(S"GA:\:57126_^9X[14UY9SV%P\%S$\$R'#)(,$5#7P\X2IR<)
MJS6Z9ZB::N@HHHJ1A1110 4444 %%%% !10H+$ #)/ KT;P5\+I;MH[W64:
M& '
&?_>]![=?I7T&2Y#C^(,2L+@87?5_9BN\GT_-]$V
!VU6X35;V/_0HFS%&P_UK#O\ [H_4_C7L--CC2&-8XU5$4855& !Z
M 4ZO[8X9X;PW#.!6$H:R>LI=9/\ 1+HNGK=GYECL9/'5?:2VZ+L%%%%?6GGA
M7,_$+Q"/#_AV9D;%U
M(3DO=CJ_T1SM%%%?Q,?IH4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!/8V_P!JOK>#&?,D5/S(%?3-?/7@FU^U^+-*CQG%PK_]\_-_2OH6
MOZB\'\/RX/%XC^:48_\ @*;_ /;CX;B*=ZE.'9-_?_PP4445_09\@%%%% !1
M110 4444 %%%% !1110!XC^VMX>?Q-^RU\0K1$+M%8+>_+U @ECG)_*,U^*M
M?T"^)M!MO%7AO5M$O!FTU*TFLYA_L2(4;]&-?@3X@T6Z\-:]J6D7R>5>Z?
4K]HMB!);W('021ME6ZG!ZC)P17U=H7_!5WQ9;
M6836/ NCZA<@#][9W4MLI_X"PD]N]?+5LKJQE^ZU1^1X[A/%TZC>$M./36S7
MK?0_2^OGG]MK]H*Q^"'P?U.V@NT'BO78'L=,M58>8N\;9+@CJ%122#_>*CN<
M?(OC'_@JAX]U:Q>#P[X8T7P](Z[?M4[27DB>Z [5S_O*P]J^1/&WCKQ!\1_$
M5SKOB;5KK6M6N,>9=73[FP.B@=%4=E '85IALLGSJ5;1+H=.5\*UU6C5QME
M%:VO=O\ 2QA4445],?JP4444 %%%% !7VC_P2MTDW/QP\2ZB5#1VOA^2($C[
MKR7$&#GMPCC\37Q=7Z._\$GO";0^'?B!XG>/*7-U;:;#)Z&)'DD _P"_T7Y"
MO/Q\N7#2/F^(JJI995?>R^]H^JOVGOB))\*_@'XV\26\I@O;>P:&TD7JEQ,1
M#$P^CR*?PK\.*_6#_@IYK$FF?LW6ULA8+J.O6MJ^WH5$
$]K37O-V7^?
MX#/A!_P3\^%/PQMX)M3TL>-M:4#?>:XH>'=CG9;?ZL+GH'#D?WJ^CM/TVTTF
MSBM+&UALK6(;8X+>,1H@] H&!5FBOCJE6I5=YNY^)8C&8C&2YZ\W)^?]:!11
M161QGY>?\%5IT;XU>%(0V94\/([+Z W,X!_\=/Y5\55],_\ !13QM%XP_:=U
MBW@<2PZ'9V^E!U.0653*X_!YG4^ZFOF:ONL'%QP\$^Q_0&2TW2RZA&7\J?WZ
MA11176>V%%%% !7]#%?SSU_0Q7SN
EZ2K8>YD &68_P ,:Y&YO< 9)%?/PA*I)0BK
MMGYS0H5,34C1I*\GLAO[3/[3/A[]F[P:;^_*W^OW:LNEZ.CX>X
)_$EZU]JM_(9'8D[8U_AC0$_*BC@+V J3XF?$
MSQ#\7?&5_P")_$]^U_JEVW)Z)$@^['&O\**.@_$Y))/+U]E@\''"QN]9/<_;
M\ER6GE5*[UJ/=_HO+\PHHHKT#Z4**** "BBNL^%_PM\2_&/QA:>&O"NG/J&I
MW'S'^&.",$;I9&Z*@R,D^H R2 5*2BKO8B
_#W7_BEXNT_P
MUX:T^34M7OGV1Q)P%'\3NW154
(?B[XRO\ Q/XGOVO]4NVY/1(D'W8XU_A11T'XG)))]; X)XA\\_A_
M,^RR'(99C)5ZZM27_DWDO+N_DO*/XC?$37?BKXRU+Q/XDO6OM5OY#([$G;&O
M\,: GY44
P%
&O"NG/J&IW
M'S'^&.",$;I9&Z*@R,D^H R2 ?V#_9E_9=\-_LV^%OL]@JZCXDO(U&I:U(N'
MF(YV(/X(@>B]^"23T\_%XR.&C;>3Z'S6
%R28=5\87T8&I:N%XQU\F'(RL0/T+$9/\*K[S117QU2I*K)SF[MGXEB,
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M'_V__P#I!
//^W#_T@MJ_9*OQ
MM_X*!?\ )W7CS_MP_P#2"VKVLI_COT_5'W7!_P#O\_\ _\ TJ)\\U_0Q7\\
M]?T,5TYQ_P N_G^AZ?&G_,/_ -O?^VF%XZ\66O@/P5KWB2^YM-(L9[Z5
+?$6IZWJ
/^^ ]?C?6F4TTJ
KB.K=O
MDE?]3I_AAX U#XJ?$+0/"6F<7FK7:6RR;21&I.7D(]%4,Q]E-?N;\._A_HWP
MM\%Z3X6\/VHM=+TV!88EP-SG^)W('+L
"ORP_X*
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M>3_\O/E^I^F\%_\ ,1_V[_[
GZL\SC#_?X?X%_P"E2"BBBO%/A0HHHH *
M*** "BBB@#\L/^"J'_)PGA[_ +%>W_\ 2N[KXVK[)_X*H?\ )PGA[_L5[?\
M]*[NOC:ON,%_N\/0_?LB_P"1;0]#]U?V<_\ DWOX8?\ 8KZ7_P"DD5>AUYY^
MSG_R;W\,/^Q7TO\ ])(J[G5-0CTG2[R^FXAM87G?G'RJI8\_05\94_B2]3\+
MQ*OB)I?S/\S\;/VX_B;)\3OVD?%,JS&33]&E_L6S7.0JP$K)CU!E,K9]&%>"
M58U&_FU74+J]N&WW%S*TTC>K,22?S-=S^SWX/B\??'+P+H%Q&)K6\U>W6XC(
MR&A5PT@_%%:ONHQ5"DETBC^@J4(8#"*/V81_)'ZJ_L3_ M?@;\'-.:YM0G
MBG7(DO\ 59G7$B%ES'!Z@1J<$?WBY[U]!445\)4J2JS
VTH.//UG6+> 1]S'&KRLWT#(@_X$*_**OK
)?^1K6_P"W?_24%<]\1/#9\9?#_P 3: &
M.JZ7=6."< ^;$R?^S5T-%>>G9W1\U&3A)26Z/YZ&4HQ5@58'!!ZBO:?V,/%B
M^#?VGOA_?.^R*>__ +/?YL _:$: 9]LR _A6+^T_X&/PY_: \=Z$(S%!%JDL
M]NN.D,Q\Z(?@DBC\*\YTG5+G1-4L]1LY##>6
IEF!>8XJ&&3M>^N]K*Y]\_\)'I/_04L_\ P(3_ !JY;W4-Y");>6.>
M(]'C8,I_$5_/97[3?L1^_9;\ VKH4DN;-]0;=U;SY7F4_P#?+K^ %=N+
MP*PL%+FO=]CW,YR".4T(U?:\S;M:UNC\V?F+^VEX7/A+]J#X@VFS:EQJ']H*
M0,!OM"+.3^
(X2#'JVG6]\,=O,C5\?AG%=!7RW_P3D^(R^-OV<;#2I9
M]_X;NI=-D4GYC&3YL38]-LFP?]
,M)\,:%<:O/JVIS""WCDT]E7=@DDG
M/ !)/H*Z7A:Z5W!V/5EE6/C%S=&5EK>SV/HFOGG_@H%_P FB^//^W#_ -+[
M:OH:OGG_ (*!?\FB^//^W#_TOMJ,-_'AZK\R
3CVR/S%?5YA_NL_E
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M&5^>?_!)/_FJO_<*_P#;ROT,KQ
?^"@7_)HOCS_ +
5^AE>+F/\ O4_E^2/A>)?^1K6_[=_])1XY^V'X9;Q;^S'\1;!%WM'I
M;7P7_KW9;C_VE7XE5_0;JVEV^MZ7>:==IYEK>0O;S)_>1U*L/R)K\"O&7AFY
M\%^+M;\/WH(N]*O9K*;(Q\T;E#^HKU,HG[LX?,^LX-KITJU#LT_OT_1'TK_P
M31\6+X?_ &EH=/=]J:YI5U8A2V 77;.#]<0,/Q-?K77X,_!KQX_PQ^*WA/Q4
MK,J:5J4-Q,%ZM"& E7\4+#\:_>*WN([JWCGAD66&10Z2(
BZ.AE7/W)II&
[0RSVU.-1SM?R_X)^@X#A3ZYA88B5;E
MW+?]3^A6&9+B-9(G62-AE70Y!'J#7F?[37Q+;X1? GQCXH@E\J^M;(PV;#J+
MF4B*(@=\.ZM]%-=!\'_#!\%_"?P;H#H8Y--T>TM)%;KO2%5;/OD&OF/_ (*E
M^(&T_P"!.A:7&^U]1UV(N,_>CCAE8C'^\8Z\W#TU4KQATN?+9=AHXC,*=#>/
M-]Z3_P C\LV8NQ9B68G))ZFO4OV9/@S)\>?C-H7A5C)'IKN;K4IH^#':Q\R8
M/8MP@/9G6O+*_0K_ ()/^#XBWC_Q5)&#,HMM,MY,
!P%6M#=*R]7I^&Y^@6CZ/8^'M)L]+TRUBL=.LXE@M[:!0J11J,
M*J@= *N445\*?S^VV[L****!!1110 4444 %%%% 'Y6?\%3)XYOVAM#1&W-
M%X9MT<>A^TW38_)A^=?'5?2G_!0_Q5'XE_:D\0PQ.)(M)MK73PPZ96(2./P>
M1A]0:^:Z^ZPBY
A^_
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M\*?%^@W"*\>H:5
XK\%Z^MRRM*K2<9?9_(_9>%<=4Q>$E2
MJN[@[?)[?=J?H?\ \$I_B9+-'XP\ 7,Q>.)4UFRC)SL!(BGQ[9,!P.Y/K7Z$
MU^/_ /P3GUI]+_:J\.VR%@NI6E[:OCN!;O-SSZQ"OV KQ\R@H8AM=5<^)XJH
M*CF3E'[:3_3] HHHKRCY **** /S[_X*Q^&=^G_#SQ$B8\N6[L)GV]=PCDC&
M?;9+Q[FOSKK]>?\ @HYX0/BC]F'5KQ$WRZ'?6NI* ,G&_P EC^"SL3["OR&K
M[#+)\V'2[-_YG[9PK6]KEL8_RMK]?U"BBBO5/KPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /T,_P""2?\ S57_ +A7_MY7Z&5^>?\ P23_ .:J
M_P#<*_\ ;ROT,KXO,?\ >I_+\D?A?$O_ "-:W_;O_I*"BBBO./F KY]\=_\
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M$_M/[F>2T5Z]#\&--4_O;^Z
4%B"LMVAZ>R'^OY5\YGV?X+AW"/%XV7I'K)]DOS>RZG;A,)
M5QE3V=->KZ(K_$[QT+G?H^GRYB!Q
OY>M>:T45_#^?9[BN(<=/
M'8IZO1+I&/1+^M7=GZ?A,+3P=)4J?_#L****^=.P**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH [/X2V?VCQ
%Y/SPO_LU>VUYA\%;
M'Y-3O".I2%3^9/\ -:]/K^S_ RP?U7ARG-K6I*4OQY5^$4?FN=U/:8V2_E2
M7Z_J%%%%?JQX(4444 %%%% !1110 4444 %%%% !7Y%_\%%OA2_P]_:"O-:@
M@\O2O%,0U&%E7"B<82X7/=MP$A_ZZBOUTKY^_;:^ K_';X+WD&G0>;XET5CJ
M.F #YI653YD _P!]<@#^\J>E>A@:_L*R;V>A])P_CU@,=&4W:,O=?SZ_)_@?
MC112LI1BK JP."#U%)7VI^[A1110 4444 %%%% !1110 4444 %%%% !1110
M 5^T_P"Q;\-'^%O[./A+3KB(PZC?0G5;Q6&&$DYWA6'8K&8U/NM?F-^Q[\#)
M/CQ\:M)TNXM_-\/:
U?M2 % & *^=S:LO=HK
MU9^9<88Y6A@HO7XG^GZO[CXY_P""IT;R?L]:"RJS!/$]NS$#.T?9;L9/IR0/
MQK\KJ_8G_@H-X3?Q5^RWXF>)#)/I4MOJ2*!V24*Y_"-W/X5^.U=>5RO0MV9[
M'"512RYQ723_ $84445ZY]J%%%% !7ZY?\$Y?B98^-/V=]/T%9U;5_#,TEE=
M0LWSB-Y'DA?']TJQ4>\;>E?D;79_"7XO>*/@GXPM_$OA34#97\8V21N-T-Q&
M>L
?2REU;$]VPS*ZCVPV/4UWEU_P4J^"MO;B2.^UFY<
MKN\J+3&# YZ?,0,]^N*^4E@\1%V<&?D%3(\RIRY70E\M5]Z/JBO'OVGOVC-$
M_9T^'MSJEW-%/X@ND>+2-+)R]Q-C[Q Y$:9!9OH.K 5\I?$[_@JN);26V^'W
MA"2&9P0NH>('7Y/<01,03[F3''0U\,>/_B)XD^*7B6XU_P 5:O<:UJT_#3W!
M'RJ.BHHPJ*,G"J !GI7?ALMG*2E6T78^BROA;$5:BJ8U
(+:&XD2*-!T"A1VZDDG)))_;ZOPJ_:,_Y.$^)__8T:I_Z5
MRUEE*7M)/R.3@V*>)JMK517YGGE%%%?3GZR%%%% !1110 5TO@SXF>+?ATM\
M/"WB35/#IOE5;EM+NGMVE"YVY9"#QN;'UKFJ*32DK,B4(U%RS5T=_
+YHFZQR:]=,IYSR#)5+_ (73\0O^A[\3?^#BX_\ BZXVBI]G#LC)
M8>BMH+[D=E_PNGXA?]#WXF_\'%Q_\71_PNGXA?\ 0]^)O_!Q
C_(ON1V7_"Z?B%_T/?B;_P<7'_Q='_"Z?B%_P!#WXF_\'%Q_P#%UQM%
M'LX=@^KT?Y%]R.R_X73\0O\ H>_$W_@XN/\ XNC_ (73\0O^A[\3?^#BX_\
MBZXVBCV<.P?5Z/\ (ON1^DO_ 2U\:>(?&'_ LW^WM>U/6_L_\ 9GD_VC>2
M7'E;OM>[;O8XSM7..N!Z5]YU^>?_ 23_P":J_\ <*_]O*_0ROCLP26)DEY?
MDC\0XDBHYI6459>[_P"DH_$']K#Q=K'B_P#:)^($NL:A-?M8:W>Z;:B4\06T
M-Q(D4:#H%"CMU)).223Y+7H?[1G_ "<)\3_^QHU3_P!*Y:\\KZ^DDJ<4NQ^U
M8.*CAJ:BK+E7Y!1116IV!1110 4444 =+X,^)GBWX=+?#PMXDU3PZ;Y56Y;2
M[I[=I0N=N60@\;FQ]:VKC]H/XI7<+13_ !*\7S1-UCDUZZ93SGD&2N HJ'"#
M=VCGEAZ,I
_$W_@XN/_ (NC_A=/
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M7ZGZ;P7_ ,Q'_;O_ +
GZL\SC#_?X?X%_Z5(****\4^%"BBB@ HHHH **
M** "OQM_X*!?\G=>//\ MP_](+:OV2K\;?\ @H%_R=UX\_[
GQI_P P_P#V]_[:
M?*__ 4J_P"38;[_ +"EG_Z$:_(^OV5_;W\-OXD_96\9K%'YD]DMO?)QG CG
MC+GVQ'OK\:JZ
-F2:Q,GWM^1\/Q1!QS2HWU47^"7Z!1117F'R@4444 %%%% !1110!!>
MWL&FV<]W=3);VMO&TLLTC;51%&68GL 37X8?M!?$YOC)\9O%?BX%OLVH7C?
M9%<8*VR 1P@CL?+1<^^:^^?^"CO[34'A#PI-\+] NPVOZQ$#JTD39^R6;#/E
M'T>48X_N9S]]37YB5]1E>'<(NM+KMZ'ZSPEELJ-*6,J*SGHO3O\ -_D%?LE_
MP3]_Y-%\!_\ ;_\ ^E]S7XVU^R7_ 3]_P"31? ?_;__ .E]S5YM_ 7K^C.C
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M_@E?_P F]^(?^QHN/_22TKZ/,_\ =WZH_3>*_P#D6OU1]DT445\>?BH4444
M%%%% !1110 5_//7]#%?SSU]'D__ "\^7ZGZ;P7_ ,Q'_;O_ +
GZL\SC
M#_?X?X%_Z5(****\4^%"BBB@ HHHH **** /RP_X*H?\G">'O^Q7M_\ TKNZ
M^-J^R?\ @JA_R<)X>_[%>W_]*[NOC:ON,%_N\/0_?LB_Y%M#T/W5_9S_ .3>
M_AA_V*^E_P#I)%70_$;_ ))[XH_[!=U_Z):N>_9S_P"3>_AA_P!BOI?_ *21
M5W6I6$6JZ;=64XS#
A_LP^+HO O[07@#6;A_*MH=6ABFD/1(Y#Y3L?8*Y/X5]Q67-2DEU3
M_(_?L=%U<'5C#=QE;YIG[DT445\"?SH%%%% !1110 4444 %%%>._M2_M"Z9
M^SK\,;O69GCFUZ\#6VCV#')GN,??(_YYID,Q^@SEA5PA*I)0BM6;T*%3$U8T
M:2O*6B/@O_@IE\7(?&_QDL?"=A.)K'PK;M%,5.1]KEVM*/?:JQ+[,'%?'M6M
M6U6[UW5+S4M0N'N[^\F>XN+B0Y:21V+,Q/J22?QJK7WE&DJ-.--=#^A<#A(X
M'#0P\?LK\>K^\_0S_@DG_P U5_[A7_MY7Z&5^>?_ 23_P":J_\ <*_]O*_0
MROD
U?7Y;
M6]I1Y'O$_:.%L
*?A?J/@*]N-VI^')C
M/:H[
'=#
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M\%_@3XG\0).(=3> V.F\_,;J4%8R/4K\TGTC->N5^47_ 46_:&3XH_$J+P;
MHMR)O#GA>1XY)(SE;F^/$C>XC'[L>_F$$AA7=@Z#KUDNBU9]!D>7O,,;N
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M@ HHHH **** "ORC_P""F'Q7C\
M/_9Y^%FH>(9VCFU>8&VTFQ<\W%RP^7(_N+]YCZ#'4BOQ+U;5
M;O7=4O-2U"X>[O[R9[BXN)#EI)'8LS$^I))_&O?RJ@W)UGLMC]&X1R^4JLL=
M-:+1>O5_):?,JU^AG_!)/_FJO_<*_P#;ROSSK]#/^"2?_-5?^X5_[>5ZN8_[
MK/Y?FCZ[B7_D55O^W?\ TI'Z&4445\6?A84444 ?//\ P4"_Y-%\>?\ ;A_Z
M7VU?C;7[)?\ !0+_ )-%\>?]N'_I?;5^-M?5Y3_ ?K^B/V'@_P#W"?\ C?\
MZ3$_0S_@DG_S57_N%?\ MY7Z&5^>?_!)/_FJO_<*_P#;ROT,KQ
?^"@7_)HOCS_ +
5^AE>+F/\ O4_E^2/A>)?^1K6_[=_]
M)05^2G_!2+X6GP+\?I-?MX=FF^*;9;Y"HPHN$ CG7ZY".?\ KK7ZUU\Z?MW?
M ^3XT? R^;3K
*S98HH_<2>N#'
MA
&-6"V.KQ@$[8RWR3 >L;<^NTN!R:^
MEQV'^L46ENM4?J7$&7/,,$XP7OQU7ZKYK\;'[0T5%:W4-]:PW-M-'<6\R"2.
M:)@R.I&0RD<$$
WL&FV<]W=3);VMO&TL
MLTC;51%&68GL 34]?&G_!2#]H6+P'\._P#A7NDW(_X2#Q)%_IGEM\UM89PV
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M9*.9T6^_YIH_*VOU&_X)5Q0K\#?%$JOFX;Q'(KIGHHMK
Y+?E7Y
"]:\3ZO+Y.FZ5:R7<
MS9Y(49"CU9CA0.Y(%;U?F_\ \%)_VFH-=NA\*/#EV)K6SF6;7KB)LJ\RG*6V
M>^P_,_HP4<%6%=6&H/$5%!;=?0]?*LOGF6*C0CMNWV77_@>9\/>,/%%YXV\6
M:SXAU%MU_JMY->SD=-\CER![9-9%%%?=I65D?T%&*BE&.R/W5_9S_P"3>_AA
M_P!BOI?_ *215Z'7GG[.?_)O?PP_[%?2_P#TDBKT.OSZI\
'H?OV1?\BVAZ'[J_LY_\F]_##_L5]+_])(J]#KSS]G/_ )-[
M^&'_ &*^E_\ I)%7H=?%U/CEZGX7BO\ >*GJ_P SYK_X*'>%W\2?LM^(IHHS
M++I5Q:Z@JCKA90CG\$D8_0&OQ[K]^_'7A.U\>>"M>\-7W%IJ]C/8RMC)59$*
M%A[C.1[BOP5\2>'[[PEXBU/1-3A-OJ.FW,EI
G*GV9
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M%?BY7T^4P:A*??\ 3_AS]7X-HRC0JUGM)I?=_P .?1'_ 3[C>3]KCP,RJS!
M!?LQ SM'V"X&3Z
"9-<^.&L>(FBW6FAZ4X\S&=L\[!$'M
ME%F_*OU-DD6-&=V"(HR68X 'J:X,TDI8BRZ(^=XNJ*IF*BOLQ2_%O]1U%?/>
MN?MD:)?>(+G0?AOX6UWXJZK:MLN)M A L(&_NO=-\HSZ@%?>J
>*_V?/$^GZ4A+/<:+J$&JRHG!W&) I'&<\\8ZUP?5ZO:WS2?W;GSRRS%-*\
M4F^C<4_N;3_ ^D**X;X3_&KP=\;="?5?"&L1ZE%"P2YMV4QW%LY'W9(VPRG@
MX.,'!P3BNYK"47%\LE9GGU*
_E-365/YGZ+P;B+3JX9];27RT?YH\@HH
MHKZ0_4@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /T,_P""2?\
MS57_ +A7_MY7Z&5^>?\ P23_ .:J_P#<*_\ ;ROT,KXO,?\ >I_+\D?A?$O_
M "-:W_;O_I*"BBBO./F KY]\=_\ (X:K_P!=C_(5]!5\^^._^1PU7_KL?Y"O
MPCQ>_P"15A_^OG_MLCZKA[_>)^GZHB\&_P#(V:3_ -?*?SKZ'KYQ\-WL6FZ_
MI]U.Q6&&=7=@,X //%?06FZQ9:Q )K*YCN8_]AN1]1U'XUQ>$.)H1P>)P[FN
M=SNHW5[
1@HJ)U(4XN
9:MK5[KET;B^N'N).VX
M\+[ = /I7XSQ%XG9;EBE1RW]_5[KX%ZO[7I'1_S(^DP>1UJ]I5O=C^/_ /G
M]QU7C+XEW.O![2P#6E@>&.<22CW]!["N(HHK^7,VSC&YWB7B\?4
,=(4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 445);6[W5Q%!&,R2.$4>Y.!51BYR48J[8F[*[/X9IV_$X'Z 5UE06-HFGV-O:Q_
N
M>*_!-O<:QX(8M+/;KF2XTODDAN[Q =).H'WNFX_3Y?CE)*C5>O0_5^'<^C5A
M'!XJ5I+2+[^3\_S]=_D*BBBO>/T0**** "BBB@ HHHH **** "BBB@ K0\/^
M']2\5ZY8Z-I%G+J&J7TRV]M:PKEY)&. HJYX+\#Z]\1?$EIH'AO2[C5]7NFV
MQ6UNN3[L3T51W8D #J:_6+]CW]C73/V>=+&MZUY&K>/+N/;+=*-T5BA',,)/
M<_Q/P3T&!G/%BL7##1N]7T1X&;9Q1RNE>6LWM'_/R.N_9,_9SL_V
M7<>)-1*W6L7D?(>;'RQ*?[D8) ]26;C=BO;***^+J3E4DYRW9^%XBO4Q565:
MJ[REJS*\5>&[+QEX8U?0-2C\W3]4M);*X0=3'(A1L>^":_![XB^!=1^&?CK7
M/"NK(4O])NWM9#MP'VGY7'^RRX8>S"OWVKX<_P""C'[+<_CC2E^)GA:Q:XUO
M381%J]I F7N;5?NS
)M.\/Z#8RZEJ
M^H2B&WMH5R68]SZ #))/ )/ H;25V3*2BG*3LD8]%>_?M:_LTC]FVZ\#6 N
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M_P U5_[A7_MY7Z&5^>?_ 23_P":J_\ <*_]O*_0ROB\Q_WJ?R_)'X7Q+_R-
M:W_;O_I*/PJ_:,_Y.$^)_P#V-&J?^E
>5Z'^T9_P G"?$__L:-4_\ 2N6O
M/*^PI_!'T/VK"_[O3]%^04445H=04444 %%%% !1110 4444 %%%% !1110
M5^AG_!)/_FJO_<*_]O*_/.OT,_X))_\ -5?^X5_[>5YV8_[K/Y?FCYCB7_D5
M5O\ MW_TI'Z&4445\6?A84444 %%%% !1110 5^-O_!0+_D[KQY_VX?^D%M7
M[)5^-O\ P4"_Y.Z\>?\ ;A_Z06U>UE/\=^GZH^ZX/_W^?^!_^E1/GFOW5_9S
M_P"3>_AA_P!BOI?_ *215^%5?NK^SG_R;W\,/^Q7TO\ ])(J[
[QE_
MN]'U?Y'H=%%%?,'Y0%%%% !1110 4444 %%%% !1110 4444 %%%% !7\\]?
MT,5_//7T>3_\O/E^I^F\%_\ ,1_V[_[
GZL\SC#_?X?X%_P"E2"BBBO%/
MA0HHHH **** "BBB@ K\;?\ @H%_R=UX\_[
//
M^W#_ -(+:O:RG^._3]4?=<'_ ._S_P #_P#2HGSS7]#%?SSU_0Q73G'_ "[^
M?Z'I\:?\P_\ V]_[:9/BSPW:>,O"NLZ!?KNL=4LYK&<#KY
./!
M^H?#_P 8:UX:U6/RM1TJ[DM)A@@%D8C<,_PG&0>X(-?O[7Y__P#!2;]F.?5%
M_P"%L>&[1IIH(EAUZWA7),:C"76!_=4!7]%"G@*QKERS$*G4=.6TOS/+X5S&
M.%Q+P]1VC4V]5M]_^1\*?";XCZA\(_B1X?\ &&E@/=Z3=+/Y3' E3!62,GL'
M1F4GT:OW)^'OC[1?BAX-TKQ1X?NUO-*U&$2Q..JG^)&'9E.5([$&OP)KW/\
M9C_:U\4_LV:P\=HO]L^%;N3?>Z'.Y52W \V)N?+DP ,X((&"#@$>OC\&\1%2
MA\2_$^RXAR5YG356C_$C^*[?Y'[2T5X_\'/VL/AI\;K6 :%XA@M=6D W:+J;
M+;WB-_="$X?KU0L/>O8*^2G"5-\LU9GXW6H5
WUSQY(FT6H;=#I^0<23D?Q#@B/@GJ
M<#&?E?X^?\%*O%GCV&YTCP#:/X-T:0%'OW8/J,JG(X8?+#D?W
21BS,Q.223U)/>O>PN6._/7^[_ #/T/*>%9
U'Q1K5[J^KWDVHZG>RM/<75PQ9Y78Y+$UZ?\4OV==6^$?PC\#>*O$'
MFV>K>*)KATTN1<&WMD2(QL_<.V\L5[#:#@Y ^FOV&OV')]6NM/\ B+\1-/:'
M3HBL^D:'=1_-
27.EQW#A!=PR89HX\_>=7WL5ZD., [6PLTA*=#3H[D\5T)ULOO!7Y9)OTL
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MG_\ !*__ )-[\0_]C1
_$/_8T7'_I):5]'F?\
MN[]4?IO%?_(M?JC[)HHHKX\_%0HHHH **** "BBB@ K^>>OZ&*_GGKZ/)_\
MEY\OU/TW@O\ YB/^W?\ VX^AO^"?O_)W7@/_ +?_ /T@N:_9*OQM_P""?O\
MR=UX#_[?_P#T@N:_9*N;-OXZ]/U9YG&'^_P_P+_TJ04445XI\*%%%% !1110
M 4444 ?EA_P50_Y.$\/?]BO;_P#I7=U\;5]D_P#!5#_DX3P]_P!BO;_^E=W7
MQM7W&"_W>'H?OV1?\BVAZ'[J_LY_\F]_##_L5]+_ /22*O0Z\\_9S_Y-[^&'
M_8KZ7_Z215Z'7Q=3XY>I^%XK_>*GJ_S/QS_;X^%
N$A*:7XB/\
M;-K(!P6D)\Y<^HE#G'HR^M?.=?LO^VC^SB/VA?A8\6G(H\5Z*7N]*
M9 2>@D"C'HRH>F:_&Z^L;G2[VXL[R"2UN[>1H9H)D*/&ZDAE93R""""#Z5]?
M@,0JU%+JM&?M/#V8QQV"C%OWX:/]'\U^-S]EOV,_VA;7X^?".PDN;I&\5Z/&
MEGJ\!;YV<#"3X]) -V>@;>.U>^5^#/PF^+GB?X)^,K;Q-X4OS9:A"-DD;#=#
M
0^"?$Q 5[34I0MK*WK
M%.<+@G^%]K9.!NQD^+C,!.G)SIJ\7^!\)GG#U;"U95\-'FIO6RWC\NW9_>?4
M-%1V]Q%=0QS02)-#(H9)(V#*P/0@CJ*DKQCX<**** "BN,^(/QF\#?"JU>;Q
M9XJTS0RJ[Q!<7 \]Q_L1#+O_ ,!4U\6_''_@J);QQ7&F?"W2&FF/R_V]K$>$
M7KS%!G)/3!
(;K7?$FJW6LZM
WB3Z5X&LY,7NJ;<-.1U@@R,,Y[MR$!R
M
;ZY::-&5<_P(K'+?WB ,X;'D-?M%^TU\.['3OV0_&O
MA?PY81Z?IVFZ*7MK2W7"I' RS$#U)$9)/4DDGDU^+M;8/$/$J4GW_ [
G:%XBM19O>S,%BMYU;=$\C'[J'+J3T!<$D $U^N,,T=S#'
M-#(LL4BATD0@JRD9!!'4$5\_F4)1Q#D]G;\C\XXIH3IYE.I):22:^22_0?16
M
ME>8U,LQ*KPU6S7=?UL?S[U
M]8_L1_MDR? G5!X4\4R27'@2^FW"7EGTN5CS(H[QD_?4<_Q+SD-RW[77[(^L
M_L[>)Y;ZPAGU'P)>RDV.I8+&W)/$$Y X<=FZ.!D
OL6J6,I=TS]ME'"
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M\+? /P;/K_B:\"'!6TL(B#<7DN.(XU_++'A1R37S1\
+-7GU?4I?E#2
M'"1)G(2-!\J*,G@ =2>I)KV,+ELZCYJNB_$^VRKAC$8J2J8M
()?WTQ\NVM$8F*T@!.R%/89.3W))/)KDM!T'4/%&MV&CZ
M3:27^IWTZ6UM;0C+RR,0%4?4FJ<,,ES-'##&TLLC!$C1269B< #J2:_4?\
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MY^2XMFP2.ZL.C*<
73ZIOR3PJBO!Q.6SIOFHZK\3\\S7A:OAY.I@USP[=5_G^9][T5R7@7XM>
M"_B9:I/X5\4:5KJLNXQV=TCRI_OQYW(?9@#76UXKBXNS1\-.$Z
+=-TVXC&?L*S"6[;Z0IES]<8]Z^#_ -HC_@I=
MK'BRWNM#^&5K<>'--D!CDURZP+Z1>0?*4$B$'^]DMW&PUV4,)5Q#]U:=^A[>
M R?&9A)>RA:/=Z+_ (/R/:/VYOVT;?X7:9?> O!=[YOC2ZC\N\OK=AC2HV'(
M!_Y[,#P!R@.[@[:_+,DL23R:?--)
A? KX%
M>)?V@/'%OX=\.V[!,J][J,B$P64)/,CG\#A>K$8'
=?!'2*\N_JPHHHKA/GS\
PK@+
)& ^.C<\!EKZ=K
M^?SPKXJUCP1X@LM
O*MUZ+JO34^\:*Y;P7\4O!_Q&M4N/#'B;2M=1EW;;&[2
M1U]F0'
"OAK;O+XI\5:3H6T9
M\N\NT25N_P L>=S'V )H47)V2"$)U)
.>@ZD@
7^/2OSY^)'Q0\4?%SQ+-KWBS6+C6-1DX5ICA(ESG9&@^5%
M']U0!7LX;+:E1\U71?B?;97POB,3)5,6N2';[3^73Y_<=1^T3^T!K_[1/C^?
MQ!J[-;6,6Z+3=+5]T=E!G.T<#
J8QNZ'R(2>#(P[\A =Q_A5OT$_;:\,Z7X,_8E\6:'HME%IVE6$.G06U
MK",+&@O[; ]SW)/)))/)KU:V)A0G##TNZ^2N?8XS-*. K8?+,)9-RBG;HKK3
MU?\ P3\@:_0S_@DG_P U5_[A7_MY7YYU^AG_ 23_P":J_\ <*_]O*US'_=9
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M7XVU^R7_ 4"_P"31?'G_;A_Z7VU?C;7U>4_P'Z_HC]AX/\ ]PG_ (W_ .DQ
M/T,_X))_\U5_[A7_ +>5^AE?GG_P23_YJK_W"O\ V\K]#*\7,?\ >I_+\D?"
M\2_\C6M_V[_Z2@HHHKSCY@_(W]O;]F>3X*_$9_$>BVFSP;XBF:6 1K\EG
DZU%73KN4K-:K_ -,)<':/]A@5XXVY)K+&9=[1NI1W
M[''GG#7UF3Q."TD]X]_-=G^!^P%%>'?"C]L_X3_%R"%;#Q/;Z-JD@&=+UQEM
M)PQ_A4L=DA_W&:O;XY%D171@Z,,AE.01ZBOFYTYTW::L?E]?#UL-+DK0<7YJ
MPZBBBLSG"BN6\=?%/PA\,[$W?BKQ+IF@Q8RHO;E4=_\ <3.YS[*":^+/CO\
M\%/].M;>?2_A7ISWUTP*?V]JL)2%/]J*$_,Q[@R;<=U-=-'#5:[M"/\ D>K@
MLKQ>822H0;7?9?>?2G[3/[4'AO\ 9P\)O
H>);J-O[-T5'_>3-T#OC[D
M0/5CUQ@9-?C;X\\=:U\2_%VI^)O$-Z^H:OJ,IFGF;@>@51_"J@!0HX %0>+
M/%VM>.O$%YKGB#4[G5]6NWWS7=TY=V/8>P X ' JKHFAZAXEU>TTK2;*
M?4=2O)%AM[6VC+R2N3@*JCDFOK,)A(86-]WU9^Q9/D]'**3;=YO=_HO+\S<^
M%_PWUGXN>/-'\)Z#!YVHZE.(E8@[(DZO*_HJ*"Q]AZU^XWPN^'>E_";X?Z'X
M1T92-/TJV6!78 -*W5Y&Q_$[%F/NQKQ/]BW]DRV_9W\*OJNL+%=>.=6A47LR
MX86<7#?9HV[X(!9APS =0H-?2M>!F&+6(GR0^%?B?G/$><+,:RHT7^[A^+[_
M .7_ 0KSW]H+X:CXO\ P8\6^$E"FXU&R86N[H+A")(2?;S$3/M7H5%>7&3A
M)26Z/DZ525&I&I#>+37R/YZ[JUFLKF6WN(G@GA
A!KU7]EO
MXVR? 'XS:-XG<,^E-FRU2)!DO:2$;R!W*D+(!W* =Z]\_P""B_[,<_@?QA/\
M2] M&?P[K
,U9KMW7R_P""?T&:/K%CXATFSU33+J*^TZ\B6>WN8&#)+&PRK*1U!!JY
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MI]W5_P!:GTM^V1^WGI_@&SU#P5\/+R/4?%,BM;WFL6[[HM-[$1D
!R68D_4DU%##)
&T^(/CZR \3,N_3-'G4'^SP>DL@/_ "V(Z+_!
MGGYON?0?N
?XL_2;8+A?!MK63^^3_ $2_#UW^(/V@/@#J'[/[>#M/UF8M
MKNKZ0-2OK4$%+21I9%$((ZE55=QY&[=C(P:\FK[M_P""KV@S0>/? FM$'[/=
M:9/9J>VZ*4.?TF%?"5=>%J.M1C.6[/7RC%3QF"IXBH[N5[_>S]T_V<9%D_9[
M^&)5@P_X1C3!E3GD6L8(_.O1:^4?^"?'Q[T3Q]\&M'\&SW\,'BOP[$UH]A(X
M62>W4DQ2QK_$H0A6QR"N3@,N?JR21(8VDD94C4%F9C@ #J2:^,Q$)4ZLHR74
M_#LQH5,/BZM.HK.[_/1_,=15#1M>TSQ%9F[TG4;34[7>T?GV
_P"Q
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M3G[,^O\ [-_C5["]62]\.WCLVE:N%^2>,'[CXX651C
JNNZ/Q[,,BQF7R?-'FA_,MOGV^9[#11
M17 ?/!112$A023@"@!:KZAJ%KI-A
Y93_
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MM>\2_ G7/@Y\,_@W'H?A:U\137UH$O+3S(4:(6Y5F(RQ)\QRS
GQ6
0.<;@>.,G@P?ML6&M:I
M\=OV=K3P[JL>B:W+?ZHMIJ$UN+A('VVGS&,\-WXK#_:B^'7Q[TWX)>)+W6/B
MI8>(] MH!)J>DV>BQV$MS;!AO42J&(XY(XR
=PO._-S)N4O?DM[/IIJT:GQ.M&;P'X=_:B^&EE_8WB6.PAU'7M*
MA($6K6+;3<13@ !GCY/F8SA,]53'U=X9\9:5XL\-Z3KEA=QM8ZG:0WL!=P&,
M
E>&)/!1GCLFD$@M[
;J6GP_VM8@#+>; "Y51ZM'Y
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MHY%D4,C!U/0J
<9./X-2_,\>I
MP[!_PZEO57_R/IVBOG"/Q)JT(Q'JEZ@_V;AQ_6I1XNUP)M_M>]Q_UW;/YYKW
M(^,&!:]["37S3_R.9\.U>E1?B?15(S!5))P!U)KYR?Q-K$@P^JWSC_:N'/\
M6J,UU-<8\V627_?8G^=
:M\7]5O R64,-@AZ-_K''XGC]*XR_U
M*[U2;SKNXDN9/[TC%L?3TJM17Y=FF?YIG+OC\1*:[-^[\HJR7W'NT,)0PW\*
M"7Y_?N%%%%> =84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !75_#'2O[3\66[LN8[4&=OJ.%_4C\JY2O7_@[I/V71;F_9?G
MNI-JG_87C^9/Y5^@
Z*,PD^J K_L9.:_._XL
M?L^^/_@G>-#XM\-W>GV^_9'J"+YMI+Z;9ERN3_=)#>H%?NK4-U:07UM+;W,,
M=Q;RJ4DBE0,CJ>H(/!%>MA\QJT?=E[R/L,NXGQ>"2IU?WD?/?[_\[G\]M%?L
ME\1OV"_@U\1I)9V\-'PW>R=;KP]+]EQ](L&+_P
9X>?Q.Q]UA^*LNK+]XW!^:_57/STHKZWUS_@F+
M\7]+9_L<_AW6$YV_9;]T8CG&1)&H!_'OUKE+K_@GM\>;>0+'X+CNAC.^+5[(
M >WS3 __ *ZZUBJ$MIK[SV89QE\U=5X_-I?F?.=%?0W_ []^/G_ $(?_E8L
M/_C];6F?\$W_ (W7T@6?1]+TX''S76J1$#/_ %S+'BF\507VU]Z*EFV7Q5W7
MA_X$O\SY?HK[A\-?\$I?&UXT9U[QGH.E1MC=]@BFO'4?1A$"?Q_&O;_ O_!+
MSX:: T
8X>'VK^AYE?B7+**TJ
^AL[&UFO;R9MD5O;QF21V]%4#)/TKZR^!_\ P3?\?_$2
M2#4/&!_X070V(8QW*;[^5?18<_N^XS(01_=-?I=\/O@_X)^%-I]G\)>&--T)
M2NQY;6 ":0?[
'*4IOFD[
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MHK[6\)?\$K_B#J
[R8ZXYVKEB,X!K]6_V8_V2
MO"W[-VBF2UQK'BNZCV7NN31@,0<$QQ+SY<>0.,DDC))X ]GT?1=/\.Z;!IVE
M6%KIFGVZ[(;2SA6&*-?144 ?05=KY_%8^IB/=6D3\XS;B'$9DG2C[E/MW]7
M^FQ\>_\ !3CX9R^+O@A8>)[6(RW7AB^$LN!DBVFQ'(1]'$)/L">U?E37]!6N
MZ'8>)M%O](U2UCO=-OX'MKFVE'RRQNI5E/L02*\'_P"'?OP#_P"A#_\ *Q?_
M /Q^NG!YA##T_9U$_D>ID?$='+L+]7Q$9.STM;9^K74_&VBOV2_X=^_ /_H0
M_P#RL7__ ,?H_P"'?OP#_P"A#_\ *Q?_ /Q^N_\ M:AV?X?YGT7^N& _DG]T
M?_DC\;:*_9+_ (=^_ /_ *$/_P K%_\ _'Z/^'?OP#_Z$/\ \K%__P#'Z/[6
MH=G^'^8?ZX8#^2?W1_\ DC\;:_6'_@G?^T!I7Q ^$>G>![R\CB\5>&XC;BVD
M8!KFT!)BDC'<*I",!TV@G[PKL?\ AW[\ _\ H0__ "L7_P#\?KJOAK^R=\*O
MA!XHC\1>$?"W]DZQ'$\*W/\ :-W-A'&&&V25EY^E<>+QU#$T^2SOTV_S/"SG
M/LOS3"NCR34EJG9;^?O;'KE?A5^T9_R<)\3_ /L:-4_]*Y:_=6OGOQ/^P;\&
M_&'B75M>U3P]=S:GJEW-?74BZG<('EE
!P*X\#B88:4G/J>-P_F
ME#*ZM2==-J2MI_PZ/QKHK]@?^'=7P,_Z%J\_\&MS_P#%T?\ #NKX&?\ 0M7G
M_@UN?_BZ]G^U:'9_U\S[C_6_+_Y9_
Q=6->M*I'9_P"1^:YQC*>/QU3$TD^65M]]$E^A^%7[
M1G_)PGQ/_P"QHU3_ -*Y:\\K]E/$_P"P;\&_&'B75M>U3P]=S:GJEW-?74BZ
MG<('EE
!P*S/^'=7P,_Z%J\_P#!K<__ !=>_#-*$8I-/^OF?HE'
MBS 4Z48.,KI);+_,_'ZBOV!_X=U? S_H6KS_ ,&MS_\ %T?\.ZO@9_T+5Y_X
M-;G_ .+JO[5H=G_7S-O];\O_ )9_
5[K_P[J^!G_0M7G_@UN?_
M (NO2_@S^SKX&^ /]L?\(7IDVG?VMY/VOSKN2??Y6_9C>QQCS7Z=<^U
F4445\\?FH4444 %%%% !
M1110 5^-O_!0+_D[KQY_VX?^D%M7[)5XU\0/V/OA%\4O%U_XH\4>$O[3UV^\
MO[1=?VE>0[]D:QI\D
$_#VEZ'I5O]ETO3+6*RM+?>S^7#&@1%W,2QPJ@9))..371CL93
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M** "BBB@ K\;?^"@7_)W7CS_ +
*/"7]
MIZ[?>7]HNO[2O(=^R-8T^2.95&$11P!TSUKT,#B(8:HYS6EK:?(^DR',J.5X
MF5:LFTXM:6[I]6NQ^)E?T,5\\_\ #OWX!_\ 0A_^5B__ /C]?0U;8_%PQ7+R
M)Z7W^1V<0YQA\V]E["+7+S7O;K;LWV"F30QW,,D,T:RQ2*4>-U!5E(P00>H(
MI]%>2?'GYP_M8?\ !.N]L+N\\5_"BT-Y8R,TMUX83_6P$DDM;?WD_P"F?WAC
MY=V0J_!=Y97&FW
AK^A*O+_BY^S/\ #CXW
M1NWBKPU:W&H%=JZI:CR+Q>,#]ZF"P'97W+[5[N&S.5-
1>+OC=\0?'BR1^(?&NO:O ^
$M!O-;O21O%O'^[B!_BD<_*B^[$"OTD_9?_X)XZ'\+YK/
MQ+X^>W\3>*(\2P6"C=8V3]0<$?O7'JPV@] 2 U?6?A?PCH?@C1XM*\/Z19:+
MIL7W+6P@6&,>^% R3W/4UKUXN)S*I67+#W5^)\+F?$^)QJ=*@N2#^]_/I\OO
M"O-_VAO@_;_'3X0Z_P"$)G2"YNHA)97$@XAN4.Z)CWQN&#CG:S5Z117E1DX2
M4H[H^0I59T*D:M-V<7=?(_G_ /%_A'6/ ?B74/#^OV$VF:O82F&XM9EPRL._
MN",$$<$$$9!K'!*D$<&OW'^-7[-?@#X_6<
@
7
MK\KAER
:,_7L'Q9@JU-?6;PEUT;7RM=GY_77CSQ+?:?\ 8+CQ%JUQ88Q]EEO96BP<
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M2K?[+I>F6L5E:6^]G\N&- B+N8ECA5 R22<
'K?0_&FD?VSI=O=+>Q6_VF:#;,J.@;=$ZL?ED<8)QSTX%=
M&'J*E5C.6R/2RW$PP>+IXBHFU%WTW/P:K]3_ /@E?_R;WXA_[&BX_P#22TKT
M/_AW[\ _^A#_ /*Q?_\ Q^O4_A7\'_"/P3\/7&A^"](_L;2[BZ:]EM_M,T^Z
M9D1"VZ5V8?+&@P#CCIR:];&8^EB*7)!._P#7F?89WQ%A
>OZ&*^>?^'?OP#_Z$/_RL7_\ \?KU
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MMMM2P.!)C[DF, 2
#LS?!XRO@:JK4)6:_'R9^ WCCX
M?^(_AKX@GT/Q1HUUHFJ0_>M[I-I(_O*>C*>S*2#V-8%?OAX_^&'A/XIZ.=+\
M6^'['7K/G8MY"&:(GJ8W^\C>ZD&OD3XC?\$K_".LS37/@SQ1J'AMV)86=_&+
MV ?[*ME74=.6+FOI*.:4Y*U56?X'ZC@>+L+62CBDX2[[K_/\/F?GMX-^+7C;
MX>8'AGQ;K6A1YR8;"^DBB;ZH#M/XBO4;#]O+X[Z; (8O'\[H,
ZRHH!_P"!'KUKCIO^"?7Q
MZBE9%\#K,H/#IK%C@_3,X/Z5UNK@ZNLG%^MOU/9EB\EQ7O5)4Y?XN7]2&;]O
MSX]3Q-&WCU@K#!*:38J?P(@!%<5XG_:<^+'C!'CU7XA>()H9,AX8;YX(F!SP
M4C*J1SZ5WMM_P3W^/,\NQ_!4=NN/OR:O9$?^.S$_I7:^&_\ @E[\5]6D0ZGJ
M/AW0X
TP5/5./RM^A'UC(\/[T737IR_H?(4TTEQ,
M\LLC2RN=S.Y)9B>Y)ZU:T;1=1\1:I;Z;I5A
DRQS^,/%NH^(&4[C:Z?"ME"?]EF)=F'T*FOK#X:?!7P-\'[
M$VO@_P ,V.B!EVR3PINGE'H\S$N__ F-
13^[7_94[N3RA%?H
MMH>AZ=X9T>TTK2;&WTW3;2,16]I:QB..)!T55' %7J*^>KXFIB'>;/S3,,TQ
M.9SYZ\M%LELOZ[[D%[9P:E9SVEU$L]M<1M%+$XRKHPPRD>A!-?B7^T[^S[JW
M[//Q,OM%NH)7T.YD>?1]0()2XM\\#=_?0$*P['GHP)_;NN:^('PW\-?%3PW/
MH/BO1[;6M+FY,-PO*-V9&&&1A_>4@\]:VP>*>%FVU=/<[
?]J.SDD=I)&TR
M\+,QR2=HY)K];J^??V??V)_ G[/6MC7M+N-3UCQ%Y+0?;M0F 5%;&X)&@50#
MC^+
OH*OG<=7AB*O/#:Q^:9_CZ.8XSVU"_*DEKIW"BBBO//FS.\0>'M,\6
M:+>:/K-A;ZGI=Y&8KBTNHP\
CW3V?
M]=S^>_4--N](OI[*_M9K*\@
MM6RW"_3S8]A ^J,:^CI9I1G\?NL_3<'Q9@JR2Q"<']Z^]:_@?GYX;\=>)?!L
MA?P_XAU70W)W;M-O9;
J>(/
M^"9GQDT>1A9+H.N)GAK+4"A(^DR)_D5Q]Y^P1\>+)-[^ I'7=M'DZG92'\EF
M)Q77[;"U-7*+];'L/'91B?>E4IOU
:Q=/=7]W/>W+_ 'IKB1I'/U).:^@;'_@GS\>+QT#>"DM4
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M /INBM:=6=&7/!V9UX7%U\%55:A+EDOZU[GX4_&#X ^.?@7K#6/B[0YK*)G
M*P:A$/,M+GWCE'!XYVG##N!7GM?T&ZKI-CKNG7&GZE9V^H6%PGES6MU$LL4J
MG^%E8$$>QKYC^)W_ 3C^$WCR26ZTBWO/!E^^6W:1(#;EO>%P0![(4KZ&CFL
M7I65O0_2L#QA2DE'&0Y7W6J^[=?B?DA%,\$BR1NT
!SBOJ+Q=_P2G\:V,C-X:\8Z)K$(.0NH
MQ2V
%[34QG&ZUU:U4?7]Y(AKT?K6%JK62^
M?_!/IEFV58I>]5BU_>T_]*.+D_;"^-$D31GXC:V%9=I*S '\"!D'WKEO$'QU
M^(_BR%X=8\>>)-2@88,%QJL[1$=/N;MOZ5Z,O[!?QX:Z:W'@&;S%ZL=2LPG_
M 'WYVT_G6[HO_!./XX:HZK
CC^A\R$EB2>317WSX)_X)0ZQ-(DGB_P =6-G&I^:WT2V>
'AK&KPX*ZGKC"ZF5AT95($:-[JH/O6%7,J%/X7S,\
M[%<4Y?AU^[;F_+;[W^ES\\OV=?V$_'7QNN+74]4MY?"7A%F#-J-]$5FN$Z_N
M(C@MD8^
GISE
,\X'3\N3;_ ()7?%;<
M=OB'P:5SP3>78/\ Z35W_7<+-:R1]%_;F4UE=U4_5/\ 5'R]J'Q6\;:K;F"]
M\8Z_>0G.8[C4YW4Y&#P6]*Y=F+L68EF)R2>IK[7TO_@E1\0YF']I>+?#-HN>
M3:M<3G&.N&B3O7J/@W_@E'X:L9DE\4^.-2U=!@FWTNT2S'T+.921] #]*EX[
M"TUI+[D9SX@RG#KW:B^2?^5C\V889+F:.&&-I99&")&BDLS$X '4DU]D_LU
M_P#!.?Q-\0+BTUSXB)<>%/#?$BZ:PVZA=C@@%3_J5/
[/K^]D)8 ]PI ]N*],KRL1FDI+EHJWF?(9CQ=
M4K1=/!1Y5W>_R6R_$Q_"/A#1? ?AVRT+P_IMOI.D6:"."UMEPJCU]23U+'))
MR22:\1_X*!?\FB^//^W#_P!+[:OH:N=^('P_T#XI>$;_ ,+^*+#^T]"OO+^T
M6OG20[]DBR)\\;*PPZ*>".F.E>/2J
;Y6_R_P#6R/C'F/TQG/.<"O;Q684J]&5.
M*=WZ=_4^[S?B3"9A@JF&I1DI2MNE;1I]WV/0Z***^>/S8**** "OS[_;R_8G
MU+7M8OOB7\/[!KZXN 9=:T6W4F5W YN(5'WB1]]!SGY@#EL?H)1710KSP\^>
M!Z>7YA6RVNJ]'YKHUV/YZ9(WAD:.161U)5E88((Z@BFU^XOQ/_9?^%_QAN'N
M_%'A"RN]1
Z_L-_\G6?#[_KZ
MF_\ 2:6ON?2?^"7_ ,(-.N!)<7WBC5$S_J;N_A5>_P#SSA0_KVKVWX9_LR_#
M#X0W,5WX6\':?8:A$#LU"8-<72Y!!VRREF7()SM(&#CI45\RHRIRA%-W1S9A
MQ5@JF'J4:2DW)-;66JMW_0]/HHHKY<_)SYY_X*!?\FB^//\ MP_]+[:OQMK]
M]OB!\/\ 0/BEX1O_ OXHL/[3T*^\O[1:^=)#OV2+(GSQLK##HIX(Z8Z5XW_
M ,._?@'_ -"'_P"5B_\ _C]>W@<=3PU-PFG>]]/EYGWF0Y]ALKPTJ-:,FW)O
M1+LEU:['SS_P23_YJK_W"O\ V\K]#*\\^$G[/_@'X%_VK_P@^@_V)_:GE?;/
M],N+CS?*W^7_ *V1\8\Q^F,YYS@5Z'7GXJM&O6E4CL_\CYO-\93S#&U,3234
M96WWT27GV"BBBN0\<*YWQ_\ #WP]\4?"]WX=\4:7#J^DW0^>"8
09]5 YKY&DC>&1HY%9'4E65A@@CJ"*_H6KR;XM?LK_#'XU&6?
MQ)X8MSJD@_Y"UCFVN\XQEI$QOQV#AA[5[V'S1Q7+65_,_1,NXNG32IXV/-_>
M6_S6S_ _$"NE\,?$[QAX)55\/>*];T)5.0NFZA- OY(P%?='CK_@E"I:27P9
MX[(7^"TUVUR?QFB_^-UXSKW_ 36^-6D.RVECHVMA>C6&IJH;KT\X1_KZUZ\
M<9AJJ^)?/_@GV5//,KQ4;.JO26GYGF]K^U[\9[2+RT^(^NLN
%R2T*ZI,D;9Z@JK $>V..U=O=?L%_'BS*"3P#,V_
MIY6I6
\F"3>$(+!?^>EQJ]F5_P#')6/Z4_:82.MX
M_@7]8R>'O*=-?.)\Z7-U->7#SW$LD\TAR\DC%F8^I)ZU'7VQX1_X)6^/]3DC
M;Q%XIT'0K=OO"T$MY,OU7;&OY/7TE\+_ /@FY\*O LD-UKB7OC74$P?^)FXC
MM@WJ(4QD>SLXK.IF.'IK1W]#EQ/$N6X=>[/G?:*_71?B?F_\&/V=O'?QZU86
MGA3199[56VW&J7 ,5G;],[Y2,9YSM7+'L#7ZF?LO_L<>%?V
4",&.W7GRUYP3G
(L3F2=*/N4^RW?J_P! HHHKS#Y0****
M *&O:#IWBC1KW2=6LH=1TR\B:"XM;A \
C66J1*&^GFE/U]*QO^'?OQ\_Z$/\
M\K%A_P#'ZV
+-:UU/^>>H7\LR#Z*S$#\!7MVE_\$Z?CEJ#
M*)_#=EI@)Y:ZU6V8#Z^6[UZ9X2_X)3^,[YE;Q)XRT72(C@E=.AEO' [@[A$,
M_0FE[?!T=4XKT_X!/U_),'[T)07^%+_VU'PY7H'PC^ OCGXX:L++PCH-Q?QJ
MX6:^<>7:6_\ UTE/RCCG;RQ[ U^E_P -/^"<'PE\"O%
XA?-=5(>'/;>I(';<$SP*_&C4-/NM)OKBRO
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M\FPV/_84O/\ T(5]45QWPG^$_AWX*^"[7POX7MI;;2X':7]_,TLCR,
Y
M]L#T KL:^4KS52K*<=FS\?S"O'%8NK7AM)MH_+#_ (*H?\G">'O^Q7M__2N[
MKXVK]Q/BI^R]\,OC9XAM]<\:>&?[9U2WM5LHKC[?=0;85=W"[8I54_-(YR1G
MGKP*XW_AW[\ _P#H0_\ RL7_ /\ 'Z]S#YE2HTHPDG=>G^9]_EO%&#P>$IX>
MI"3<5;1*W_I1Z'^SG_R;W\,/^Q7TO_TDBKT.L[PYX?L/"?A[2]#TJW^RZ7IE
MK%96EOO9_+AC0(B[F)8X50,DDG')K1KY^
\
M??#_ ,/_ !0\*WOAWQ/ID.K:1=KB2"8=".C*PY5@>0P((K\R/VC/^"=7B_X;
MW%SJ_@..X\9>&LE_LT2[M0M5]&C'^M _O(,^JC&:_5BBNS#XJIAG[FW8]O+<
MXQ65RO1=XO=/;_@/S/YZIH9+::2&:-HI8V*/&ZD,K X((/0@TROW(^*O[,WP
MT^-&^7Q3X5L[K4&'_(2MP;>[X&!F6,AFQZ-D>U?*?CG_ ()1:7<223>#_'-U
M8KU6TUJT6
#^]?>O\ )'PIX4^,
MGCWP+&D7A[QGKVC0(,+!9ZC+'%CTV!MI_*N_MOVW/CA:PB-/B%J#*.\D,#M^
M;1DUZ-X@_P""8WQ@TEF^PR^'];3DK]DOVC8^Q$L: '\<>]
G.F_7E_4Q;O\ ;9^-][#Y
M
Q*C_OF8G]*['P[_P $P?BWJSH=1N_#VAQ?
MQ?:+UY7 XZ".-@3S_>'0T>UPE/5.*]+?H"QF38;WH3IKTY?T/D2K6E:3?:[J
M-OI^FV=QJ%_1EV27:H9+F0>C3.
M2Y''0G'M7+5S2C!?N_>9Y.,XMP5%-8=.;^Y?CK^!\+_LR_\ !-O4M7N;3Q%\
M5T.FZ:N)(O#D4G^D3]QY[+_JUZ?*#NZ@[,<_HWI>EV6AZ;:Z?IUI!86%K&L,
M%K;1B..)%& JJ!@ #L*M45\[B,34Q$KS9^9YAFF)S.ISUWHMDMD%?/7[37@/
MQ)H_B3PU\8_ =DVI^*/"J/;:AI$8^;5-+
-*;P%^UQXF^''Q"\/^)Y$N_!=Q<7)T?:B
MW"/*(@T=Q&3N3:8A@C(.3@FO8?B9X3L?'GP[\2^'-3NOL-AJNG3V
RNBV,;F*':S?[3
M*3P.<5RP_83\!ZA(@\1^(/&OC*R1]XL->\02RP=<@80(>,#OVKIYJ4K-2:ML
MK7MU[GJ.IA)\DE5E%0V7*FUK?1W5]7UL>67$S?&+PSX?_9V^&FL3>(/".CI#
M;^*_&\48C@2SC?*VL+CY7E8!5)7(.WN"^W[6TK2[30]+L].L($M;&SA2WMX(
MQA8XT4*JCV 'X50\)>#M#\!Z%;Z+X=TFTT72K
M
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MU%K5?+'_ QW?SE_Z2?!\08GGJQH1^SJ_5_\#\PHHHK]\/DPHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIKV\KK^SJ.D]I?F?><)YA]7Q+PLW[L]O\2_S7Z'P)1117U1^OA1110 4444
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MKZGY'6JRK5)5)[O4****[S(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX5<-NC2EGF(CK/W8>GVI?-Z+R3Z,^'S[&
/_M2?L_V/[1/PMO-!D\NWUNV)NM)O
M7_Y8W '"D_W''RM]0>JBO1P.*^KU-?A>_P#F?3Y!FKRS$^^_W
WN;688>*120RD>H(JC7VFY^YIJ2N@HHHH&
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MRTIQUF^T?\WLOOV3/,S#&1P5%S>[V]3JM#T>#0=+M[&W'[N)<%L
['W)J_
M117]U4*-/#4HT*,>6,4DDNB6B1^62E*
(I?&WA6RQX(U2;]];PK\NF7#'[F.T3G[O922G'RY^DRW&7_ '%1
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M<.G6D5M;QB*")=J(O85/7]S<*\-T.&
LWK.7>7^2V2^>[9^6X_&SQU9
MU'MT79!1117V)YP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% !1110!^AG_ 23_P":J_\ <*_]O*_0ROSS_P""2?\ S57_ +A7_MY7Z&5\
M7F/^]3^7Y(_"^)?^1K6_[=_])04445YQ\P%?/OCO_D<-5_Z['^0KZ"KY]\=_
M\CAJO_78_P A7X1XO?\ (JP__7S_ -MD?5
P%:T:-3$5(T:,7*4G9):MM]$3
M*2@G*3LD2Z#H-UXBU*.SM4RS
,GR4_@7X^?^04445^K'@!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
^+O@V_P##'B>P6_TN[7D='B
_5M1\-WDC?V;K4:X28#G8X_@E ZKWY()'3
MQ>OWY\=>!-!^)7A>^\.^)--AU72+Q"DMO,N<>C*>JL.H88(/(-?DG^UA^QKK
M_P"SKJDFIV'G:WX&N),6VI[
P?;!1110 4444 %%%% 'Z&?\$D_^:J_
M]PK_ -O*_0ROSS_X))_\U5_[A7_MY7Z&5\7F/^]3^7Y(_"^)?^1K6_[=_P#2
M4%%%%>
&_#-[XHOA;VB?*.
M9)F^Y&/4_P"%=6%PM?&UHX?#0
OZA'9V<>^5
MNI_A4=V)["O=/"/A&U\)V'E18EN9!F:
%[/PO8BWM5W.W,D
MS#YG/O[>U;%?V!P3P+1X=@L9C+3Q+7R@GTCY]Y?):7O^=YGFLL8_9T](?GZ_
MY!1117ZV?/A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55U32[+7--NM/U&T
M@O["ZC:&>UN8Q)'*C#!5E(P01V-6J*!IM.Z/S'_:V_X)[WW@EKOQ9\,K:?5/
M#_,EUH2YDN;(=2T7>6/V^\O^T,D?#Y!4D$8-?T,5\B_M3_L!:!\8&O/$G@W[
M/X:\8OF26+;ML[]NI+@#]VY/\:CD_>!)R/H<)F5K0K_?_F?I63<4
*-)N-&U:W/SV]PO4=F5AD.I[,I(
M/8US]?1IJ2NC]-C*,XJ47=,****984444 ?H9_P23_YJK_W"O_;ROT,K\\_^
M"2?_ #57_N%?^WE?H97Q>8_[U/Y?DC\+XE_Y&M;_ +=_])04445YQ\P%?/OC
MO_D<-5_Z['^0KZ"KY]\=_P#(X:K_ -=C_(5^$>+W_(JP_P#U\_\ ;9'U7#W^
M\3]/U1@T445_*)]\%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%.CC>:18XT:1V.%51DD^@%>F^#?A23LO-;7 ^\E
MF#_Z&?Z#\?2OI
_HNR\NO5O0_.L=F-7'2][2/1
M?UN%%%%?>GDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!P?Q?^!_@[XZ>'#H_B[28[Z-03;W:?)
BDZJ>G'*G R"*_,#]I#]@WQ
MK\$3=:QHZR>+O!Z9
(<@#^^N5XR=N<5^O=%=V&QE3#.T=5V/
MH,LSO%96[4W>'\KV^7;^KG\\]%?KC^T+_P $_? OQA:ZU?P^J>"_%$F7,]G$
M/LEPW_36$8 )/5TP>
83,DHPERS_ )7O\N_R/,****[CZ$_0S_@D
MG_S57_N%?^WE?H97YY_\$D_^:J_]PK_V\K]#*^+S'_>I_+\D?A?$O_(UK?\
M;O\ Z2@HHHKSCY@*^??'?_(X:K_UV/\ (5]!5\^^._\ D<-5_P"NQ_D*_"/%
M[_D58?\ Z^?^VR/JN'O]XGZ?JC!HHHK^43[X**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBK>F:3>:Q
2YE/\ "@Z>Y/0#
MW-:TJ52O-4J47*3V25V_1(F4E%
XDX1?\3["
MN^\,?".&VV7&L.+B0
/4_3I]:]$AACMXDBB18HU&%1!@ >@%?O'#
M/A;B<4XXG.G[.'\B^)^KVBOO?H?*XW/84[PPVK[]/^"<_P"%? NG^%D#QK]H
MO",-
@8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !5;4M-L]9L+BQU"T@OK*X0QS6US&)(Y%/565@00?0U9HH&FT[H^+OCA_
MP3-\'>-&GU+P!>GP;JC$L;"4--82'V'WXO\ @)91T""O@?XO_LT_$3X'7+CQ
M3X=N(; /M35;4>?9R>F)5X4GLK;6]J_
2"XB2>"12CQR*&5E/4$
M'J*]:AF5:EI+WE_74^OR_B?&X.T*O[R/GO\ ?_G<_/C_ ())_P#-5?\ N%?^
MWE?H97&> _@WX,^&&L:[J7A3P_:Z!<:WY)ODL08X9#%YFPB('8F/-?[H&<\]
M*[.N/%5E7K.I'K;\CQLVQD,PQL\3332E;?R27Z!1117*>0%?/OCO_D<-5_Z[
M'^0KZ"KY]\=_\CAJO_78_P A7X1XO?\ (JP__7S_ -MD?5
:I))>9SM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD
GYG%45TDWPY\109W:8[?[DB-_(U3D\'ZY#][2;P\X^6%F_D*\"K
MD>:T?XN$J1]827Z'7'%4)?#43^:,>BM!_#NK1MAM+O%/HUNX_I2?V!JG_0-N
M_P#OPW^%<3P&+3LZ,O\ P%_Y&OM:?\R^\H45?'A_5&( TV\)_P"N#_X5/'X1
MUN3.-(O1_O6[#^8JXY;CJFD*$W_VZ_\ (3K4EO)?>9-%=##\/O$,_P!W2Y1_
MOLJ_S-7[?X4>()L;X88/^NDP/_H.:]2CPSGF(_AX*H_^W))?>U8PECL+#XJL
M?O1Q]%>BVOP7OFQ]HU&WB'?RD9_YXK9L_@SIL6#
+'X>
M>']/P5TZ.9A_%.3)G\"
95XBIK^%3;]=/\ ,\,TWX::_J6#]C^RH?X[EMGZ=?TKKM+^#-O'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9
end
XML
9
R1.htm
IDEA: XBRL DOCUMENT
Cover
Feb. 19, 2026
Cover [Abstract]
Document Type
8-K
Document Period End Date
Aug. 25, 2026
Entity Registrant Name
Jazz Pharmaceuticals plc
Entity Incorporation, State or Country Code
L2
Entity File Number
001-33500
Entity Tax Identification Number
98-1032470
Entity Address, Address Line One
Fifth Floor, Waterloo Exchange,
Entity Address, Address Line Two
Waterloo Road,
Entity Address, City or Town
Dublin 4,
Entity Address, Country
IE
Entity Address, Postal Zip Code
D04 E5W7
Country Region
353
City Area Code
1
Local Phone Number
634-7800
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Ordinary shares, nominal value $0.0001 per share
Trading Symbol
JAZZ
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
Entity Central Index Key
0001232524
Amendment Flag
false
XML
10
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
.report table.authRefData a {
display: block;
font-weight: bold;
}
.report table.authRefData p {
margin-top: 0px;
}
.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
.report table.authRefData .hide a:hover {
background-color: #2F4497;
}
.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
.report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
.report hr {
border: 1px solid #acf;
}
/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
.report td.pl div.a {
width: 200px;
}
.report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}
.report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}
.report .rou td {
border-bottom: 1px solid black;
}
.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}
/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
.report .nump {
padding-left: 2em;
}
.report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}
.report .text .big {
margin-bottom: 1em;
width: 17em;
}
.report .text .more {
display: none;
}
.report .text .note {
font-style: italic;
font-weight: bold;
}
.report .text .small {
width: 10em;
}
.report sup {
font-style: italic;
}
.report .outerFootnotes {
font-size: 1em;
}
XML
11
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
13
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.26.1
html
1
24
1
false
0
0
false
0
false
false
R1.htm
0000001 - Document - Cover
Sheet
http://www.jazzpharma.com/role/Cover
Cover
Cover
1
false
false
All Reports
Book
All Reports
jazz-20260825.htm
jazz-20260825.xsd
jazz-20260825_lab.xml
jazz-20260825_pre.xml
http://xbrl.sec.gov/dei/2026
true
false
JSON
16
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"jazz-20260825.htm": {
"nsprefix": "jazz",
"nsuri": "http://www.jazzpharma.com/20260825",
"dts": {
"inline": {
"local": [
"jazz-20260825.htm"
]
},
"schema": {
"local": [
"jazz-20260825.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.sec.gov/dei/2026/dei-2026.xsd"
]
},
"labelLink": {
"local": [
"jazz-20260825_lab.xml"
]
},
"presentationLink": {
"local": [
"jazz-20260825_pre.xml"
]
}
},
"keyStandard": 24,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 3,
"http://xbrl.sec.gov/dei/2026": 3
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 25,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2026": 24
},
"report": {
"R1": {
"role": "http://www.jazzpharma.com/role/Cover",
"longName": "0000001 - Document - Cover",
"shortName": "Cover",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "c-1",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "jazz-20260825.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "c-1",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "jazz-20260825.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AmendmentFlag",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Amendment Flag",
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CityAreaCode",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "City Area Code",
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CountryRegion": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CountryRegion",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Country Region",
"label": "Country Region",
"documentation": "Region code of country"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"terseLabel": "Cover [Abstract]",
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Document Period End Date",
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentType",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Document Type",
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, Address Line One",
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine2": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine2",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, Address Line Two",
"label": "Entity Address, Address Line Two",
"documentation": "Address Line 2 such as Street or Suite number"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, City or Town",
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCountry": {
"xbrltype": "countryCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressCountry",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, Country",
"label": "Entity Address, Country",
"documentation": "ISO 3166-1 alpha-2 country code."
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Address, Postal Zip Code",
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Central Index Key",
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Emerging Growth Company",
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityFileNumber",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity File Number",
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Incorporation, State or Country Code",
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityRegistrantName",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Registrant Name",
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Entity Tax Identification Number",
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "LocalPhoneNumber",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Local Phone Number",
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Pre-commencement Issuer Tender Offer",
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Pre-commencement Tender Offer",
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "Security12bTitle",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Title of 12(b) Security",
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SecurityExchangeName",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Security Exchange Name",
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SolicitingMaterial",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Soliciting Material",
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "TradingSymbol",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Trading Symbol",
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "WrittenCommunications",
"presentation": [
"http://www.jazzpharma.com/role/Cover"
],
"lang": {
"en-us": {
"role": {
"terseLabel": "Written Communications",
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r6"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
}
}
}
ZIP
17
0001628280-26-058864-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001628280-26-058864-xbrl.zip
M4$L#!!0 ( -&@&5U=1;])MB4 '= 0 97AH:6)I=#DY,7!R+FAT
M;>U]67,;-[/V_?
[
:#4"CT?WT@L9/HW0<_OS32/#@Y__WT_^OU]F)
M\K.QB%+F)X*G(F"9EM&0?0B$OF'UNGWJ6,6S1 Y'*6LU6GOL@TINY(2;^ZE,
M0_&S^\Y//YJ_?_J1&OFIKX+9SS\%
T>DL%/]Y-I91?22P_9?[76\O3H^F,DA'+YN-
MQG?/JD_R9 @/]U6:JO'+@SB%VP,5I="1!#YL?IKO+[22BD]IG8=R&+WT820B
ML>^Z^[X*5?+R>8/^.\([]0$?RW#V\OM>(GGX?4WS2->U2.3 W-;R;_&RV83^
MTI]3.P1X.Y21<$-JMG 4K-J[=6,Z*O649N7>.MJ%CIY^&LF^3-GAH=>\?9]O
MW\5C&%@_D;?M9&=I)W-JRO&0\3#]S[,_^=]_QR.>C/E_0S54GP99&%(ON/=G
M/'S&=.+?XB'3>]M4>S_^=%0=:1=Z-Q%)*GT>VAFBR3*W+=NV6JWXTS(^_Z
(X41.AV4
(N2I
MG(BC5,4OZVUO"7W[7 O\P+.?7SQO[G>.V%?L[BTIM_,WCT"TI7S,^_51(N4N
MF\ITQ'@4T ^5I>Q:ZA#Z^7<&S[ XS#0['HFQ2I' \8S)B)W)1*?UM_!U]LOI
M9>L'U@LF//)!)K_F.DV4T IX
^#)28[YR%:[BIR72\ &X<''E
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M70UG*(.Y:G5K!FIN@QQX\?R@U6S^LXIE>
!
'2" #XU%RE$?2)]42]V0;"+8
M#FF:73:
A7H?"NMP@#MP4"
MO'C>[AQ=CZ2V2@A$%OYF8_XGR#N=BA@EZ!1!+DK26*@89"-)2S/$7#R"9//^
MY1P#E(O4M% WQ"N( %E?ZECX
XZYJMQ'[X86",6C8\F
MX$AR^P#AU]M A:U3GH[
:=>/CO
ME7?LG<(O\4GX&6G*B?0%BT'/R@ _P(:AZ@/3H>,26T,%#-K2F/&!F(A0Q=22
MI8 4 \+9()[A<:"G2/"U99C-8Y:YR;0__WCQK@Y$J3>:V @I?1GY818(FK!0
M14.@A 'Q$0/2)DA5G243B:LB$;%*<,: %!R;TH*U@1(25TP$GX#)UR(%L3"L
MH:G3VO,Z; P\,X*.?! ,J3@$U"<&68CF$K9): %8PL
:8RI"S2Y_4Y.S::A?7"4.)/;VLY$+%0&>?CJD&$
MFB.B0:+&Q%H.X,PA)\([3AE/!5 VS@@[&F"$;VZ#"? .F.$T&H8X5V]4ED2$
M%MEO"!P1P-Z_6*8E038!8E]T:0>($GM7QQ?(0NAVK=VQ5U\
)RF*&?KPEE$&R@'P8"0NT'1@#K*X(:%LA&I">0'<;_#-#+086>@36
MU#8LQ>7ARU_%;'YQ7=I%N#(J$N-(HV$]%(/T97O/)27("$VIE_7FG4+^UQ*!
M*ZZ42T !$8SF"[3:WKU[Q8XJQ&AV$!0\^_E]HH; 1:B;ZH-$B,)^VWE_=F4]
MKZ_ B-X*,?5@GHJ*WXH<#\9<9!JP%'HI $ &@
"R1^@9%KH4BL+;SB4%'>@ *=\3Z,];N?F<,M4^I,"C%&N#8
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M4==J)..M14_VQ#C
QTW?-0Z]E+V%7+$HV[P[)
+B8CJ
M]*13W60,8X-+7-S0X :G]I((SQ,V_7QL"H@&IZ+@+&U,Z"'\E1#_ 2S3P*@T
M:7ZBM+9Q.)QS$S^":7!&DRZ'"88"\!6/P2ZGU ?K^R@'>IZF[O-$W?+)W KH
MGB>YS,D[H#O&/#"+1?.!2&<(OP<2_BPQF(EB)!+8JY1) X, AD*/,=T'09$D
M(\$9-T&3
!$]"RK&%-D7JL;
0P#+*[,,@DQ^>!Q^0W[;!@[+6
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M7F,#4V%BAC>1FD:4&U%$OII=BF1I@[)QFEEJ.V<3-E/HE_%:N. (95
M,Z(#/*HG&/#7W\I3PTVM&^6?LL)(D?GYUC=1#N9QIPR^X
M729?\/]V^3R7FE,*CV&>&M (>2V+ PP#.WE3UO>E'!OCI.-CXW%WDSCF,UB4
M@$=]H3%:E(>(SO,D=VW8UP8@S;PNR\BQ/"/ZFG(E+ =,IU.OV -6I.\ HV%L
MD ' R6 )
PH*^]W+2[OZ#VLQ17;22TVU^R5^@1<
M]($GB-.-%BF@-+J[Q_UDINJ S4DY? )F39?XJK=EZGM%A"U'#NS*F!9E#B#W
M.2Y"Q3Z>GX,LZK%,$WI!B8099T8@!;!T0C4%5@HI.@!8@^&V3\=:L5W=N7D[
M1T]8R:,TC8TF)ZU!_\1Q29"@_#!7)?WO;\,5GHB\WZ_>GWMQ,-AB@E-ZQ(8M
MB%5/['T"[\]H=X,W^G8ME^?E_L9+^8<%+]I$0J<1;!+5FDS$6CD5,;M+!J)Y
MDW^K*7+-VD,ER14P"8V0$=Q".Z$O0
X$]<
O0 2%I'XZ64D(Q&
M);1,2=W&O@'.&%1ME,?&$7M;+I$?Y>;\^P="=JODP@Z]91'$;T)_/!9K<=7$
MF$T_\[M4 @F65667"EE7 /P#33;35&'B1@*F3!AFZ$)""X;,3'S?8Z^D\7B!
MF"K;G'DB9VDG!D/W%R;JV:T+:*K1N] .-Q$XNFS#4M!NG.>3&$4,?14QNA^L
ME4N>*H9=0Z$Y@$YZ[&.I%]"W#%-1CT^.:ZQW
D^"&W#I6/@@6*4>
M:]M3
)FF*
S0<0$7:LU$!N')B01 8#>$PQ\3]6CD\/Y#H\JM
^R,=O M0T[LF^U]_J+@/P"CH_*V7,V
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M1%HP/DP$I1K9#94?9V,Q5
UNV/*32V@FDESWVN
MW*71GG
Y2!,P4LQ&?!P+F.U:%!;6EN(!8"Y\(
5Y*..LT1GHKQ'.!%#W$F#<^I0T )?D KBR8U GG;1
MV-M(YH
_)*ZQW&J])<=$_"A=_GN_-WK
M?[!NY]KF3\Y[EY>_V)3.T]]>7?[O1?WL]+KWEEU?_,_Y\?GU_]ZR9,#G4'C]
M6KR7"?QR"EJ1M]QC_T] -?+\8\DV5%L99;A-A"FL1$F Y3 $P$E!P!:0$C5C
MRN<8V*/!C&._HTU1WM]2V4"S?+\,6!HBRK/PX#$LJA,M#UE0K#, [0YM_4:;
M:E;NJ=%9C.H%T_W'@F-B+IEDI3V4N;?( \T#$YUDL=M":2KM!;B-@!(BW58;
MD?
K22E8@XE0M2)I/*!UJ)VH7;< XOL0.E/""K$8(#9SA/C-<*, ++'YUP0
MA5[[D93O5]#\]T-H/-[DQ*Z$?UX-+#]>Q
<\_S(FB3(NO
M&J^XA20VI*HM"-O:O+2UVW],JC:26OE^EN0%'L.EFQB-2>IVAMMIP0\OR/;\
MT]*D'6*VYQQU*ILA:6@+V\>7#-#F"]IO4E?*F[=HH^2+YP<'C>X1V[,;H8IM
MZR @9BJ+AB(I[;.:7_PIA@+PR"J2W^@[#C,9Z!KKBR&Z>BO:PA V4JD
CL@VMGG@"9-CVHU.F:VR1'FBNG[H( PR[]:NJE[.)VO ;%%B6EQU1$\
M:.:%@_/Y-1X'Y-*<&^]QC7KL%;%1J;-V5YY!-:%"W*!3I<+U2V99IRLE@5B)
M
HL(9!?],0=U25;$R>
5@Y3<8&9,\&,=3-@N
.;:DN/!\8MW*E#"V1:ITJ.[MX>W;Q/S6@!P*5DA8Q:H<470:VC Q9'Z3N
MRH#J0T&3=6/;C!FW="I/RB4^R@6*#KJT\:F-.\/=%./(78 XKUQ2BG,D6.N^
MPW9:7O.[W9K]NPU_=[ZS9YR82RVVTX8G&%900NA[1@9!7A"A*!-"$8\J2K68
MH^EUOZO6*
H>+[L'R2W6^2(EJ[[2]@ZK/=K2&3_/
M,6FMM$LVS6?/"9]%
]@V]WH3=P<)L7>N?1+/3M\&:N=AO?OV>3O7(X
MDQ*AW*8KRBNQ.Z@7G9^%F]JX RH^ -HT9GW<*9MB)3J:[,0
9!4(3WXTYR['H 8+@;,2GJ)GW8@:6+CV';YJY]R"W]U@"NNO
M<)Y'!=:J<"X-5(*L-F\]>T^"L3: K .3 %3#2+,["L8HP?W8TBU4<
D;$1*E>#]"LP#Z+IV+(Q+P/-ZC'6M;Z^CZ U^;F5)1.?E,44.DV4# J SY
ML/J7(I$[*9>5JA1Y 2:!BW/BM'!VEGA&F*S*S=]W686;@RW6 093GE?YS#L'
MDMY&38C+BPV'2P(RM^B3(I9<$9?!/,10+/'XT8"A/WGW!BH,U=19MR'F5LV9
MN-LJX=Z*0
/B
M3UM)B)+1;/=/SY:=*[@=*[:G-2;88B<+_EZZ\(RK-;5)68G9!4P962ZLG9^B
ME?LR\@CRG=T7)E.Q6K9R"S3T
K-%4P7GH*IASF
MIG6$)L)
-#F2=EZN94),F]J
MM>?\'W-.E" CW8@ME9$[YM/:=]A.PR.#:@DL-T$@^R*B'V@*/T68W#MTZFJ'
MZD6:$'W3:^&;K
Q#!X%P\\S9W?!-/\ZC(@)F%56
MO#-#-98S5(?.).GFMRU#!25D46&NQI;9Y
6E7@>&GH*O3\'7I^#K-QE\?>^L"SJH="'X6@KI@1%N#HXV
M^%?1-B6J>IO;S"A'//:;BNC([1PPH3V,FUYL!NQL',-(R?:&%YR=DMLSML6D
MV":[(C^6T9JE'*Q0.)7FQ)S'?N$3P8H>:ULW5"2TI8:)OS)IJO:B7P.-).I^
MJ2 M=CM/KT)GP,.KGY7!6Q#S2$N3]55C.E131N?/J]@Z;0Q97&I.D?F$.WC
MQ,0ANG/!S;D QF9
A
7&W-A(K [%J++S3TP
MSN:"$I5(!"W>.P-?D;N@7;!DW@BC[^;VEG5PV_W'IJPU"$UK6#;WYUZ^&%0S
M!*
A*KCBVNL;W
MUCKL5)9@]= 8CZW^&#QL7(!5-K9+5I1.0]H!R0TK% 7!#JW5B1I+
BK'D>,VD/_GH>+R10200EOZ9)3.VT_;H4W$DLC%@)YY?B= ,YYA*
M12\[IPZ5D@'X"E]RMPBB1:8INN1<@>OIA8]6QFFJ6MFQ+NWL.Z!/\ZBUBSOM
M$J"&SP: ?C/
Q*]FATES(\<2#QJ;9B$X4? 6
M\ \PW[:2_GK#B6B:[3B"4.K0M+Q;B^T
V@7O+!?K>G#*P5[2(L9"]^[/"BRWS/4HPR74&
MA76V=(KN+D'GPPOW*$$W2,M&C@.:9FHJIR::B]^H.-T_K(C3SC*AN52\-JJR
M
RNTD(WK!_M@"8B\W'-Z37Q#K OVNQ?T'>$Q@R5:H(10P
MP-*"_ERNPT2L3G;(!W!OL=NU!'TMDD6"/C(=>D
XJK?9-QM0L$
MHZW2WG"0#*!+_ZX>[O9Y\F01V=;0I98(H]&;[4-C\VRH7N QK,$YRJ(@H43K
M@&GY"?1QUT$#>FNO6]_OV'('^$R[;1!PZ1'WX7WWX0=7V2OQ46*2:/(Z#P +
M9>"R5XQSUHVFO
&CS<:CE-#O
M5'[:7R ' T&)A;2:;2(W#2F7PGV13M&RV;#4D2AN35&=W:W,5J5*A8G'?LTH
M1QU3E$'2@=2@E'X0(;I\/.RR
/79_^
<<+CZE.K[KQ&+%%E]7G8<^O8TNW=
QAH;9\@2V
MK%Z(2YD*'#18RI__8#86!L(E=^$68%-RW-5XK..VQB'^-<[K(U.Y<:&PT+W)
M%:*/F$,[41"TFJTC:#L55CB'
D-^$PW<,K,!P
M^D"%4N$H\K8K)2A=G)X^*+&F8Q#0\7IP4<0R1'
I2BP*
M^2S7^?6!\JG*&SWH4WB]'B14@I)2MC!;+U93_%8,_1:"DNBP(CA/_)$]7:(X
MF=Z6#3
MN&I1AHM.LCY\H<;.44A%@3V3W>1OK>A4R/LJP4+21)HQC[(!X#>3#CC JB&T
MU=+F[<6AF@FC"XJS#=Q)#>3QE*GE&]0.U4(F>05J=V#V1&IIU^IT.BV=>ET(
M4SK^VM7='F,.6[DPS)87L3[FE).'FUG?*5B5Q[@WD@[_9F
#?
M=& /,<8W>*[HAL,1Z$1UW&D'3$M\D1] /[!4"BV5=$ZETKJOL7Z6DH/5R954
MU4J/EA4V[;XM[7@M)(\][47/G_))>Y<'%8!9R!=:6:6G:]6J_"#X]H]TJ4$R
M>O&095=FGS[-B:OM<0'5\OJE U%H1[8[+[1T[E_Q1&G(%+@Q>\13,%8U+F],
MF,*EK=VYH*NI2Z^Z?8>KE>GWYI9+#(U!Y,#$J/Z?9K,N%J0#FVMLCJ+"#"4_
M+64!(Z**RG\B)+
FL'O@XUH(T#V8X;N2/E'16#X05U<,W9[!:
MM88;9.R9K:8:#HHIW'1)@)9AGY!UH3%;_5_9ZL2^C+D-=ND,#SE90R0#F&B#
MLRDIJ\6J?KHS4VP$K)97$"2>M:;KBG>A(:U\2=URA;.P
3>40*XM
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M0-H^1<:>(F-/D;%O\216DBO%7JIUDMO
?$
GHU>0/4$6G-$E @F.5Q.B($;T!
M .]$4Z_PU*L7S_
M9J>)]W_WKBP7_M"$
MBUUVL+?/.H>=@ZV=A_,(;$: UP\[%?\:QXLC]RH>^ZJ$N)TJ?2!"E%<2RY=2
MA^T?-!K_'GZH"(R];@.$Q1YK[3?W/T-@/,@).+
(TJGC&J,"J#9WC*1H]=O+UY='/?>%9XW$TUPV1ID]N+)
MBB$6$LM=\N0=:._E3D5,#S_HE@YA9L<]TT"/'9OFWZ@LB>S1V\?D[I$<(S?0
MEP[KQ8D,35I'H*2GDB$=B]EL>.TV=A5^^YS[7JMYT.Z
8!N
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M8
Z!Y^8X!A_P'XPR7&[I2R$>JC1,I=]KYTQ-)Y^8BE]SQ4K!=BZH2#
M^LM
GHM,C R-C X,C4N:'1M[5WM>]HX$O^^?X6.O;N29V/C
M-UY,$NYA"6W9S=L#Z75OO]PC; &Z&MLKR0GTK[^1;!,(D$":$K*;?F@!R]+,
MZ#>CF=%(/?[79!R@&\(XC<*3=Z9NO$,D]"*?AL.3=\U>J]-Y]Z_&#\=_T[3?
M?NZ>H=/(2\8D%*C%"!;$1[=4C) 8$?0Y8E_H#497 1:#B(TU+7VM%<531H
L;IC8,"N^I54
H]0^']8IG$-OO
M$ZWJ&EASS'Y9P_V*K9G$<:N5?F50LZU#OUZNVKYC&-ATJYZ#^Z9K6ZY;\09.
MS1@0 GW+<4<"> :^0WY2& D1UTNEV]M;_=;6(S8LF:[KEB:R32%M5*<3H7'B
M+32&[_HPNBG1,* AD;(I"89#+EG' H19L@RSK!DUS3;O^EGH8M)G@1H16MIS
M'
"V0
M4/O4*S2.1P3[C>,Q$1C)5S7R1T)O3@JM*!2 7>UZ&L,(7OKMI"#(1)34?)<:
M/_SPP[&@(B"-_^&O7S7)JE&SRL>E],?C4MIU/_*GC6.?WB NI@$Y*?B4QP&>
MUL,H)$ G=1E0\+2C]3W2:@^PO,+4"!&O73\B>B2P4G!TP D(1[+G@BMMT,8
M;MH"ZA@..J%/)K^2:0%1_Z0PT"RKT#!@^BS;*EO.<6FAURT&:8(>^U*7WP=X
M..O<+C0&..#DZ?VFQ'?)D'*)3G$!3V;=.X7&+R!8=#7"@%F/)()Z,!R* V]I
MQ-*BZ!@9$ :VB? 5,RZ14.<*S$ 34LBH"YCGDP*GXSB0B%*_C9@D>6%R]0GW
M8>K5>'>#9&/R*&'JFT)Z/>-;L2/YSG\GBNG\&_7E]P$E#"F:R$K3T>K\NCB3
M]U]NY#\M]AZ#>"(__P;ZQ<0IV.*&Y$
#U):X#L7
MTDPJI3FDET ?4J60TJ&/F>+_2NG=O9,ITIB&VHC(]:+N6'JU'(NC6^J+4=TT
MC'\45-/&,8\Q8*+/Y*2EG]-^EGJ39EL#NAGV1)TGXS%FTR/X:PBC]",AHG'=
MU,U8%-(^\]>\*(A8_4=#_3D: ._: (]I,*V_NZ9C . %N47=:(S#=X<
INQ 5U(>YVS95J2D7_^:%:,HT7RY\60TBBBN&[K-O0HI:_A
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M;*
\V6I_NNZTFF<]=/7IY[-."YUUSI4O#1[I5?/B/\LK\RX07MN(C6)[
M L&34GJ):S:+ZQ'FB,?$DZ&JCVB(J. (3!_ G+T6F$O E-? 1>!^0/+V_8A!
MC*L!W0&..:GG'X[RQ$^:D]/42_
.L2_3XC "S"BZ9Q@#,EB:Y3'U_8!D([YU^(T=?LOLI$I]O^]4
M 7?J,QC;.5AI+K43>A$#_T'E^'L"/(Q6E(2"35N1O^ANR7Q7G?A#S&(6W7AI
MJSM7RRXT.HP$./37NEC"?[:IR\3[-"R\[AE[3P,"C?NPD&2B=V2JU]1LNVP8
M;\+_KL*_QI-.ED/WE,HLSD2YT'!KFFG8EE-]>"K^/!:GJ*R&#*@O(9!FZ!<(
M5KE/5;BM\NC@V2U8F8,M,&E(WO\42"NVHO&8
:H_C
M()H2IN2QJ%;+DE$*4U(^\,,^M[,?:;)M+4O3]QGA//OG#/HS
Y36^';)6+EDJH7&3!C="/LK!/&TP5KP\9)=
M1[
&.<\W2NI$+;M9F7
%JV+&E4PEQ(R&'HUQ@,B$>(F@-S+# -:%\$,$CX)$6DKT
ME<8@+)\LYQ0>XVO5%O%^B<,P36US7&10E*45T0QQIEEHV&7[/@JVZ5:"C1&\
M #"KT#"_H<^S"-:OJU$4WG.#30A!*K:C56O+;O!^ _>NH.4=1X($));
++_2%.QTD@<$BBA =3Q,$+X8.I>C-[(0+C/TR=DW3/
M:#Y?F4 _#.%PFC\;1 $,+M^3T3*5;A^OO[RPMDI=[CQ1Z59UHUK9.D^IFV;E
M6?)XKJ-7:LY.\WC;.N!-@'> /H546@%TW@,DX)!KV\-AR_#W,Z,"M$4&,4F8
M.>E\V7'I1U'0QP!] 0HX,\R.!)Y;=9RC':8G=JE;2IB9B("'>1FA>&X7NIN
M-CE6.;,7TE#,[>[*3=VB646M]UUDV88.#5?$0-\#?*M-@+5-\=I+ ;,7!=0#
M^87#
2D>7.">M1.FHZO6<7^
MP6: 3-N^07(%)#N<)X0] 9C5-V"N!*9--*?H;0;,K.TFR
NTGHZ;X2\ '.^ \?O-0J*
M895]ZDW'_2@H\H,W,:T2TT56QJ;@1/(% >SC[8C"+W=&=(7X'M'+S Q*=D&(
MB(,W[Z.
6K[ 2CZ G:>J J8>WL#E".@#D(+2?00#5ET*T8RR(CE?@'FR"<#&$+5
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M%PZ\E,(L%2O82F$$&:.:;I@ZR@H^V_(4&E]>'-8=H-K]>GT9HGO' _1NJM"
M4%%JRC]_K%F6<9197_7-/#J I9PGH&@8=$X6&@$""08MQV$(:NE)M10C+)2N
M?=)[.GH?@9*#GJ)3E@Q1TP= *(.A5%.5*]Q(NW ;H=\I!5EB4,>J
U$:/T0)/K!H;780QI=L8DY,I\I!4*C M-\@TVAF"ALIB@\]A/ L%3
MNY*$0#(8!95="V0)30#.AW\C;]#QI;615]J 40%)H(_MKJ6E2G-#4%%^_>D
M#>$QBPB/XA&@7UHCGX30$0/&87I0\4.[>5#/.0%9)AQ=@PD;]QE^[M6GHCOW
M3\JMFOH5QD+"4+-UI[:<'92W \D>5)E$U=G6*C[;DED4E = R==$3O__^! \
M.@DB>=U+)%4.Q]-L5E#G8PO9/\GYDY^LGTJ=WL>?#@Y5^X696/_R"K_N$=7=
ME\6["8MG/"NY6=1)\%L'- !H \LD75FEWSNB?2J0Z^JF$A&=%:9G+<$'AZ5^
M=E7/_KB\JTO'I#5.EW W-
BY]_L+U0!5#M^RM
MD_-EO>(^4SV0I9O&?M<#/5=2H.AO
!,I4IZ7"KQ/BJ[D[)=QC-%;'K/:IZ.&Y5%BN
MT=]UOAY:KP>#[\%42II/O.PD7%T5$*0NYS'.R5BX6(ZD&#YZ2=I0>K%A1HKK
MFC'31V*L*B? X^IF'I>OG*@LT#HNX5?)DO5:"2^_5L+S>WGPVGV /X$Q S=R
MUVN/K?Y\-W90*P)BT!4>$M21&UD -)DM.,4"(W6XM4A@R?7][")G"*QDD-91
MWA-2%S[[V15/WUP;]98IW$)(>W#@J=?Y<-&\_M1]X*K/U;
$JZ;M9?(
M(LY?)Y=F__](*,LB[,WVV Y5H^[BMH&?!%/DX42F^M5^6WJAEQRF#V$)3)1,
MT*5W(/7)" <#F:*0'2GKFC60R8LDA'=4=S@1HX@!<_ZZ#,;;H:.[>,QRRMO&
M8U)+GRD@J^BFN]W-16N)JNI5\^&N-EQ0O^6F@?V\NV
B%A!@<0T&#?4#@2XE"%DMM,K??J3!M
MU]SNUZ2#-%^HH/RUJ;/JK$X%#.1ME%/-K]/X-_4(DAD@]9]*J"VFUHB2 3HC
M0QR@2W7;!EN,19;BNSVI1MHA"?(2W_K]
'^!
BTR,#(V,#@R-2YX
M
#BEMX1]*TAJN*BQ7AE:>>\NQ=T
M4RL4AW'J8,XK%F%$PB@M8YQ.RQ,\"XLIS@HH\3R&
8Y&F"(YAFLS1/JWD2VZ [N9!%#2U!NC4F%SNY]&JEND40;+=;
M?YOX7&R". RCX.;S^KN%>@.VH>QVA-[EHG'X)##NG$AP\%_DX6$$-X:N)J(E
M?L';P#0
DH16%4H^] 3/8$>"16Q&Q
M ?6%M" [4L!?I5U-$#+SH&W'A4+L1?*X1
Z'N.8%458;KU+,'W8\
M;$PXBG$2^3M9>L$_U' 8\W$U.-[Q-=A@$@I_P^^"$J@=X
*,LRP+KU4JT9"(*P1MX&QQT
M@G<@% 7Y6,HV0"V@6GI&2-C)YV
5.,BS!.,K,&Z= :06L>UW?6C(A5#W
MG0XA]3TTL!_1_]Q_0_)C^]<4:(YLW!"OM!_1
\C8KB\_O;7E-M\>
M[N*YB"54E%&KN=!^$<*'EQLCRSH-GF*?1.DEE%_9RIZ?WNM 'B!O$ O2%'US
M/.]0UJNTP>C&-ZQ7,-ZO_?^C';2&_6*O)G\ 4$L#!!0 ( -&@&5VJ!PEJ
MMPD --; 5 :F%Z>BTR,#(V,#@R-5]L86(N>&ULS9Q=;]LX%H;O\RNX
MWIM=H*Q%?;-H,^AFVD6PF;9H4LQ@%XN I*A$&%D*9*5)_OV2LIU(%F63E*TL
M!F@=FSGO>8_]F.0AI^]_>5SDX">OEEE9?)BAM\X,\(*525;
%B0M#/PE@Y# ?8L83&+L\\2,/
M8R>F;V[>A
9:J (B^9__'9QR6[Y@L"L6-:D8%)@F;U;-D]>E(S43=7WY@4&1\B?X&88
ME$]!Y$(/O7U<)K/3$P!6Y:C*G'_G*9!___A^/BB)YW+$O. W\KW]QJNL3"YK
M4M47A/)<9-]$JY_N^(?9,EO
^Z?OYP7_,"_KC
5VPUVPEU.=.O$CI=:0,A
M#KKJ8"7_?OZ2\9AZY=-5(9^F "7K2.1R
U/^
MG(L8<[F8D@^@?-# LC_RO/>>?:PV>9.*[2GG>L2
1C<1Z$B=."&DBEFZ^
MQP)BBJQ"91I
M_/R?6KLP@T39DA(@R>2L^NI$F
M@T-IH$V&>H Y%I>
",>32JZS.^389OB?(("B"(:*4B@>,8FTRMH,?&8Y&
M Y0I0.[?Z-_!1EV?D5XQ]F,RQJ(9*:;NC( 9LF'%3"_89-@,V6B3,SC&'![9
M@LZ_W9;%P#(,^R$D'B,"GBA!- R#%&LOP[:#'QF>1@XT>L;+L%X=]G,SQIT9
M-P;&C) 9
C)M&&C9,6P7*%*W;!>T(TW8+E 8Z+8+5 ,.=QZ$>N=!S(/8]T+Q8^H0/^8Q
M#?#8\R#TFN=!7PN#Y=QPG70[U"/=6[6JS8T?Y#P(C4)N..JKGP
%[/4%9LLYMAQV9&9&,R5-A#B0*I;
M$H^2!./0Y
WT 1L89X[6QP4O$MDW^9R3F]Y4%XH=&G8#B/S(P6GJ\\#GNDQU(A\9IF
JZWT^/M2
)'1D<(0]92Q^L$@"K
M#$"3@CY.>RNWG[!#UL,,NE&E,$)1UZ,5G7N#3P:LKLTVP]J_,W*'=R8>?JVN
MRH=>5S((D;PY[\"$!<1U>800UNY*#FA,O+>3PJ(L0$I;;NQ:]3'
E
MTS)LOY_K6QJ_F6O%?)V=7-_4X#9.,=06O_."E=5=635WZR]K4O-U7U79:4E]
M2!.:0@^[,0L<')#0,4-QI]XT6'92> .:).2'==.&MVF_["ZC+K$'*XX5O:/J
M8@&SEML18.^./S'D6F;[P.O]VMBY=Q6R=]Z!$HCEQ$MX0GDL7G+U[TFJ!*:>
M=5>JMA/NNBBFLZVYU9%3[1Z7(V;9KI4#3+'K@*\TOW;M#$^N6^/,X?J]RNJ:
M%W+=?%^L_[>UY39=S(]AS-U(((8CG/J!CW"L2Y=2X
^GQ]J3&3::=HQP4:9NQ4DWTF2 * VTR5 /L+_A?R5^=9N(5&Z0
M4!C!P(U"S,5_L>.:7NR7@8\,Q/,U=ZEE?HF_L;X?!UM#9C3H>;&ZI]].?-3U
M_";0Y+?RV^FK+N-W7K>X/BRW214GJN:@XP>0^&D("4\1Y1BE*-'>T+0#'QF$
MIC
L.KUT8?2.XZC
M0\E$RAR(DX!CXA+BN-I@#,M,?1!]D!/H46?/KW/J?/3CYB,=-/\_'#&;'2X?
M\ECY3,2K2'XN(C[^B_=ZVY2%
>,#.BP[T=<>(6]X"A?H][:* M9I\6O+H16ZQ_
M5N5#?2M@OB-%#S:.'4A]0F'L<.Q3Y!)*$C/8E#K3(+>1!BMML!8W!4]=*5W\
M1ONW@M#4N@6*.XV- %(==V(L=YKKP[E[^!"B[7?C0CPZ/=D\DZW^#>C3D_\!
M4$L#!!0 ( -&@&5T@&I-3(08 -HT 5 :F%Z>BTR,#(V,#@R-5]P
M
&ULU9M=
=/1Q9+.+
MP2-(X_37K\!Q6QNG90T[IC>Q#8)7YST/0CJ09\^7\]3[!+9(\NQTY!_CD0>9
MRG6234]'[VY?(39Z?G9T].P7A#[\?GWIO
T
+#)=%9Z!)-HW6R]UYY@7V _T@1%5(
"Z\K*A_GHYF9;DX&8_O[^^/E]*FQ[F=C@G&P7C=>O38?-EH?Q_4K7W.
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MU6#=T+&6$U8ULKL)[6.+\4)8=R*D9DFJUT<;F\_[R%69]^#<*BVNNR//16W
M6M"7JZP\&5P=6>D&5*A;]I'Q*[!)KE]F^H4;<;<#D#A$C&F!1( CI@EUXZ'H
M)?4;LJT8(,-G8'\O#PS#RZQ,RH=KF":5$UGY1LR;, N-9!!*1"261/. 1+'N
MQ,(NU58H!,-%H;.3@R#APLW2["*WM?$WSG^8Y'=9:1\FN6Z$PYAC6DJ&!&58
MZ=A%Q54/8'RW$ZTXH4/GI#^?!X'-JR2%-W=S"7:[[P8SY.;0&OG:YTJ%6I+8
M],#(5\560(1#!V)/!P>1_5NQO-#.J\0DJ\7'[D!X[!976OE( C.1HIH$BO:
MPA/RK;B(ALY%']X. I)SK5T*BL"(APY'5T\'"@;9#H)B-V_2&% <44.I3SFEX?\"!FD%!OOYP/AOG@X)C(G[
M^M;>YO=9(P2WIF(Z,"B*J.+:;<1!'PN3AG K*/A/ L6>?@X*B=5<>;O_RGV3
MH2%NM
WPC\+#7M8.204KO*B%.E?R6+7P@D3AGC$#"(0
M^0PHEVZBU!\0&]KML!AP/;,G6P\,QR//51TF;PQPN%I(8^,C(P,1^40:'9!.
M/&S(M4-@P.7,_
./WO
M;5*6D$WR^?PN>RR-%(TG+W& )"8QBF(IC# 8E-_MTM\IVPZ$ 9<@NYMY8!IN
M\C1129EDT]?"G3$1:7/.$B(F XXX)\IG?J!"VFTJV-1LQ\& 2XX=;3PP!%<6
M*H(A4U _EZ]>Z;!OC6D.;+[R$9
!28T^V#@N.
MBZ*X _N=6"K&!:88,8X#$8++MNYVZ_A1#]J!,N#28Z\6'_J& NK.W10?W#+G
M-BG3QLS8^#'B$!D4<.J6PH$FV.]6>MQ6;(?#@(N.G2P\5;UYF,N\
M<0\,.4&"<4!,2: ^CXS!W9YC;LBU>R=JP/7%_
JBJAN
MK/,989S';E5DNE4>-N3:97_ 5
LMZ\_&#?,NW8:SH\<=U9_J7V'.COX%
M4$L! A0#% @ T: 975U%OTFV)0 =T ! ( !
M &5X:&EB:70Y.3%P
BTR,#(V,#@R-2YH=&U02P$"% ,4
M" #1H!E=^8N(*V(" #_!@ $0 @ %P-0 :F%Z>BTR,#(V
M,#@R-2YX
BTR,#(V,#@R-5]L86(N>&UL4$L! A0#% @ T: 9
M72 :DU,A!@ VC0 !4 ( !ZT$ &IA>GHM,C R-C X,C5?
=<')E+GAM;%!+!08 !0 % $(! _2 !
end
XML
18
jazz-20260825_htm.xml
IDEA: XBRL DOCUMENT
0001232524
2026-02-19
2026-02-19
0001232524
false
Jazz Pharmaceuticals plc
8-K
2026-08-25
L2
001-33500
98-1032470
Fifth Floor, Waterloo Exchange,
Waterloo Road,
Dublin 4,
IE
D04 E5W7
353
1
634-7800
false
false
false
false
Ordinary shares, nominal value $0.0001 per share
JAZZ
NASDAQ
false